[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-posts-en":3},[4,596,1855,2442,3343,3834,4159,4393,4692,4926,7310],{"_path":5,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":9,"description":10,"cat":11,"icon":12,"accent":13,"date":14,"dateLabel":15,"read":16,"author":17,"image":18,"body":19,"_type":590,"_id":591,"_source":592,"_file":593,"_stem":594,"_extension":595},"\u002Fblog\u002Fen\u002Fsemaglutide-lifespan-mice","en",false,"","Semaglutide gave old mice 92 extra days: what the Nature study shows, and what it does not","This is general educational information, not medical advice and not a recommendation to get hold of anything or to use it. The study behind it was done in mice. You cannot read a human dose off an animal dose, and we are not naming one here.","Research","tabler:hourglass","#3F8A9B","2026-09-03","September 2026","10 min","myPeptides Team","\u002Fassets\u002Fsema_ageing_hero.png",{"type":20,"children":21,"toc":577},"root",[22,29,42,49,54,134,139,144,149,155,160,165,178,183,210,216,221,226,238,244,249,261,273,300,306,311,323,328,333,339,351,356,390,396,401,406,411,416,422,427,439,445,450,463,483,489],{"type":23,"tag":24,"props":25,"children":26},"element","p",{},[27],{"type":28,"value":10},"text",{"type":23,"tag":24,"props":30,"children":31},{},[32,34,40],{"type":28,"value":33},"The short version: on 2 September 2026, ",{"type":23,"tag":35,"props":36,"children":37},"em",{},[38],{"type":28,"value":39},"Nature",{"type":28,"value":41}," published a study in which old mice were given a daily semaglutide injection and lived a median 92 days longer than the control animals. That is roughly 12%. The work comes out of a university lab, was paid for by NIH grants, and had no money from Novo Nordisk behind it. It contains one finding that goes beyond \"eat less, weigh less\", and several points where the jump to humans breaks down.",{"type":23,"tag":43,"props":44,"children":46},"h2",{"id":45},"what-was-measured",[47],{"type":28,"value":48},"What was measured",{"type":23,"tag":24,"props":50,"children":51},{},[52],{"type":28,"value":53},"Danica Chen's group at the University of California, Berkeley started with 20-month-old female mice, an age that puts them somewhere in their early sixties in human terms. From that day on, every animal got an injection under the skin: either semaglutide or saline. The controls were handled and jabbed daily too, so the handling stress was the same in both groups.",{"type":23,"tag":55,"props":56,"children":57},"table",{},[58,77],{"type":23,"tag":59,"props":60,"children":61},"thead",{},[62],{"type":23,"tag":63,"props":64,"children":65},"tr",{},[66,72],{"type":23,"tag":67,"props":68,"children":69},"th",{},[70],{"type":28,"value":71},"Measure",{"type":23,"tag":67,"props":73,"children":74},{},[75],{"type":28,"value":76},"Result",{"type":23,"tag":78,"props":79,"children":80},"tbody",{},[81,95,108,121],{"type":23,"tag":63,"props":82,"children":83},{},[84,90],{"type":23,"tag":85,"props":86,"children":87},"td",{},[88],{"type":28,"value":89},"Median lifespan, controls (39 animals)",{"type":23,"tag":85,"props":91,"children":92},{},[93],{"type":28,"value":94},"742 days",{"type":23,"tag":63,"props":96,"children":97},{},[98,103],{"type":23,"tag":85,"props":99,"children":100},{},[101],{"type":28,"value":102},"Median lifespan, semaglutide (40 animals)",{"type":23,"tag":85,"props":104,"children":105},{},[106],{"type":28,"value":107},"834 days",{"type":23,"tag":63,"props":109,"children":110},{},[111,116],{"type":23,"tag":85,"props":112,"children":113},{},[114],{"type":28,"value":115},"Difference",{"type":23,"tag":85,"props":117,"children":118},{},[119],{"type":28,"value":120},"92 days, about 12%",{"type":23,"tag":63,"props":122,"children":123},{},[124,129],{"type":23,"tag":85,"props":125,"children":126},{},[127],{"type":28,"value":128},"Food intake on semaglutide",{"type":23,"tag":85,"props":130,"children":131},{},[132],{"type":28,"value":133},"−24%",{"type":23,"tag":24,"props":135,"children":136},{},[137],{"type":28,"value":138},"The difference is statistically clear (P = 5.7 × 10⁻⁶), which effectively rules out chance as the explanation. No animal was dropped from the analysis. The weight came off mostly as fat, and the lean fraction went up.",{"type":23,"tag":24,"props":140,"children":141},{},[142],{"type":28,"value":143},"If you see 11% in one report and 12% in another, both are right. 92 days out of 742 is 12.4%; 92 out of 834 is 11.0% — same number, different denominator. The press releases say \"about 100 days\"; the figure is 92, and it is a median, not an average.",{"type":23,"tag":24,"props":145,"children":146},{},[147],{"type":28,"value":148},"One thing almost every write-up drops: there were three separate sets of animals. The 79 mice in the lifespan arm were never tested for motor function, memory or stem cells; those had cohorts of their own. The obvious line, that the longer-lived mice were also the fitter ones, appears nowhere in the paper, because no single animal was ever measured for both.",{"type":23,"tag":43,"props":150,"children":152},{"id":151},"the-real-story-semaglutide-versus-fasting",[153],{"type":28,"value":154},"The real story: semaglutide versus fasting",{"type":23,"tag":24,"props":156,"children":157},{},[158],{"type":28,"value":159},"We have known since the 1930s that less food makes rodents live longer. So the obvious reading of this result is that semaglutide blunts appetite, the mice eat 24% less, and what you are looking at is calorie restriction with a needle.",{"type":23,"tag":24,"props":161,"children":162},{},[163],{"type":28,"value":164},"The authors tested exactly that. In a separate arm, one group had its food cut by exactly what the semaglutide animals had given up of their own accord: the same 24%, delivered through the bowl instead of through the appetite. Both groups and a control were tested repeatedly over five months.",{"type":23,"tag":24,"props":166,"children":167},{},[168,170,176],{"type":28,"value":169},"On voluntary activity, balance on the rotating rod, hanging strength and treadmill endurance, semaglutide and fasting came out ",{"type":23,"tag":171,"props":172,"children":173},"strong",{},[174],{"type":28,"value":175},"level",{"type":28,"value":177},", both holding their starting point while the controls declined. On three measures semaglutide beat fasting, and beat the animals' own baseline: exploring a new environment, spatial memory in the maze, and glucose tolerance. Weight loss and fat loss were comparable in both groups, so the calorie saving on its own cannot explain it.",{"type":23,"tag":24,"props":179,"children":180},{},[181],{"type":28,"value":182},"That is the most interesting finding in the paper, and three caveats belong in the same breath:",{"type":23,"tag":184,"props":185,"children":186},"ul",{},[187,200,205],{"type":23,"tag":188,"props":189,"children":190},"li",{},[191,193,198],{"type":28,"value":192},"The fasting arm was the ",{"type":23,"tag":171,"props":194,"children":195},{},[196],{"type":28,"value":197},"only unblinded",{"type":28,"value":199}," part of the study, because you cannot hide who is being fed less. So the most-quoted headline comes out of the arm most vulnerable to experimenter effects — and from endpoints that rest on watching behaviour.",{"type":23,"tag":188,"props":201,"children":202},{},[203],{"type":28,"value":204},"With around nine endpoints and ten animals per group, there was no correction for multiple testing across the endpoint family as a whole. Three hits are hypothesis-generating, not proof of superiority.",{"type":23,"tag":188,"props":206,"children":207},{},[208],{"type":28,"value":209},"For lifespan itself there was no fasting comparison at all. The study cannot say whether semaglutide extends life more than fasting does.",{"type":23,"tag":43,"props":211,"children":213},{"id":212},"what-happened-inside-the-animals",[214],{"type":28,"value":215},"What happened inside the animals",{"type":23,"tag":24,"props":217,"children":218},{},[219],{"type":28,"value":220},"The authors checked whether semaglutide flips the same switches as calorie restriction, and broadly it does: NAD⁺ rose in liver and muscle, several sirtuins were upregulated, blood levels of the growth factor IGF-1 fell, and a FOXO-controlled longevity gene was expressed more strongly. In liver tissue, inflammation and fat-metabolism programmes were turned down, while protein quality control and insulin response were turned up.",{"type":23,"tag":24,"props":222,"children":223},{},[224],{"type":28,"value":225},"Two things belong alongside that. First, it is not a clean sweep. Not all seven sirtuins responded, and the ones that did were not the same in liver as in muscle. Much of this is measured at the level of gene expression, with five to six animals per group, so the mechanism findings stand on far shakier ground than the survival curve. Second, if you follow the longevity debate: mTOR, AMPK and rapamycin do not appear in this paper at all. Anyone reading them into it is making them up.",{"type":23,"tag":24,"props":227,"children":228},{},[229,231,236],{"type":28,"value":230},"One detail that keeps getting told backwards: the number of blood stem cells in the bone marrow went ",{"type":23,"tag":171,"props":232,"children":233},{},[234],{"type":28,"value":235},"down",{"type":28,"value":237}," on semaglutide, not up. That counts as a good sign, because these cells get more numerous but worse with age. \"More stem cells\" is the wrong translation of the result.",{"type":23,"tag":43,"props":239,"children":241},{"id":240},"the-muscle-question",[242],{"type":28,"value":243},"The muscle question",{"type":23,"tag":24,"props":245,"children":246},{},[247],{"type":28,"value":248},"For most readers this is the question that matters: what does it do to muscle, especially in old age?",{"type":23,"tag":24,"props":250,"children":251},{},[252,254,259],{"type":28,"value":253},"The honest answer is that the study only answers half of it. ",{"type":23,"tag":171,"props":255,"children":256},{},[257],{"type":28,"value":258},"Performance",{"type":28,"value":260}," was better, on the rotating rod, hanging from an upside-down grid, and on the treadmill. For the first two, the advantage survived adjustment for body weight; lighter animals hang more easily, and that was corrected for.",{"type":23,"tag":24,"props":262,"children":263},{},[264,266,271],{"type":28,"value":265},"What was ",{"type":23,"tag":171,"props":267,"children":268},{},[269],{"type":28,"value":270},"not",{"type":28,"value":272}," measured is lean mass in grams. Only lean mass as a percentage is reported, and that necessarily rises when total weight falls through fat loss. There is no grip-strength measurement, no individual muscle weights, no tissue sections. This paper can no more show that muscle mass was preserved than it can show the opposite.",{"type":23,"tag":24,"props":274,"children":275},{},[276,278,283,285,289,291,298],{"type":28,"value":277},"There is also a study pointing the other way. Karasawa and colleagues reported in ",{"type":23,"tag":35,"props":279,"children":280},{},[281],{"type":28,"value":282},"Cell Metabolism",{"type":28,"value":284}," in 2025 that mice on semaglutide had reduced force generation in skeletal muscle, and that loss of mass alone could ",{"type":23,"tag":171,"props":286,"children":287},{},[288],{"type":28,"value":270},{"type":28,"value":290}," explain it. Different study design, different question, but the direction is opposite. Letting both stand is more honest than picking a side. We went into the human side of this question in more detail in our ",{"type":23,"tag":292,"props":293,"children":295},"a",{"href":294},"\u002Fblog\u002Fretatrutide-liver-damage-myths",[296],{"type":28,"value":297},"fact-check on retatrutide and the liver",{"type":28,"value":299},".",{"type":23,"tag":43,"props":301,"children":303},{"id":302},"the-brain-and-the-reality-check-in-humans",[304],{"type":28,"value":305},"The brain, and the reality check in humans",{"type":23,"tag":24,"props":307,"children":308},{},[309],{"type":28,"value":310},"The finding the authors push hardest themselves is about the brain: in the dentate gyrus, the one region where the adult brain still makes new nerve cells, semaglutide markedly increased how many of them appeared.",{"type":23,"tag":24,"props":312,"children":313},{},[314,316,321],{"type":28,"value":315},"That headline already has a reality check in humans, and it came back negative. In the EVOKE and EVOKE+ trials, 3,808 people with early-stage Alzheimer's disease took oral semaglutide daily for two years. The primary endpoint was ",{"type":23,"tag":171,"props":317,"children":318},{},[319],{"type":28,"value":320},"missed",{"type":28,"value":322},", clearly so in both trials, and the planned extension phase was stopped. A few inflammation and tau markers improved slightly; other markers actually got worse.",{"type":23,"tag":24,"props":324,"children":325},{},[326],{"type":28,"value":327},"That does not refute the mouse finding. The trials tested a different question, whether semaglutide slows Alzheimer's disease that is already under way, not whether it does anything to a healthy ageing brain. But it is the most obvious translation there is, it was tested in the largest trial of its kind so far, and it did not work.",{"type":23,"tag":24,"props":329,"children":330},{},[331],{"type":28,"value":332},"And there is a plainer explanation that should not be waved away. The neuroscientist Tara Spires-Jones, speaking to the UK's Science Media Centre, pointed out that the treated animals simply moved about more, and that exercise is known to do the ageing brain good in much the same way, with no GLP-1 drug involved at all. This study cannot rule that out.",{"type":23,"tag":43,"props":334,"children":336},{"id":335},"why-the-dose-does-not-translate",[337],{"type":28,"value":338},"Why the dose does not translate",{"type":23,"tag":24,"props":340,"children":341},{},[342,344,349],{"type":28,"value":343},"The mice got 10 nmol per kilogram, ",{"type":23,"tag":171,"props":345,"children":346},{},[347],{"type":28,"value":348},"every day",{"type":28,"value":350},", under the skin, until the end of life. People inject once a week, usually for months to a few years, and usually when they are a good deal younger than 60.",{"type":23,"tag":24,"props":352,"children":353},{},[354],{"type":28,"value":355},"You can attempt a conversion, but different methods give different answers. Scale it the way the regulators do, by body surface area, and you land in the region of the approved maintenance doses. Scale it bluntly per kilogram of body weight, and the mice were getting eight to twelve times as much. Both figures are correct; they simply answer different questions. A real comparison would have to go by the amount of drug circulating in the blood, and that the study never measured. Semaglutide stays in the human body for roughly a week and in rodents for orders of magnitude less time, which is why animal work has to dose daily. The mice therefore lived through daily peaks and troughs, while a person on a weekly shot sits at a largely flat level. Nobody knows which of the two patterns produces the effect, because the study has no blood levels to show.",{"type":23,"tag":24,"props":357,"children":358},{},[359,361,366,368,373,375,381,383,389],{"type":28,"value":360},"Here is the claim that holds up: a ",{"type":23,"tag":171,"props":362,"children":363},{},[364],{"type":28,"value":365},"comparable effect",{"type":28,"value":367}," is defensible, since the mice ate 24% less and lost mostly fat, which is the same order of magnitude as in humans. A ",{"type":23,"tag":171,"props":369,"children":370},{},[371],{"type":28,"value":372},"comparable dose",{"type":28,"value":374}," is not. If you want to know why units and milligrams get muddled so easily, that is in ",{"type":23,"tag":292,"props":376,"children":378},{"href":377},"\u002Fmg-ml-iu",[379],{"type":28,"value":380},"mg, mL and IU",{"type":28,"value":382},"; what happens when you get it wrong is in ",{"type":23,"tag":292,"props":384,"children":386},{"href":385},"\u002Fblog\u002Fglp1-dosing-errors",[387],{"type":28,"value":388},"GLP-1 dosing errors",{"type":28,"value":299},{"type":23,"tag":43,"props":391,"children":393},{"id":392},"so-is-12-a-lot",[394],{"type":28,"value":395},"So is 12% a lot?",{"type":23,"tag":24,"props":397,"children":398},{},[399],{"type":28,"value":400},"The useful yardstick is the best-studied ageing compound there is. Rapamycin, started at the same age as semaglutide was here, extended the median lifespan of female mice by around 15%. The 12% in this study is the same order of magnitude: solid, but no outlier on the high side.",{"type":23,"tag":24,"props":402,"children":403},{},[404],{"type":28,"value":405},"What matters just as much is how rapamycin was tested. It went through the Interventions Testing Program, run by the US ageing-research agency, which puts every substance through three independent sites at once, in genetically mixed mice and in both sexes. That design exists precisely because single-lab results in this field so often fail to replicate. Semaglutide is on none of those lists, for a mundane reason: substances there are given in the food, and a peptide that has to be injected daily does not fit the protocol.",{"type":23,"tag":24,"props":407,"children":408},{},[409],{"type":28,"value":410},"So this is a single-site result, in one mouse strain, in one sex, with just under 40 animals per group. That lifespan went up is statistically clear; that the figure is exactly 12% is a rough estimate. And female animals were chosen deliberately, to avoid dominance fights among males, so for males there is simply no data.",{"type":23,"tag":24,"props":412,"children":413},{},[414],{"type":28,"value":415},"One point that matters especially to this readership and appeared in none of the coverage: the mice were not fat. This was no obesity model. The animals were on ordinary chow and held their weight into old age, so the effect arose without any pre-existing obesity. In humans it is the other way round, because practically the entire body of evidence on semaglutide comes from people carrying excess weight. Whether a lean sixty-year-old would get the same benefit, or whether the weight loss would be more of a problem for them, is wide open.",{"type":23,"tag":43,"props":417,"children":419},{"id":418},"who-paid-for-the-study",[420],{"type":28,"value":421},"Who paid for the study",{"type":23,"tag":24,"props":423,"children":424},{},[425],{"type":28,"value":426},"The work was funded by three grants from the National Institutes of Health, not by a manufacturer. Novo Nordisk appears nowhere.",{"type":23,"tag":24,"props":428,"children":429},{},[430,432,437],{"type":28,"value":431},"One line of small print belongs here anyway, and it was in none of the coverage we saw: the University of California has a ",{"type":23,"tag":171,"props":433,"children":434},{},[435],{"type":28,"value":436},"patent application",{"type":28,"value":438}," pending on GLP-1 receptor agonists for healthy ageing. The senior author's institution therefore has a commercial interest in exactly the use that was studied. That does not devalue the data, but it is the context in which you read the wording of a press release.",{"type":23,"tag":43,"props":440,"children":442},{"id":441},"bottom-line",[443],{"type":28,"value":444},"Bottom line",{"type":23,"tag":24,"props":446,"children":447},{},[448],{"type":28,"value":449},"This is a good study with a real finding: a GLP-1 drug, started late in life, made old mice live longer and slowed their decline, and on three of around nine measures it did so more strongly than fasting on the same calorie saving. For ageing research, that is a result worth taking seriously.",{"type":23,"tag":24,"props":451,"children":452},{},[453,455,461],{"type":28,"value":454},"For you it changes nothing. There is no human data on semaglutide and lifespan, the most obvious translation to the brain has just failed, the muscle question is open, and the treatment that worked here was a daily injection until the end of life. Semaglutide is prescription-only and approved to treat obesity and type 2 diabetes; which other peptides carry an approval is set out in our ",{"type":23,"tag":292,"props":456,"children":458},{"href":457},"\u002Ffda-approved-peptides",[459],{"type":28,"value":460},"list of FDA-approved peptides",{"type":28,"value":462},". \"Living longer\" is not among them, and nothing in this study is an argument for using a drug to that end.",{"type":23,"tag":24,"props":464,"children":465},{},[466,468,474,476,482],{"type":28,"value":467},"If you want to know how the drug class works in the first place, start with ",{"type":23,"tag":292,"props":469,"children":471},{"href":470},"\u002Fwhat-are-peptides",[472],{"type":28,"value":473},"what peptides are",{"type":28,"value":475},"; the drug-specific background is under ",{"type":23,"tag":292,"props":477,"children":479},{"href":478},"\u002Fglp1\u002Fsemaglutide",[480],{"type":28,"value":481},"semaglutide",{"type":28,"value":299},{"type":23,"tag":43,"props":484,"children":486},{"id":485},"sources",[487],{"type":28,"value":488},"Sources",{"type":23,"tag":184,"props":490,"children":491},{},[492,505,517,529,541,553,565],{"type":23,"tag":188,"props":493,"children":494},{},[495,497],{"type":28,"value":496},"Feng et al., Nature 2026, ",{"type":23,"tag":292,"props":498,"children":502},{"href":499,"rel":500},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41586-026-10940-7",[501],"nofollow",[503],{"type":28,"value":504},"Late-life semaglutide treatment slows ageing and extends lifespan in female mice",{"type":23,"tag":188,"props":506,"children":507},{},[508,510],{"type":28,"value":509},"Strong et al., Aging Cell 2020, ",{"type":23,"tag":292,"props":511,"children":514},{"href":512,"rel":513},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Facel.13269",[501],[515],{"type":28,"value":516},"Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects",{"type":23,"tag":188,"props":518,"children":519},{},[520,522],{"type":28,"value":521},"Karasawa et al., Cell Metabolism 2025, ",{"type":23,"tag":292,"props":523,"children":526},{"href":524,"rel":525},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40769122\u002F",[501],[527],{"type":28,"value":528},"Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice",{"type":23,"tag":188,"props":530,"children":531},{},[532,534],{"type":28,"value":533},"Cummings et al., The Lancet 2026, ",{"type":23,"tag":292,"props":535,"children":538},{"href":536,"rel":537},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F41865758\u002F",[501],[539],{"type":28,"value":540},"Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer's disease (evoke and evoke+)",{"type":23,"tag":188,"props":542,"children":543},{},[544,546],{"type":28,"value":545},"Lincoff et al., New England Journal of Medicine 2023, ",{"type":23,"tag":292,"props":547,"children":550},{"href":548,"rel":549},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2307563",[501],[551],{"type":28,"value":552},"Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)",{"type":23,"tag":188,"props":554,"children":555},{},[556,558],{"type":28,"value":557},"Di Francesco et al., Nature 2024, ",{"type":23,"tag":292,"props":559,"children":562},{"href":560,"rel":561},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41586-024-08026-3",[501],[563],{"type":28,"value":564},"Dietary restriction impacts health and lifespan of genetically diverse mice",{"type":23,"tag":188,"props":566,"children":567},{},[568,570],{"type":28,"value":569},"Harrison et al., Nature 2009, ",{"type":23,"tag":292,"props":571,"children":574},{"href":572,"rel":573},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnature08221",[501],[575],{"type":28,"value":576},"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice",{"title":8,"searchDepth":578,"depth":578,"links":579},2,[580,581,582,583,584,585,586,587,588,589],{"id":45,"depth":578,"text":48},{"id":151,"depth":578,"text":154},{"id":212,"depth":578,"text":215},{"id":240,"depth":578,"text":243},{"id":302,"depth":578,"text":305},{"id":335,"depth":578,"text":338},{"id":392,"depth":578,"text":395},{"id":418,"depth":578,"text":421},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"markdown","content:blog:en:semaglutide-lifespan-mice.md","content","blog\u002Fen\u002Fsemaglutide-lifespan-mice.md","blog\u002Fen\u002Fsemaglutide-lifespan-mice","md",{"_path":597,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":598,"description":599,"cat":11,"icon":600,"accent":601,"date":602,"dateLabel":603,"read":604,"author":17,"image":605,"body":606,"_type":590,"_id":1852,"_source":592,"_file":1853,"_stem":1854,"_extension":595},"\u002Fblog\u002Fen\u002Fnisotirostide-ly3457263","Nisotirostide (LY3457263): the PYY drug that only exists as a stack — and what the data actually shows","This is general education, not medical advice, and not a suggestion to obtain or take anything. Nisotirostide is an investigational drug, approved nowhere, and neither legally purchasable nor prescribable. We give no doses — none have been published, and there is a reason for that, covered below. The numbers here come from separate trials with different participants and durations; none of it is a head-to-head comparison.","tabler:flask-2","#2E9E8F","2026-08-05","August 2026","12 min","\u002Fassets\u002Fnisotirostide_hero.png",{"type":20,"children":607,"toc":1840},[608,612,631,636,642,661,698,716,728,734,739,902,920,925,930,936,945,970,989,994,1006,1012,1017,1029,1046,1063,1068,1139,1144,1162,1174,1179,1185,1196,1227,1237,1337,1349,1354,1359,1583,1588,1594,1599,1609,1619,1637,1643,1655,1660,1666,1695,1699,1704,1708],{"type":23,"tag":24,"props":609,"children":610},{},[611],{"type":28,"value":599},{"type":23,"tag":24,"props":613,"children":614},{},[615,617,622,624,629],{"type":28,"value":616},"A new name has been circulating in the forums for a few months now, almost always in the same phrasing: ",{"type":23,"tag":171,"props":618,"children":619},{},[620],{"type":28,"value":621},"nisotirostide",{"type":28,"value":623},", \"the thing you add on top of tirzepatide or semaglutide\". The code is ",{"type":23,"tag":171,"props":625,"children":626},{},[627],{"type":28,"value":628},"LY3457263",{"type":28,"value":630},", the company is Eli Lilly, and unlike most grey-market novelties, part of that story is genuinely true. This molecule really is built as an add-on. There is not one trial in which it was tested alone against placebo in obesity — the combination isn't the biohacker's interpretation, it's the trial design.",{"type":23,"tag":24,"props":632,"children":633},{},[634],{"type":28,"value":635},"Except that the same research turns up an awkward second finding, and it belongs in this article every bit as much as the first one.",{"type":23,"tag":43,"props":637,"children":639},{"id":638},"what-nisotirostide-actually-is",[640],{"type":28,"value":641},"What nisotirostide actually is",{"type":23,"tag":24,"props":643,"children":644},{},[645,647,652,654,659],{"type":28,"value":646},"Nisotirostide is a ",{"type":23,"tag":171,"props":648,"children":649},{},[650],{"type":28,"value":651},"synthetic peptide that activates the Y2 receptor",{"type":28,"value":653}," (also written NPY2R) — in other words, a long-acting analogue of ",{"type":23,"tag":171,"props":655,"children":656},{},[657],{"type":28,"value":658},"PYY",{"type":28,"value":660},". It is injected under the skin once a week.",{"type":23,"tag":24,"props":662,"children":663},{},[664,666,672,674,683,685,690,692,696],{"type":28,"value":665},"PYY is one of your body's own satiety signals. The L-cells in the lower small intestine and colon release it after a meal — alongside GLP-1, from the very same cells. Once in circulation, the released PYY",{"type":23,"tag":667,"props":668,"children":669},"sub",{},[670],{"type":28,"value":671},"1-36",{"type":28,"value":673}," gets trimmed to the shorter ",{"type":23,"tag":171,"props":675,"children":676},{},[677,678],{"type":28,"value":658},{"type":23,"tag":667,"props":679,"children":680},{},[681],{"type":28,"value":682},"3-36",{"type":28,"value":684},", and that trim changes the address label. The long form also binds Y1 and Y5, receptors that ",{"type":23,"tag":35,"props":686,"children":687},{},[688],{"type":28,"value":689},"stimulate",{"type":28,"value":691}," appetite; PYY",{"type":23,"tag":667,"props":693,"children":694},{},[695],{"type":28,"value":682},{"type":28,"value":697}," hits Y2 almost exclusively — and Y2 turns hunger down. That is why obesity research only ever cares about the short form.",{"type":23,"tag":24,"props":699,"children":700},{},[701,703,707,709,714],{"type":28,"value":702},"Two things kept it from becoming a drug. Native PYY",{"type":23,"tag":667,"props":704,"children":705},{},[706],{"type":28,"value":682},{"type":28,"value":708}," has a half-life of roughly ",{"type":23,"tag":171,"props":710,"children":711},{},[712],{"type":28,"value":713},"10 minutes",{"type":28,"value":715},", and at the doses that produce noticeable satiety it produces nausea. You could hardly design a narrower therapeutic window. The entire modern class of PYY analogues — nisotirostide included — is an attempt to widen it: re-engineer the peptide so it lasts days instead of minutes, and make it as precisely Y2-selective as possible so you don't accidentally hit the appetite-stimulating relatives.",{"type":23,"tag":24,"props":717,"children":718},{},[719,721,726],{"type":28,"value":720},"Worth keeping straight: this is ",{"type":23,"tag":171,"props":722,"children":723},{},[724],{"type":28,"value":725},"not an incretin",{"type":28,"value":727},". Nisotirostide is not a GLP-1, not a GIP, not a glucagon agonist. It's an entirely different lever — which is exactly why it makes an interesting combination partner in the first place. Stacking two GLP-1s just hits the same receptor twice. Putting a Y2 agonist next to a GLP-1 opens a second pathway.",{"type":23,"tag":43,"props":729,"children":731},{"id":730},"the-point-where-most-write-ups-stop",[732],{"type":28,"value":733},"The point where most write-ups stop",{"type":23,"tag":24,"props":735,"children":736},{},[737],{"type":28,"value":738},"Look at the actual trial record and a remarkably clear pattern shows up. This is the complete public clinical programme for LY3457263:",{"type":23,"tag":55,"props":740,"children":741},{},[742,773],{"type":23,"tag":59,"props":743,"children":744},{},[745],{"type":23,"tag":63,"props":746,"children":747},{},[748,753,758,763,768],{"type":23,"tag":67,"props":749,"children":750},{},[751],{"type":28,"value":752},"Trial",{"type":23,"tag":67,"props":754,"children":755},{},[756],{"type":28,"value":757},"Phase",{"type":23,"tag":67,"props":759,"children":760},{},[761],{"type":28,"value":762},"Population",{"type":23,"tag":67,"props":764,"children":765},{},[766],{"type":28,"value":767},"What was tested",{"type":23,"tag":67,"props":769,"children":770},{},[771],{"type":28,"value":772},"Status",{"type":23,"tag":78,"props":774,"children":775},{},[776,809,841,871],{"type":23,"tag":63,"props":777,"children":778},{},[779,784,789,794,804],{"type":23,"tag":85,"props":780,"children":781},{},[782],{"type":28,"value":783},"NCT04641312",{"type":23,"tag":85,"props":785,"children":786},{},[787],{"type":28,"value":788},"1",{"type":23,"tag":85,"props":790,"children":791},{},[792],{"type":28,"value":793},"Healthy + type 2 diabetes, n = 67",{"type":23,"tag":85,"props":795,"children":796},{},[797,799],{"type":28,"value":798},"Single doses, alone ",{"type":23,"tag":171,"props":800,"children":801},{},[802],{"type":28,"value":803},"and with dulaglutide",{"type":23,"tag":85,"props":805,"children":806},{},[807],{"type":28,"value":808},"completed 12\u002F2021",{"type":23,"tag":63,"props":810,"children":811},{},[812,817,821,826,836],{"type":23,"tag":85,"props":813,"children":814},{},[815],{"type":28,"value":816},"NCT05377333",{"type":23,"tag":85,"props":818,"children":819},{},[820],{"type":28,"value":788},{"type":23,"tag":85,"props":822,"children":823},{},[824],{"type":28,"value":825},"Type 2 diabetes, n = 94",{"type":23,"tag":85,"props":827,"children":828},{},[829,831],{"type":28,"value":830},"Multiple doses, alone ",{"type":23,"tag":171,"props":832,"children":833},{},[834],{"type":28,"value":835},"and with a GLP‑1 RA",{"type":23,"tag":85,"props":837,"children":838},{},[839],{"type":28,"value":840},"completed 11\u002F2023",{"type":23,"tag":63,"props":842,"children":843},{},[844,849,853,858,866],{"type":23,"tag":85,"props":845,"children":846},{},[847],{"type":28,"value":848},"NCT05582096",{"type":23,"tag":85,"props":850,"children":851},{},[852],{"type":28,"value":788},{"type":23,"tag":85,"props":854,"children":855},{},[856],{"type":28,"value":857},"Overweight\u002Fobesity, n = 38",{"type":23,"tag":85,"props":859,"children":860},{},[861],{"type":23,"tag":171,"props":862,"children":863},{},[864],{"type":28,"value":865},"only in combination with tirzepatide",{"type":23,"tag":85,"props":867,"children":868},{},[869],{"type":28,"value":870},"completed 06\u002F2023",{"type":23,"tag":63,"props":872,"children":873},{},[874,879,884,889,897],{"type":23,"tag":85,"props":875,"children":876},{},[877],{"type":28,"value":878},"NCT06897475",{"type":23,"tag":85,"props":880,"children":881},{},[882],{"type":28,"value":883},"2",{"type":23,"tag":85,"props":885,"children":886},{},[887],{"type":28,"value":888},"Type 2 diabetes, n = 240",{"type":23,"tag":85,"props":890,"children":891},{},[892],{"type":23,"tag":171,"props":893,"children":894},{},[895],{"type":28,"value":896},"add-on to semaglutide or tirzepatide",{"type":23,"tag":85,"props":898,"children":899},{},[900],{"type":28,"value":901},"recruiting, ends 01\u002F2027",{"type":23,"tag":24,"props":903,"children":904},{},[905,907,913,915],{"type":28,"value":906},"Four trials, and every last one has a GLP-1 in the room. The single trial in people with obesity — NCT05582096 — tested only the combination with ",{"type":23,"tag":292,"props":908,"children":910},{"href":909},"\u002Fglp1\u002Ftirzepatide",[911],{"type":28,"value":912},"tirzepatide",{"type":28,"value":914},", ran eleven weeks, enrolled 38 people, and had tolerability as its primary endpoint, not weight. ",{"type":23,"tag":171,"props":916,"children":917},{},[918],{"type":28,"value":919},"No results have ever been posted for it.",{"type":23,"tag":24,"props":921,"children":922},{},[923],{"type":28,"value":924},"That's the second finding, and it's the uncomfortable one. That obesity trial finished in June 2023. No weight-loss Phase 2 followed. What started in March 2025 was a diabetes trial. Drug databases now list the obesity indication for nisotirostide as inactive, with Phase 1 as the highest stage reached. The live development path is type 2 diabetes.",{"type":23,"tag":24,"props":926,"children":927},{},[928],{"type":28,"value":929},"Don't read more into that than it supports — companies shelve programmes for all sorts of reasons, and Lilly still shows the molecule in its metabolic-portfolio investor materials. But the picture of a \"nisotirostide weight-loss shot\" heading for market doesn't survive contact with the record.",{"type":23,"tag":43,"props":931,"children":933},{"id":932},"what-the-ongoing-trial-actually-measures",[934],{"type":28,"value":935},"What the ongoing trial actually measures",{"type":23,"tag":24,"props":937,"children":938},{},[939,943],{"type":23,"tag":171,"props":940,"children":941},{},[942],{"type":28,"value":878},{"type":28,"value":944}," is the study running right now, and it's worth reading closely, because it gets misquoted a lot.",{"type":23,"tag":24,"props":946,"children":947},{},[948,950,955,957,961,963,968],{"type":28,"value":949},"It enrols adults with ",{"type":23,"tag":171,"props":951,"children":952},{},[953],{"type":28,"value":954},"type 2 diabetes",{"type":28,"value":956},", HbA1c between 7.5% and 10.5%, BMI 27 or above, who have been stable on ",{"type":23,"tag":292,"props":958,"children":959},{"href":478},[960],{"type":28,"value":481},{"type":28,"value":962}," or tirzepatide for at least three months ",{"type":23,"tag":171,"props":964,"children":965},{},[966],{"type":28,"value":967},"and still haven't hit their blood-sugar target",{"type":28,"value":969},". Those people get weekly nisotirostide or placebo on top, at three blinded dose levels. 240 participants, double-blind, sites in the US, Canada, Germany, Poland, Puerto Rico and the UK.",{"type":23,"tag":24,"props":971,"children":972},{},[973,975,980,982,987],{"type":28,"value":974},"The ",{"type":23,"tag":171,"props":976,"children":977},{},[978],{"type":28,"value":979},"primary endpoint is HbA1c reduction at 24 weeks",{"type":28,"value":981},". Weight change is a ",{"type":23,"tag":35,"props":983,"children":984},{},[985],{"type":28,"value":986},"secondary",{"type":28,"value":988}," endpoint. That's not pedantry: trials are powered for their primary endpoint, and the entry criteria follow it too. The people selected here are people whose blood sugar is running away — not people looking to lose the most weight.",{"type":23,"tag":24,"props":990,"children":991},{},[992],{"type":28,"value":993},"As for doses: the arms are literally named \"Dose 1\", \"Dose 2\" and \"Dose 3\". The milligram figures are not public. So if someone quotes you a nisotirostide dose, they didn't get it from the trial — it isn't in there to read.",{"type":23,"tag":24,"props":995,"children":996},{},[997,999,1004],{"type":28,"value":998},"The earliest possible first results come after primary completion in ",{"type":23,"tag":171,"props":1000,"children":1001},{},[1002],{"type":28,"value":1003},"December 2026",{"type":28,"value":1005},"; the trial as a whole wraps in January 2027.",{"type":23,"tag":43,"props":1007,"children":1009},{"id":1008},"what-a-pyy-analogue-in-a-stack-actually-delivers",[1010],{"type":28,"value":1011},"What a PYY analogue in a stack actually delivers",{"type":23,"tag":24,"props":1013,"children":1014},{},[1015],{"type":28,"value":1016},"There are no published efficacy data on nisotirostide itself. There are, however, data on the drug class — and one unusually well-documented experiment that asks precisely the question at hand: what happens when you add a weekly Y2 analogue on top of ongoing semaglutide?",{"type":23,"tag":24,"props":1018,"children":1019},{},[1020,1022,1027],{"type":28,"value":1021},"Novo Nordisk ran exactly that with its molecule ",{"type":23,"tag":171,"props":1023,"children":1024},{},[1025],{"type":28,"value":1026},"PYY1875",{"type":28,"value":1028}," and published the whole thing in 2025, rats through Phase 2. A different molecule from nisotirostide, same principle: selective Y2 agonist, half-life around 10 days, once weekly.",{"type":23,"tag":24,"props":1030,"children":1031},{},[1032,1037,1039,1044],{"type":23,"tag":171,"props":1033,"children":1034},{},[1035],{"type":28,"value":1036},"In animals it looked spectacular.",{"type":28,"value":1038}," Obese rats lost 12.5% of body weight on semaglutide alone — and ",{"type":23,"tag":171,"props":1040,"children":1041},{},[1042],{"type":28,"value":1043},"24.6%",{"type":28,"value":1045}," on semaglutide plus PYY1875. Food intake fell from 389 g to 215 g. PYY1875 on its own, incidentally, did nothing at all; those animals gained weight. The effect existed only in combination. That is textbook synergy.",{"type":23,"tag":24,"props":1047,"children":1048},{},[1049,1054,1056,1061],{"type":23,"tag":171,"props":1050,"children":1051},{},[1052],{"type":28,"value":1053},"In humans, very little of it survived.",{"type":28,"value":1055}," The Phase 2 design was built precisely around the stack question: 32 weeks of open-label semaglutide 2.4 mg as a run-in — during which participants lost 14.3% on average, from 102.1 kg to 87.5 kg — and only ",{"type":23,"tag":35,"props":1057,"children":1058},{},[1059],{"type":28,"value":1060},"then",{"type":28,"value":1062}," randomisation to added PYY1875 or placebo, with semaglutide continuing throughout.",{"type":23,"tag":24,"props":1064,"children":1065},{},[1066],{"type":28,"value":1067},"The result after 16 further weeks:",{"type":23,"tag":55,"props":1069,"children":1070},{},[1071,1085],{"type":23,"tag":59,"props":1072,"children":1073},{},[1074],{"type":23,"tag":63,"props":1075,"children":1076},{},[1077,1080],{"type":23,"tag":67,"props":1078,"children":1079},{},[],{"type":23,"tag":67,"props":1081,"children":1082},{},[1083],{"type":28,"value":1084},"Additional weight loss from week 32",{"type":23,"tag":78,"props":1086,"children":1087},{},[1088,1101,1114],{"type":23,"tag":63,"props":1089,"children":1090},{},[1091,1096],{"type":23,"tag":85,"props":1092,"children":1093},{},[1094],{"type":28,"value":1095},"PYY1875 1.0 mg + semaglutide 2.4 mg",{"type":23,"tag":85,"props":1097,"children":1098},{},[1099],{"type":28,"value":1100},"−5.6%",{"type":23,"tag":63,"props":1102,"children":1103},{},[1104,1109],{"type":23,"tag":85,"props":1105,"children":1106},{},[1107],{"type":28,"value":1108},"Placebo + semaglutide 2.4 mg",{"type":23,"tag":85,"props":1110,"children":1111},{},[1112],{"type":28,"value":1113},"−3.1%",{"type":23,"tag":63,"props":1115,"children":1116},{},[1117,1124],{"type":23,"tag":85,"props":1118,"children":1119},{},[1120],{"type":23,"tag":171,"props":1121,"children":1122},{},[1123],{"type":28,"value":115},{"type":23,"tag":85,"props":1125,"children":1126},{},[1127,1132,1134],{"type":23,"tag":171,"props":1128,"children":1129},{},[1130],{"type":28,"value":1131},"−2.2 percentage points",{"type":28,"value":1133}," (95% CI −4.2 to −0.1) — about ",{"type":23,"tag":171,"props":1135,"children":1136},{},[1137],{"type":28,"value":1138},"2.2 kg",{"type":23,"tag":24,"props":1140,"children":1141},{},[1142],{"type":28,"value":1143},"Two kilos. Statistically significant by a hair, with the lower end of the confidence interval nearly touching zero.",{"type":23,"tag":24,"props":1145,"children":1146},{},[1147,1149,1154,1156,1161],{"type":28,"value":1148},"And the price was steep. ",{"type":23,"tag":171,"props":1150,"children":1151},{},[1152],{"type":28,"value":1153},"Gastrointestinal adverse events hit 68% of the combination group",{"type":28,"value":1155},", against 29% on semaglutide plus placebo. Severe events: 15% versus 4%. Discontinuations for adverse events: 21.3% versus 10.7%. Of 47 participants, only 30 ever reached the target dose, and by the end of treatment just ",{"type":23,"tag":171,"props":1157,"children":1158},{},[1159],{"type":28,"value":1160},"20 — 42.6% — were still on it",{"type":28,"value":299},{"type":23,"tag":24,"props":1163,"children":1164},{},[1165,1167,1172],{"type":28,"value":1166},"The higher dose level never even completed: ",{"type":23,"tag":171,"props":1168,"children":1169},{},[1170],{"type":28,"value":1171},"seven of eight",{"type":28,"value":1173}," participants dropped out between weeks 3 and 12 with gastrointestinal side effects. The authors' verdict, in their own words: modest efficacy as an add-on to semaglutide, \"but the treatment was not well tolerated\".",{"type":23,"tag":24,"props":1175,"children":1176},{},[1177],{"type":28,"value":1178},"That isn't a footnote, it's the most informative data point in existence on this idea. It doesn't mean nisotirostide must fail — different molecule, different selectivity, different titration, and Lilly proved with tirzepatide that it takes tolerability seriously. But it shifts the burden of proof. Anyone claiming a PYY analogue is the big multiplier for your GLP-1 stack owes you an explanation of why it goes differently this time.",{"type":23,"tag":43,"props":1180,"children":1182},{"id":1181},"the-competition-and-why-it-has-moved-elsewhere",[1183],{"type":28,"value":1184},"The competition — and why it has moved elsewhere",{"type":23,"tag":24,"props":1186,"children":1187},{},[1188,1190,1195],{"type":28,"value":1189},"While PYY was learning that lesson, a different drug class answered the \"what do you add to a GLP-1\" question rather convincingly: ",{"type":23,"tag":171,"props":1191,"children":1192},{},[1193],{"type":28,"value":1194},"amylin",{"type":28,"value":299},{"type":23,"tag":24,"props":1197,"children":1198},{},[1199,1204,1206,1211,1213,1218,1220,1225],{"type":23,"tag":171,"props":1200,"children":1201},{},[1202],{"type":28,"value":1203},"CagriSema",{"type":28,"value":1205}," (cagrilintide + semaglutide, Novo Nordisk) is the finished proof. In the Phase 3 trial REDEFINE 1, with 3,417 adults without type 2 diabetes, participants lost ",{"type":23,"tag":171,"props":1207,"children":1208},{},[1209],{"type":28,"value":1210},"20.4%",{"type":28,"value":1212}," at 68 weeks — and ",{"type":23,"tag":171,"props":1214,"children":1215},{},[1216],{"type":28,"value":1217},"22.7%",{"type":28,"value":1219}," among those who stayed fully on treatment, with 40.4% losing at least a quarter of their body weight. For comparison, in the same trial: cagrilintide alone 11.5%, semaglutide alone 14.9%, placebo 3%. In REDEFINE 2, in people ",{"type":23,"tag":171,"props":1221,"children":1222},{},[1223],{"type":28,"value":1224},"with",{"type":28,"value":1226}," type 2 diabetes, it was 13.7% versus 3.4% on placebo, and 74% reached an HbA1c of 6.5% or below.",{"type":23,"tag":24,"props":1228,"children":1229},{},[1230,1235],{"type":23,"tag":171,"props":1231,"children":1232},{},[1233],{"type":28,"value":1234},"Eloralintide",{"type":28,"value":1236}," (LY3841136) is Lilly's own amylin — and the numbers explain where the attention inside the company is going. From the 48-week Phase 2 in 263 adults without diabetes, reported in November 2025:",{"type":23,"tag":55,"props":1238,"children":1239},{},[1240,1256],{"type":23,"tag":59,"props":1241,"children":1242},{},[1243],{"type":23,"tag":63,"props":1244,"children":1245},{},[1246,1251],{"type":23,"tag":67,"props":1247,"children":1248},{},[1249],{"type":28,"value":1250},"Eloralintide, weekly",{"type":23,"tag":67,"props":1252,"children":1253},{},[1254],{"type":28,"value":1255},"Weight loss at 48 weeks",{"type":23,"tag":78,"props":1257,"children":1258},{},[1259,1272,1285,1298,1311,1324],{"type":23,"tag":63,"props":1260,"children":1261},{},[1262,1267],{"type":23,"tag":85,"props":1263,"children":1264},{},[1265],{"type":28,"value":1266},"1 mg",{"type":23,"tag":85,"props":1268,"children":1269},{},[1270],{"type":28,"value":1271},"−9.5%",{"type":23,"tag":63,"props":1273,"children":1274},{},[1275,1280],{"type":23,"tag":85,"props":1276,"children":1277},{},[1278],{"type":28,"value":1279},"3 mg",{"type":23,"tag":85,"props":1281,"children":1282},{},[1283],{"type":28,"value":1284},"−12.4%",{"type":23,"tag":63,"props":1286,"children":1287},{},[1288,1293],{"type":23,"tag":85,"props":1289,"children":1290},{},[1291],{"type":28,"value":1292},"6 mg",{"type":23,"tag":85,"props":1294,"children":1295},{},[1296],{"type":28,"value":1297},"−17.6%",{"type":23,"tag":63,"props":1299,"children":1300},{},[1301,1306],{"type":23,"tag":85,"props":1302,"children":1303},{},[1304],{"type":28,"value":1305},"9 mg",{"type":23,"tag":85,"props":1307,"children":1308},{},[1309],{"type":28,"value":1310},"−20.1%",{"type":23,"tag":63,"props":1312,"children":1313},{},[1314,1319],{"type":23,"tag":85,"props":1315,"children":1316},{},[1317],{"type":28,"value":1318},"6\u002F9 mg escalation",{"type":23,"tag":85,"props":1320,"children":1321},{},[1322],{"type":28,"value":1323},"−19.9%",{"type":23,"tag":63,"props":1325,"children":1326},{},[1327,1332],{"type":23,"tag":85,"props":1328,"children":1329},{},[1330],{"type":28,"value":1331},"Placebo",{"type":23,"tag":85,"props":1333,"children":1334},{},[1335],{"type":28,"value":1336},"−0.4%",{"type":23,"tag":24,"props":1338,"children":1339},{},[1340,1342,1347],{"type":28,"value":1341},"Twenty percent — as ",{"type":23,"tag":171,"props":1343,"children":1344},{},[1345],{"type":28,"value":1346},"monotherapy",{"type":28,"value":1348},", with no incretin alongside it. And the tolerability was the genuinely notable part: mostly mild-to-moderate gastrointestinal symptoms and fatigue, on par with placebo at 1 and 3 mg, and markedly lower with slower escalation. Lilly has announced Phase 3 as a monotherapy and is testing the tirzepatide combination in parallel.",{"type":23,"tag":24,"props":1350,"children":1351},{},[1352],{"type":28,"value":1353},"Hold those two pictures side by side. A Y2 agonist added to semaglutide buys about two percentage points and makes two thirds of people sick. An amylin agonist buys twenty percentage points on its own and is well tolerated. It's no mystery where the money is going.",{"type":23,"tag":24,"props":1355,"children":1356},{},[1357],{"type":28,"value":1358},"The rest of the field, for completeness:",{"type":23,"tag":55,"props":1360,"children":1361},{},[1362,1387],{"type":23,"tag":59,"props":1363,"children":1364},{},[1365],{"type":23,"tag":63,"props":1366,"children":1367},{},[1368,1373,1378,1383],{"type":23,"tag":67,"props":1369,"children":1370},{},[1371],{"type":28,"value":1372},"Drug",{"type":23,"tag":67,"props":1374,"children":1375},{},[1376],{"type":28,"value":1377},"What it is",{"type":23,"tag":67,"props":1379,"children":1380},{},[1381],{"type":28,"value":1382},"Best result in its own trial",{"type":23,"tag":67,"props":1384,"children":1385},{},[1386],{"type":28,"value":772},{"type":23,"tag":78,"props":1388,"children":1389},{},[1390,1415,1440,1466,1492,1518,1548],{"type":23,"tag":63,"props":1391,"children":1392},{},[1393,1400,1405,1410],{"type":23,"tag":85,"props":1394,"children":1395},{},[1396],{"type":23,"tag":171,"props":1397,"children":1398},{},[1399],{"type":28,"value":1203},{"type":23,"tag":85,"props":1401,"children":1402},{},[1403],{"type":28,"value":1404},"amylin + GLP‑1 (Novo)",{"type":23,"tag":85,"props":1406,"children":1407},{},[1408],{"type":28,"value":1409},"22.7% at 68 wks",{"type":23,"tag":85,"props":1411,"children":1412},{},[1413],{"type":28,"value":1414},"Phase 3 complete",{"type":23,"tag":63,"props":1416,"children":1417},{},[1418,1425,1430,1435],{"type":23,"tag":85,"props":1419,"children":1420},{},[1421],{"type":23,"tag":171,"props":1422,"children":1423},{},[1424],{"type":28,"value":1234},{"type":23,"tag":85,"props":1426,"children":1427},{},[1428],{"type":28,"value":1429},"selective amylin (Lilly)",{"type":23,"tag":85,"props":1431,"children":1432},{},[1433],{"type":28,"value":1434},"20.1% at 48 wks, alone",{"type":23,"tag":85,"props":1436,"children":1437},{},[1438],{"type":28,"value":1439},"Phase 3 starting",{"type":23,"tag":63,"props":1441,"children":1442},{},[1443,1451,1456,1461],{"type":23,"tag":85,"props":1444,"children":1445},{},[1446],{"type":23,"tag":171,"props":1447,"children":1448},{},[1449],{"type":28,"value":1450},"Petrelintide",{"type":23,"tag":85,"props":1452,"children":1453},{},[1454],{"type":28,"value":1455},"amylin (Zealand\u002FRoche)",{"type":23,"tag":85,"props":1457,"children":1458},{},[1459],{"type":28,"value":1460},"10.7% at 42 wks",{"type":23,"tag":85,"props":1462,"children":1463},{},[1464],{"type":28,"value":1465},"Phase 2 positive (03\u002F2026)",{"type":23,"tag":63,"props":1467,"children":1468},{},[1469,1477,1482,1487],{"type":23,"tag":85,"props":1470,"children":1471},{},[1472],{"type":23,"tag":171,"props":1473,"children":1474},{},[1475],{"type":28,"value":1476},"Amycretin",{"type":23,"tag":85,"props":1478,"children":1479},{},[1480],{"type":28,"value":1481},"GLP‑1 + amylin in one molecule (Novo)",{"type":23,"tag":85,"props":1483,"children":1484},{},[1485],{"type":28,"value":1486},"24.3% at 36 wks",{"type":23,"tag":85,"props":1488,"children":1489},{},[1490],{"type":28,"value":1491},"Phase 1b\u002F2a",{"type":23,"tag":63,"props":1493,"children":1494},{},[1495,1503,1508,1513],{"type":23,"tag":85,"props":1496,"children":1497},{},[1498],{"type":23,"tag":171,"props":1499,"children":1500},{},[1501],{"type":28,"value":1502},"MariTide",{"type":23,"tag":85,"props":1504,"children":1505},{},[1506],{"type":28,"value":1507},"GLP‑1 agonist + GIP blocker, monthly (Amgen)",{"type":23,"tag":85,"props":1509,"children":1510},{},[1511],{"type":28,"value":1512},"~20% at 52 wks",{"type":23,"tag":85,"props":1514,"children":1515},{},[1516],{"type":28,"value":1517},"Phase 2",{"type":23,"tag":63,"props":1519,"children":1520},{},[1521,1533,1538,1543],{"type":23,"tag":85,"props":1522,"children":1523},{},[1524],{"type":23,"tag":171,"props":1525,"children":1526},{},[1527],{"type":23,"tag":292,"props":1528,"children":1530},{"href":1529},"\u002Fglp1\u002Fretatrutide",[1531],{"type":28,"value":1532},"Retatrutide",{"type":23,"tag":85,"props":1534,"children":1535},{},[1536],{"type":28,"value":1537},"GLP‑1 + GIP + glucagon (Lilly)",{"type":23,"tag":85,"props":1539,"children":1540},{},[1541],{"type":28,"value":1542},"~24% at 48 wks",{"type":23,"tag":85,"props":1544,"children":1545},{},[1546],{"type":28,"value":1547},"Phase 3",{"type":23,"tag":63,"props":1549,"children":1550},{},[1551,1559,1567,1575],{"type":23,"tag":85,"props":1552,"children":1553},{},[1554],{"type":23,"tag":171,"props":1555,"children":1556},{},[1557],{"type":28,"value":1558},"Nisotirostide",{"type":23,"tag":85,"props":1560,"children":1561},{},[1562],{"type":23,"tag":171,"props":1563,"children":1564},{},[1565],{"type":28,"value":1566},"Y2\u002FPYY agonist (Lilly)",{"type":23,"tag":85,"props":1568,"children":1569},{},[1570],{"type":23,"tag":171,"props":1571,"children":1572},{},[1573],{"type":28,"value":1574},"none published",{"type":23,"tag":85,"props":1576,"children":1577},{},[1578],{"type":23,"tag":171,"props":1579,"children":1580},{},[1581],{"type":28,"value":1582},"Phase 2, diabetes",{"type":23,"tag":24,"props":1584,"children":1585},{},[1586],{"type":28,"value":1587},"That last row is this whole article in one line.",{"type":23,"tag":43,"props":1589,"children":1591},{"id":1590},"the-honest-answer-to-the-original-question",[1592],{"type":28,"value":1593},"The honest answer to the original question",{"type":23,"tag":24,"props":1595,"children":1596},{},[1597],{"type":28,"value":1598},"Can you think of nisotirostide as a weight-loss shot stacked on tirzepatide or semaglutide?",{"type":23,"tag":24,"props":1600,"children":1601},{},[1602,1607],{"type":23,"tag":171,"props":1603,"children":1604},{},[1605],{"type":28,"value":1606},"Conceptually: yes, and that's explicitly the design.",{"type":28,"value":1608}," It isn't an incretin, it's a separate satiety pathway, and every trial pairs it with a GLP-1 for exactly that reason. The pharmacology is sound.",{"type":23,"tag":24,"props":1610,"children":1611},{},[1612,1617],{"type":23,"tag":171,"props":1613,"children":1614},{},[1615],{"type":28,"value":1616},"Evidentially: no, at least not today.",{"type":28,"value":1618}," There are zero published efficacy numbers for the molecule. The only obesity trial was an eleven-week tolerability study in 38 people with no results posted. The live development path targets blood sugar, not weight. And the one fully published human experiment in this drug class produced about two kilos at a side-effect rate that drove one in five participants out of the study.",{"type":23,"tag":24,"props":1620,"children":1621},{},[1622,1624,1630,1632,1636],{"type":28,"value":1623},"Then there's the part that never changes: whatever is circulating as \"nisotirostide\" right now is by definition unapproved grey-market material of unknown identity and purity. An NCT number doesn't vouch for the vial someone ships you — and in this case it doesn't even vouch for a dose, because the trial doses are blinded. Our primer ",{"type":23,"tag":292,"props":1625,"children":1627},{"href":1626},"\u002Fare-peptides-legal",[1628],{"type":28,"value":1629},"Are peptides legal?",{"type":28,"value":1631}," lays out the legal picture, and if you want to start from scratch, ",{"type":23,"tag":292,"props":1633,"children":1634},{"href":470},[1635],{"type":28,"value":473},{"type":28,"value":299},{"type":23,"tag":43,"props":1638,"children":1640},{"id":1639},"what-you-can-watch-for",[1641],{"type":28,"value":1642},"What you can watch for",{"type":23,"tag":24,"props":1644,"children":1645},{},[1646,1648,1653],{"type":28,"value":1647},"One date decides whether this story continues: ",{"type":23,"tag":171,"props":1649,"children":1650},{},[1651],{"type":28,"value":1652},"primary completion of NCT06897475 in December 2026",{"type":28,"value":1654},". That is the first time there will be numbers on the molecule itself — HbA1c primary, weight secondary, against placebo, on top of semaglutide or tirzepatide. If the weight curve moves meaningfully and dropout rates stay decent, that shelved obesity programme comes back fast. If it stays flat, or the gastrointestinal pattern repeats, the question is settled.",{"type":23,"tag":24,"props":1656,"children":1657},{},[1658],{"type":28,"value":1659},"Until then, nisotirostide is a drug to watch, not to source.",{"type":23,"tag":43,"props":1661,"children":1663},{"id":1662},"what-this-means-for-you-today",[1664],{"type":28,"value":1665},"What this means for you today",{"type":23,"tag":24,"props":1667,"children":1668},{},[1669,1671,1677,1679,1685,1687,1693],{"type":28,"value":1670},"For the compounds people actually run, the neutral part is the arithmetic. If you're tracking what you have, at what concentration, and when, ",{"type":23,"tag":292,"props":1672,"children":1674},{"href":1673},"\u002Fpeptides-list",[1675],{"type":28,"value":1676},"our peptide tracker",{"type":28,"value":1678}," is built for exactly that. If reconstitution is the shaky step, ",{"type":23,"tag":292,"props":1680,"children":1682},{"href":1681},"\u002Fcalculator",[1683],{"type":28,"value":1684},"our calculator",{"type":28,"value":1686}," turns a target dose into units on the syringe once you know the vial concentration and the bacteriostatic water you added. And because these are weekly injections whose levels rise and fall between shots, ",{"type":23,"tag":292,"props":1688,"children":1690},{"href":1689},"\u002Fplotter",[1691],{"type":28,"value":1692},"the level plotter",{"type":28,"value":1694}," draws that curve. None of it is a recommendation to take anything — it's the maths, kept honest.",{"type":23,"tag":43,"props":1696,"children":1697},{"id":441},[1698],{"type":28,"value":444},{"type":23,"tag":24,"props":1700,"children":1701},{},[1702],{"type":28,"value":1703},"Nisotirostide (LY3457263) is Lilly's once-weekly PYY analogue at the Y2 receptor, and it genuinely is engineered as a combination partner — it has never been tested any other way. That much of the forum story holds up. The rest doesn't: there are no published efficacy data, the only obesity trial was a small tolerability study with no results, active development is aimed at type 2 diabetes, and the best published experiment in the class delivered about two extra kilos alongside 68% gastrointestinal side effects. Meanwhile amylin has answered the combination question: CagriSema at 22.7%, eloralintide at 20.1% flying solo and well tolerated. If you want to see where the next generation of weight-loss drugs is heading, watch the amylins. Nisotirostide is an interesting footnote with a date in December 2026 — not an answer yet.",{"type":23,"tag":43,"props":1705,"children":1706},{"id":485},[1707],{"type":28,"value":488},{"type":23,"tag":184,"props":1709,"children":1710},{},[1711,1723,1734,1745,1756,1768,1780,1792,1804,1816,1828],{"type":23,"tag":188,"props":1712,"children":1713},{},[1714,1716],{"type":28,"value":1715},"ClinicalTrials.gov, ",{"type":23,"tag":292,"props":1717,"children":1720},{"href":1718,"rel":1719},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06897475",[501],[1721],{"type":28,"value":1722},"NCT06897475 — LY3457263 as an add-on to semaglutide or tirzepatide in type 2 diabetes (Phase 2)",{"type":23,"tag":188,"props":1724,"children":1725},{},[1726,1727],{"type":28,"value":1715},{"type":23,"tag":292,"props":1728,"children":1731},{"href":1729,"rel":1730},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05582096",[501],[1732],{"type":28,"value":1733},"NCT05582096 — LY3457263 in combination with tirzepatide in overweight\u002Fobesity (Phase 1)",{"type":23,"tag":188,"props":1735,"children":1736},{},[1737,1738],{"type":28,"value":1715},{"type":23,"tag":292,"props":1739,"children":1742},{"href":1740,"rel":1741},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05377333",[501],[1743],{"type":28,"value":1744},"NCT05377333 — LY3457263 alone and with a GLP-1 RA in type 2 diabetes (Phase 1)",{"type":23,"tag":188,"props":1746,"children":1747},{},[1748,1749],{"type":28,"value":1715},{"type":23,"tag":292,"props":1750,"children":1753},{"href":1751,"rel":1752},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04641312",[501],[1754],{"type":28,"value":1755},"NCT04641312 — first-in-human single ascending dose study (Phase 1)",{"type":23,"tag":188,"props":1757,"children":1758},{},[1759,1761],{"type":28,"value":1760},"Wulff et al., Obesity 2025, ",{"type":23,"tag":292,"props":1762,"children":1765},{"href":1763,"rel":1764},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Foby.24329",[501],[1766],{"type":28,"value":1767},"Long-acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies",{"type":23,"tag":188,"props":1769,"children":1770},{},[1771,1773],{"type":28,"value":1772},"Østergaard et al., Science Translational Medicine 2025, ",{"type":23,"tag":292,"props":1774,"children":1777},{"href":1775,"rel":1776},"https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscitranslmed.adq6392",[501],[1778],{"type":28,"value":1779},"Variant screening of PYY3–36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity",{"type":23,"tag":188,"props":1781,"children":1782},{},[1783,1785],{"type":28,"value":1784},"Eli Lilly, ",{"type":23,"tag":292,"props":1786,"children":1789},{"href":1787,"rel":1788},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-and-favorable-tolerability-in-a-phase-2-study-of-adults-with-obesity-or-overweight-302607061.html",[501],[1790],{"type":28,"value":1791},"Eloralintide: Phase 2 results for the selective amylin agonist",{"type":23,"tag":188,"props":1793,"children":1794},{},[1795,1797],{"type":28,"value":1796},"Novo Nordisk \u002F NEJM, ",{"type":23,"tag":292,"props":1798,"children":1801},{"href":1799,"rel":1800},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fcagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html",[501],[1802],{"type":28,"value":1803},"CagriSema 2.4 mg\u002F2.4 mg — 22.7% mean weight reduction in REDEFINE 1",{"type":23,"tag":188,"props":1805,"children":1806},{},[1807,1809],{"type":28,"value":1808},"NEJM 2025, ",{"type":23,"tag":292,"props":1810,"children":1813},{"href":1811,"rel":1812},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fabs\u002F10.1056\u002FNEJMoa2502082",[501],[1814],{"type":28,"value":1815},"Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2)",{"type":23,"tag":188,"props":1817,"children":1818},{},[1819,1821],{"type":28,"value":1820},"Roche, ",{"type":23,"tag":292,"props":1822,"children":1825},{"href":1823,"rel":1824},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-03-05",[501],[1826],{"type":28,"value":1827},"Positive Phase II results for the amylin analogue petrelintide",{"type":23,"tag":188,"props":1829,"children":1830},{},[1831,1833],{"type":28,"value":1832},"Amgen, ",{"type":23,"tag":292,"props":1834,"children":1837},{"href":1835,"rel":1836},"https:\u002F\u002Fwww.amgen.com\u002Fnewsroom\u002Fpress-releases\u002F2024\u002F11\u002Famgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study",[501],[1838],{"type":28,"value":1839},"Phase 2 results for MariTide at 52 weeks",{"title":8,"searchDepth":578,"depth":578,"links":1841},[1842,1843,1844,1845,1846,1847,1848,1849,1850,1851],{"id":638,"depth":578,"text":641},{"id":730,"depth":578,"text":733},{"id":932,"depth":578,"text":935},{"id":1008,"depth":578,"text":1011},{"id":1181,"depth":578,"text":1184},{"id":1590,"depth":578,"text":1593},{"id":1639,"depth":578,"text":1642},{"id":1662,"depth":578,"text":1665},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"content:blog:en:nisotirostide-ly3457263.md","blog\u002Fen\u002Fnisotirostide-ly3457263.md","blog\u002Fen\u002Fnisotirostide-ly3457263",{"_path":1856,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":1857,"description":1858,"cat":1859,"icon":1860,"accent":1861,"date":1862,"dateLabel":603,"read":1863,"author":17,"image":1864,"body":1865,"_type":590,"_id":2439,"_source":592,"_file":2440,"_stem":2441,"_extension":595},"\u002Fblog\u002Fen\u002Fparadigm-peptides-coa-fraud-sentence","70 months in prison for faked certificates of analysis — the Paradigm Peptides case","This is a report on a criminal case, not medical or legal advice, and not an invitation to obtain any substance. Everything below comes from the charging document, the prosecutors' announcement and the reporting; sources are at the end.","Safety","tabler:file-certificate","#E0533D","2026-08-01","8 min","\u002Fassets\u002Fparadigm_coa_hero.png",{"type":20,"children":1866,"toc":2428},[1867,1871,1910,1922,1928,1970,1975,1987,1993,1998,2021,2026,2038,2044,2070,2075,2087,2093,2104,2109,2115,2134,2139,2145,2226,2232,2237,2301,2319,2325,2344,2349,2353],{"type":23,"tag":24,"props":1868,"children":1869},{},[1870],{"type":28,"value":1858},{"type":23,"tag":24,"props":1872,"children":1873},{},[1874,1876,1881,1883,1888,1890,1895,1897,1902,1904,1909],{"type":28,"value":1875},"On Thursday 30 July 2026, US District Judge Cristal C. Brisco sentenced ",{"type":23,"tag":171,"props":1877,"children":1878},{},[1879],{"type":28,"value":1880},"Matthew J. Kawa, 48",{"type":28,"value":1882},", to ",{"type":23,"tag":171,"props":1884,"children":1885},{},[1886],{"type":28,"value":1887},"70 months in prison",{"type":28,"value":1889}," — just under six years, followed by a year of supervised release — in South Bend, Indiana. Kawa ran ",{"type":23,"tag":171,"props":1891,"children":1892},{},[1893],{"type":28,"value":1894},"Paradigm Peptides",{"type":28,"value":1896},", one of the better-known shops in the \"research only\" corner of the internet. His sister ",{"type":23,"tag":171,"props":1898,"children":1899},{},[1900],{"type":28,"value":1901},"Jennifer L. Stechkober, 32",{"type":28,"value":1903},", the business's main employee, got ",{"type":23,"tag":171,"props":1905,"children":1906},{},[1907],{"type":28,"value":1908},"16 months",{"type":28,"value":299},{"type":23,"tag":24,"props":1911,"children":1912},{},[1913,1915,1920],{"type":28,"value":1914},"For a peptide vendor, that is a rare criminal penalty. The striking part, though, is not the length of the sentence. It is what Kawa admitted to: he ",{"type":23,"tag":171,"props":1916,"children":1917},{},[1918],{"type":28,"value":1919},"forged certificates of analysis",{"type":28,"value":1921}," — the very documents half the industry waves around as proof of quality.",{"type":23,"tag":43,"props":1923,"children":1925},{"id":1924},"what-paradigm-was",[1926],{"type":28,"value":1927},"What Paradigm was",{"type":23,"tag":24,"props":1929,"children":1930},{},[1931,1933,1938,1940,1947,1949,1954,1956,1961,1963,1968],{"type":28,"value":1932},"From ",{"type":23,"tag":171,"props":1934,"children":1935},{},[1936],{"type":28,"value":1937},"April 2019 to March 2024",{"type":28,"value":1939},", Paradigm Peptides sold peptides, SARMs and hCG through ",{"type":23,"tag":1941,"props":1942,"children":1944},"code",{"className":1943},[],[1945],{"type":28,"value":1946},"paradigmpeptides.com",{"type":28,"value":1948},", shipping from Michigan City, Indiana. Prosecutors put the customer base at roughly ",{"type":23,"tag":171,"props":1950,"children":1951},{},[1952],{"type":28,"value":1953},"54,000 people across all 50 US states and 80 countries",{"type":28,"value":1955},"; the charging document values the unapproved drugs pushed into commerce at ",{"type":23,"tag":171,"props":1957,"children":1958},{},[1959],{"type":28,"value":1960},"more than $3 million",{"type":28,"value":1962},". Kawa agreed to forfeit ",{"type":23,"tag":171,"props":1964,"children":1965},{},[1966],{"type":28,"value":1967},"$5 million",{"type":28,"value":1969}," in proceeds, and both defendants were ordered to pay $78,317.52 in restitution.",{"type":23,"tag":24,"props":1971,"children":1972},{},[1973],{"type":28,"value":1974},"The website read the way plenty of shops still read today: made in America, 99% pure, third-party tested — with a line at the bottom saying it was all strictly for research.",{"type":23,"tag":24,"props":1976,"children":1977},{},[1978,1980,1985],{"type":28,"value":1979},"None of it was true. Kawa imported the ingredients from ",{"type":23,"tag":171,"props":1981,"children":1982},{},[1983],{"type":28,"value":1984},"China, India and other countries",{"type":28,"value":1986}," to addresses in Indiana and Illinois, had them packaged in Michigan City, and sold them as his own manufacture. Nothing was ever tested. In his plea he stated plainly that he \"did not test the SARM products that my business sold to customers.\"",{"type":23,"tag":43,"props":1988,"children":1990},{"id":1989},"the-watermark-trick",[1991],{"type":28,"value":1992},"The watermark trick",{"type":23,"tag":24,"props":1994,"children":1995},{},[1996],{"type":28,"value":1997},"The charging document lists six ways the pair misled regulators and customers. One of them should interest anyone who has ever downloaded a COA:",{"type":23,"tag":1999,"props":2000,"children":2001},"blockquote",{},[2002],{"type":23,"tag":24,"props":2003,"children":2004},{},[2005,2007,2012,2014,2019],{"type":28,"value":2006},"forging Certificates of Analysis associated with Paradigm products by editing the information ",{"type":23,"tag":171,"props":2008,"children":2009},{},[2010],{"type":28,"value":2011},"and the watermarks",{"type":28,"value":2013}," on ",{"type":23,"tag":171,"props":2015,"children":2016},{},[2017],{"type":28,"value":2018},"other businesses'",{"type":28,"value":2020}," Certificates of Analysis",{"type":23,"tag":24,"props":2022,"children":2023},{},[2024],{"type":28,"value":2025},"That is not sloppiness. That is craft, applied deliberately. You take a real lab's PDF — letterhead, layout, watermark, everything that signals independence — swap the compound name and the numbers, then retouch the watermark so it points at your own shop. What the customer sees looks exactly like an outside verification.",{"type":23,"tag":24,"props":2027,"children":2028},{},[2029,2031,2036],{"type":28,"value":2030},"The other five items complete the picture. They falsely presented the products as research chemicals not intended for human consumption. They claimed Paradigm was licensed and registered with the FDA. They claimed it manufactured and lab-tested its own products in the United States. They misstated what was actually in the SARMs. And outbound international parcels were declared to customs as ",{"type":23,"tag":171,"props":2032,"children":2033},{},[2034],{"type":28,"value":2035},"\"cosmetic samples\"",{"type":28,"value":2037}," to slip past inspection.",{"type":23,"tag":43,"props":2039,"children":2041},{"id":2040},"what-was-actually-in-the-vial",[2042],{"type":28,"value":2043},"What was actually in the vial",{"type":23,"tag":24,"props":2045,"children":2046},{},[2047,2049,2054,2056,2061,2063,2068],{"type":28,"value":2048},"When the government tested six compounds sold as testosterone mimics, ",{"type":23,"tag":171,"props":2050,"children":2051},{},[2052],{"type":28,"value":2053},"all six contained real testosterone",{"type":28,"value":2055}," — a prescription steroid hormone, and a controlled substance in the US. The charging document names two from 1 September 2023: what was sold as ",{"type":23,"tag":171,"props":2057,"children":2058},{},[2059],{"type":28,"value":2060},"YK-11",{"type":28,"value":2062}," was testosterone. What was sold as ",{"type":23,"tag":171,"props":2064,"children":2065},{},[2066],{"type":28,"value":2067},"Ostarine (MK-2866)",{"type":28,"value":2069}," was testosterone.",{"type":23,"tag":24,"props":2071,"children":2072},{},[2073],{"type":28,"value":2074},"This is where mislabelling turns into a health problem. Someone who thinks they are taking a SARM is not expecting a full androgen dose — not the effects, not the side effects, and certainly not a failed drug test.",{"type":23,"tag":24,"props":2076,"children":2077},{},[2078,2080,2085],{"type":28,"value":2079},"The hCG followed the same pattern. From 2020 to March 2024, Kawa regularly imported shipments from abroad. ",{"type":23,"tag":171,"props":2081,"children":2082},{},[2083],{"type":28,"value":2084},"On at least fifteen occasions",{"type":28,"value":2086}," he was notified that a parcel of hCG addressed to him had been stopped at the border as a misbranded drug. He kept going. The second count concerns exactly one such parcel, from 16 January 2024.",{"type":23,"tag":43,"props":2088,"children":2090},{"id":2089},"one-customer-who-paid-for-it",[2091],{"type":28,"value":2092},"One customer who paid for it",{"type":23,"tag":24,"props":2094,"children":2095},{},[2096,2098,2103],{"type":28,"value":2097},"Dan Murphy, then in his early thirties and working as a marketing consultant, started taking Paradigm SARMs in 2023 to put on muscle. Within months came insomnia, painful cystic acne, grandiose thinking, then paranoid delusions — he became convinced his wife was conspiring against him — and recurring suicidal thoughts. The medical assessment was ",{"type":23,"tag":171,"props":2099,"children":2100},{},[2101],{"type":28,"value":2102},"steroid-induced psychosis",{"type":28,"value":299},{"type":23,"tag":24,"props":2105,"children":2106},{},[2107],{"type":28,"value":2108},"He only learned why in February 2025, through a letter from investigators: what he had been taking contained testosterone. \"I lost friends, family, colleagues, clients and almost lost my life,\" he said afterwards. Judge Brisco summed it up from the bench: Kawa \"focused on what you wanted to build instead of thinking about the people,\" leaving \"an incredible trail of harm.\"",{"type":23,"tag":43,"props":2110,"children":2112},{"id":2111},"the-warnings-started-in-2020",[2113],{"type":28,"value":2114},"The warnings started in 2020",{"type":23,"tag":24,"props":2116,"children":2117},{},[2118,2120,2125,2127,2132],{"type":28,"value":2119},"What makes the case remarkable is how little of it was a surprise. The FDA had been sending warnings ",{"type":23,"tag":171,"props":2121,"children":2122},{},[2123],{"type":28,"value":2124},"since 2020",{"type":28,"value":2126},". On ",{"type":23,"tag":171,"props":2128,"children":2129},{},[2130],{"type":28,"value":2131},"30 March 2022",{"type":28,"value":2133}," came a formal warning letter: Paradigm was marketing its SARMs and peptides with claims about preventing, treating and curing disease — cancer, diabetes, cardiovascular disease, osteoporosis, Lyme — which made them unapproved new drugs. The letter pointed specifically at the known risks of LGD-4033, Ostarine, GW-501516 and MK-677: life-threatening reactions, liver toxicity, raised risk of heart attack and stroke.",{"type":23,"tag":24,"props":2135,"children":2136},{},[2137],{"type":28,"value":2138},"The shop then ran for another two years. In September 2023 the FDA seized products for testing, which is where the testosterone findings came from. On 20 March 2024 it was over.",{"type":23,"tag":43,"props":2140,"children":2142},{"id":2141},"the-judgment-for-the-record",[2143],{"type":28,"value":2144},"The judgment, for the record",{"type":23,"tag":184,"props":2146,"children":2147},{},[2148,2172,2182,2206,2216],{"type":23,"tag":188,"props":2149,"children":2150},{},[2151,2156,2158,2163,2165,2170],{"type":23,"tag":171,"props":2152,"children":2153},{},[2154],{"type":28,"value":2155},"Case:",{"type":28,"value":2157}," ",{"type":23,"tag":35,"props":2159,"children":2160},{},[2161],{"type":28,"value":2162},"United States of America v. Kawa et al.",{"type":28,"value":2164},", No. ",{"type":23,"tag":171,"props":2166,"children":2167},{},[2168],{"type":28,"value":2169},"3:25-cr-00091",{"type":28,"value":2171},", U.S. District Court, Northern District of Indiana, South Bend Division",{"type":23,"tag":188,"props":2173,"children":2174},{},[2175,2180],{"type":23,"tag":171,"props":2176,"children":2177},{},[2178],{"type":28,"value":2179},"Counts:",{"type":28,"value":2181}," introducing unapproved new drugs into interstate commerce with intent to defraud and mislead (21 U.S.C. §§ 331(d), 333(a)(2)); plus, for Kawa, fraudulent importation (18 U.S.C. § 545)",{"type":23,"tag":188,"props":2183,"children":2184},{},[2185,2190,2192,2197,2199,2204],{"type":23,"tag":171,"props":2186,"children":2187},{},[2188],{"type":28,"value":2189},"Guilty plea:",{"type":28,"value":2191}," 10 December 2025 · ",{"type":23,"tag":171,"props":2193,"children":2194},{},[2195],{"type":28,"value":2196},"Sentencing:",{"type":28,"value":2198}," 30 July 2026 · ",{"type":23,"tag":171,"props":2200,"children":2201},{},[2202],{"type":28,"value":2203},"Judge:",{"type":28,"value":2205}," Cristal C. Brisco",{"type":23,"tag":188,"props":2207,"children":2208},{},[2209,2214],{"type":23,"tag":171,"props":2210,"children":2211},{},[2212],{"type":28,"value":2213},"Sentences:",{"type":28,"value":2215}," Kawa 70 months plus 1 year supervised release; Stechkober 16 months plus 1 year; $5m forfeiture, $78,317.52 restitution",{"type":23,"tag":188,"props":2217,"children":2218},{},[2219,2224],{"type":23,"tag":171,"props":2220,"children":2221},{},[2222],{"type":28,"value":2223},"Investigated by:",{"type":28,"value":2225}," FDA Office of Criminal Investigations and the U.S. Postal Inspection Service",{"type":23,"tag":43,"props":2227,"children":2229},{"id":2228},"how-to-read-a-coa",[2230],{"type":28,"value":2231},"How to read a COA",{"type":23,"tag":24,"props":2233,"children":2234},{},[2235],{"type":28,"value":2236},"A certificate of analysis is a snapshot of one batch — no more than that, but no less either. What it is worth comes down to a handful of checkable things:",{"type":23,"tag":2238,"props":2239,"children":2240},"ol",{},[2241,2251,2261,2271,2281,2291],{"type":23,"tag":188,"props":2242,"children":2243},{},[2244,2249],{"type":23,"tag":171,"props":2245,"children":2246},{},[2247],{"type":28,"value":2248},"Who issued it?",{"type":28,"value":2250}," An independent lab with a name, an address and a way to reach it. A PDF with no traceable sender is a picture, not evidence.",{"type":23,"tag":188,"props":2252,"children":2253},{},[2254,2259],{"type":23,"tag":171,"props":2255,"children":2256},{},[2257],{"type":28,"value":2258},"Is there a batch number — and does it match the one on your vial?",{"type":28,"value":2260}," Without that link, the certificate belongs to some batch, just not necessarily yours.",{"type":23,"tag":188,"props":2262,"children":2263},{},[2264,2269],{"type":23,"tag":171,"props":2265,"children":2266},{},[2267],{"type":28,"value":2268},"Does the date fit the batch?",{"type":28,"value":2270}," A two-year-old COA for a product that shipped last week makes no sense.",{"type":23,"tag":188,"props":2272,"children":2273},{},[2274,2279],{"type":23,"tag":171,"props":2275,"children":2276},{},[2277],{"type":28,"value":2278},"Which method?",{"type":28,"value":2280}," HPLC answers \"how pure\"; mass spectrometry answers \"which molecule\". That gap is exactly where Paradigm lived: a clean purity number says nothing about whether the vial holds what the label claims.",{"type":23,"tag":188,"props":2282,"children":2283},{},[2284,2289],{"type":23,"tag":171,"props":2285,"children":2286},{},[2287],{"type":28,"value":2288},"Can the lab confirm it?",{"type":28,"value":2290}," Reputable testing labs will answer a question about a report number. That single step would have exposed the forgeries.",{"type":23,"tag":188,"props":2292,"children":2293},{},[2294,2299],{"type":23,"tag":171,"props":2295,"children":2296},{},[2297],{"type":28,"value":2298},"Red flags:",{"type":28,"value":2300}," identical purity figures across an entire catalogue, missing batch numbers, watermarks that do not match the named lab, and certificates delivered as screenshots rather than PDFs.",{"type":23,"tag":24,"props":2302,"children":2303},{},[2304,2306,2311,2313,2318],{"type":28,"value":2305},"And the phrase that proved worthless in court: ",{"type":23,"tag":171,"props":2307,"children":2308},{},[2309],{"type":28,"value":2310},"\"for research use only\"",{"type":28,"value":2312}," protects nobody — not the vendor from prosecution, not you from the contents. For the legal picture, see our overview of ",{"type":23,"tag":292,"props":2314,"children":2315},{"href":1626},[2316],{"type":28,"value":2317},"whether peptides are legal",{"type":28,"value":299},{"type":23,"tag":43,"props":2320,"children":2322},{"id":2321},"the-irony-at-the-end",[2323],{"type":28,"value":2324},"The irony at the end",{"type":23,"tag":24,"props":2326,"children":2327},{},[2328,2330,2335,2337,2343],{"type":28,"value":2329},"Among the unapproved drugs listed in Kawa's charging document is ",{"type":23,"tag":171,"props":2331,"children":2332},{},[2333],{"type":28,"value":2334},"BPC-157",{"type":28,"value":2336},". One week before he was sentenced, an FDA advisory committee recommended releasing that very peptide for pharmacy compounding — against the advice of the agency's own scientists. We covered that vote ",{"type":23,"tag":292,"props":2338,"children":2340},{"href":2339},"\u002Fblog\u002Ffda-peptides-503a-vote",[2341],{"type":28,"value":2342},"here",{"type":28,"value":299},{"type":23,"tag":24,"props":2345,"children":2346},{},[2347],{"type":28,"value":2348},"Same molecule, two worlds. In one, people argue about formulation standards, purity requirements and oversight. In the other, a repainted PDF gets emailed out. The difference between them is not chemistry. It is whether anyone is accountable in a way you can check.",{"type":23,"tag":43,"props":2350,"children":2351},{"id":485},[2352],{"type":28,"value":488},{"type":23,"tag":184,"props":2354,"children":2355},{},[2356,2368,2380,2392,2404,2416],{"type":23,"tag":188,"props":2357,"children":2358},{},[2359,2361],{"type":28,"value":2360},"U.S. Attorney's Office, Northern District of Indiana, 30 July 2026, ",{"type":23,"tag":292,"props":2362,"children":2365},{"href":2363,"rel":2364},"https:\u002F\u002Fwww.justice.gov\u002Fusao-ndin\u002Fpr\u002Fillinois-man-and-indiana-woman-sentenced-respectively-70-months-and-16-months-prison",[501],[2366],{"type":28,"value":2367},"Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce",{"type":23,"tag":188,"props":2369,"children":2370},{},[2371,2373],{"type":28,"value":2372},"U.S. Attorney's Office, Northern District of Indiana, ",{"type":23,"tag":292,"props":2374,"children":2377},{"href":2375,"rel":2376},"https:\u002F\u002Fwww.justice.gov\u002Fusao-ndin\u002Funited-states-v-matthew-kawa",[501],[2378],{"type":28,"value":2379},"United States v. Matthew Kawa — victim information",{"type":23,"tag":188,"props":2381,"children":2382},{},[2383,2385,2390],{"type":28,"value":2384},"Information (charging document), ",{"type":23,"tag":35,"props":2386,"children":2387},{},[2388],{"type":28,"value":2389},"United States v. Kawa et al.",{"type":28,"value":2391},", No. 3:25-cr-00091 (N.D. Ind.)",{"type":23,"tag":188,"props":2393,"children":2394},{},[2395,2397],{"type":28,"value":2396},"CBS News, 30 July 2026, ",{"type":23,"tag":292,"props":2398,"children":2401},{"href":2399,"rel":2400},"https:\u002F\u002Fwww.cbsnews.com\u002Fnews\u002Fpeptides-seller-prison-sentence-unapproved-drugs\u002F",[501],[2402],{"type":28,"value":2403},"Judge sentences peptide vendor to nearly 6 years in prison for \"an incredible trail of harm\"",{"type":23,"tag":188,"props":2405,"children":2406},{},[2407,2409],{"type":28,"value":2408},"BBC News, 31 July 2026, ",{"type":23,"tag":292,"props":2410,"children":2413},{"href":2411,"rel":2412},"https:\u002F\u002Fwww.bbc.co.uk\u002Fnews\u002Farticles\u002Fc4gd82vvvdno",[501],[2414],{"type":28,"value":2415},"He bought a fitness supplement online to bulk up, but ended up losing his mind",{"type":23,"tag":188,"props":2417,"children":2418},{},[2419,2421],{"type":28,"value":2420},"The Times of Northwest Indiana, 31 July 2026, ",{"type":23,"tag":292,"props":2422,"children":2425},{"href":2423,"rel":2424},"https:\u002F\u002Fnwitimes.com\u002Fnews\u002Flocal\u002Flaporte\u002Fmichigan-city\u002Farticle_7fc64142-b21b-4974-a410-bd572f84b84a.html",[501],[2426],{"type":28,"value":2427},"Michigan City woman, Illinois man sentenced for fraud",{"title":8,"searchDepth":578,"depth":578,"links":2429},[2430,2431,2432,2433,2434,2435,2436,2437,2438],{"id":1924,"depth":578,"text":1927},{"id":1989,"depth":578,"text":1992},{"id":2040,"depth":578,"text":2043},{"id":2089,"depth":578,"text":2092},{"id":2111,"depth":578,"text":2114},{"id":2141,"depth":578,"text":2144},{"id":2228,"depth":578,"text":2231},{"id":2321,"depth":578,"text":2324},{"id":485,"depth":578,"text":488},"content:blog:en:paradigm-peptides-coa-fraud-sentence.md","blog\u002Fen\u002Fparadigm-peptides-coa-fraud-sentence.md","blog\u002Fen\u002Fparadigm-peptides-coa-fraud-sentence",{"_path":2443,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":2444,"description":2445,"cat":11,"icon":600,"accent":2446,"date":2447,"dateLabel":2448,"read":2449,"author":17,"image":2450,"body":2451,"_type":590,"_id":3340,"_source":592,"_file":3341,"_stem":3342,"_extension":595},"\u002Fblog\u002Fen\u002Fenicepatide-ct-388-roche","Enicepatide (Roche's CT-388): what it is, and how it compares to semaglutide, tirzepatide, retatrutide and the amylins","This is general educational information, not medical advice and not a suggestion to obtain or use any substance. Enicepatide is an investigational drug that is not approved anywhere and cannot be legally bought or prescribed. Nothing here is dosing, stacking or purchasing guidance, and cross-trial numbers below come from separate studies — they are not head-to-head comparisons.","#6D5FC7","2026-07-24","July 2026","11 min","\u002Fassets\u002Fenicepatide_hero.png",{"type":20,"children":2452,"toc":3331},[2453,2457,2476,2482,2501,2526,2569,2574,2580,2599,2652,2664,2683,2689,2700,2916,2921,3003,3015,3021,3026,3035,3067,3072,3158,3170,3174,3198,3221,3225,3244,3248],{"type":23,"tag":24,"props":2454,"children":2455},{},[2456],{"type":28,"value":2445},{"type":23,"tag":24,"props":2458,"children":2459},{},[2460,2462,2467,2469,2474],{"type":28,"value":2461},"If you follow the obesity-drug pipeline, a new name showed up at the American Diabetes Association's 2026 meeting in New Orleans and refused to leave the headlines: ",{"type":23,"tag":171,"props":2463,"children":2464},{},[2465],{"type":28,"value":2466},"enicepatide",{"type":28,"value":2468},". It is Roche's, it is injectable, once a week, and in its Phase 2 trial it produced roughly ",{"type":23,"tag":171,"props":2470,"children":2471},{},[2472],{"type":28,"value":2473},"22.5% weight loss at 48 weeks",{"type":28,"value":2475}," — the kind of number that only tirzepatide and retatrutide had reached before. This article is the plain-language version: what enicepatide is, where it sits next to semaglutide, tirzepatide, retatrutide, cagrilintide and eloralintide, how far along the research actually is, and whether it makes any sense to combine it with anything — the CagriSema question, and the biohacking-forum \"reta + cagri\" question.",{"type":23,"tag":43,"props":2477,"children":2479},{"id":2478},"what-enicepatide-actually-is",[2480],{"type":28,"value":2481},"What enicepatide actually is",{"type":23,"tag":24,"props":2483,"children":2484},{},[2485,2487,2492,2494,2499],{"type":28,"value":2486},"Enicepatide is the newer name for a molecule you may already know by its code: ",{"type":23,"tag":171,"props":2488,"children":2489},{},[2490],{"type":28,"value":2491},"CT-388",{"type":28,"value":2493}," (also written RO7795068). It came to Roche through the December 2023 acquisition of ",{"type":23,"tag":171,"props":2495,"children":2496},{},[2497],{"type":28,"value":2498},"Carmot Therapeutics",{"type":28,"value":2500}," for about $2.7 billion, and Roche\u002FGenentech has been pushing it hard ever since.",{"type":23,"tag":24,"props":2502,"children":2503},{},[2504,2506,2511,2513,2517,2519,2524],{"type":28,"value":2505},"Mechanically, it is a ",{"type":23,"tag":171,"props":2507,"children":2508},{},[2509],{"type":28,"value":2510},"once-weekly subcutaneous dual GLP-1\u002FGIP receptor agonist",{"type":28,"value":2512}," — one molecule that switches on two of the gut hormone receptors involved in appetite and blood sugar. That much it shares with ",{"type":23,"tag":292,"props":2514,"children":2515},{"href":909},[2516],{"type":28,"value":912},{"type":28,"value":2518},". What sets it apart is ",{"type":23,"tag":35,"props":2520,"children":2521},{},[2522],{"type":28,"value":2523},"how",{"type":28,"value":2525}," it hits those receptors:",{"type":23,"tag":184,"props":2527,"children":2528},{},[2529,2546],{"type":23,"tag":188,"props":2530,"children":2531},{},[2532,2537,2539,2544],{"type":23,"tag":171,"props":2533,"children":2534},{},[2535],{"type":28,"value":2536},"Balanced, not lopsided.",{"type":28,"value":2538}," Tirzepatide leans much harder on the GIP receptor than on GLP-1. Enicepatide is engineered for roughly ",{"type":23,"tag":35,"props":2540,"children":2541},{},[2542],{"type":28,"value":2543},"equal",{"type":28,"value":2545}," activation of both — a genuinely different pharmacological profile, not just a stronger version of the same thing.",{"type":23,"tag":188,"props":2547,"children":2548},{},[2549,2554,2556,2561,2563,2568],{"type":23,"tag":171,"props":2550,"children":2551},{},[2552],{"type":28,"value":2553},"Signalling-biased.",{"type":28,"value":2555}," This is the technical headline. Enicepatide is designed to trigger the useful \"cAMP\" signal inside the cell while recruiting very little ",{"type":23,"tag":171,"props":2557,"children":2558},{},[2559],{"type":28,"value":2560},"β-arrestin",{"type":28,"value":2562}," — the protein that normally pulls a receptor back inside the cell and switches it off. Less of that internalisation means the receptor stays responsive longer, which is the mechanistic reason Roche gives for the drug's durable effect and the fact that weight loss had ",{"type":23,"tag":171,"props":2564,"children":2565},{},[2566],{"type":28,"value":2567},"not plateaued at 48 weeks",{"type":28,"value":299},{"type":23,"tag":24,"props":2570,"children":2571},{},[2572],{"type":28,"value":2573},"You do not need the biochemistry to use the takeaway: enicepatide is a refined dual agonist that tries to stay effective for longer per dose, rather than a brand-new class of drug.",{"type":23,"tag":43,"props":2575,"children":2577},{"id":2576},"the-phase-2-numbers",[2578],{"type":28,"value":2579},"The Phase 2 numbers",{"type":23,"tag":24,"props":2581,"children":2582},{},[2583,2585,2590,2592,2597],{"type":28,"value":2584},"The data everyone reacted to came from a Phase 2 study (CT388-103) in ",{"type":23,"tag":171,"props":2586,"children":2587},{},[2588],{"type":28,"value":2589},"469 adults",{"type":28,"value":2591}," with overweight or obesity, testing five doses from ",{"type":23,"tag":171,"props":2593,"children":2594},{},[2595],{"type":28,"value":2596},"4 mg to 24 mg",{"type":28,"value":2598}," against placebo over 48 weeks. It showed a clean dose-response curve, and at the top dose:",{"type":23,"tag":184,"props":2600,"children":2601},{},[2602,2619],{"type":23,"tag":188,"props":2603,"children":2604},{},[2605,2610,2612,2617],{"type":23,"tag":171,"props":2606,"children":2607},{},[2608],{"type":28,"value":2609},"~22.5% placebo-adjusted weight loss at 48 weeks",{"type":28,"value":2611}," (efficacy estimand), with ",{"type":23,"tag":171,"props":2613,"children":2614},{},[2615],{"type":28,"value":2616},"no plateau",{"type":28,"value":2618}," yet — the curve was still heading down when the trial window closed.",{"type":23,"tag":188,"props":2620,"children":2621},{},[2622,2624,2629,2631,2636,2638,2643,2645,2650],{"type":28,"value":2623},"Among people on the 24 mg dose at week 48, ",{"type":23,"tag":171,"props":2625,"children":2626},{},[2627],{"type":28,"value":2628},"95.7%",{"type":28,"value":2630}," lost at least 5% of their body weight, ",{"type":23,"tag":171,"props":2632,"children":2633},{},[2634],{"type":28,"value":2635},"87%",{"type":28,"value":2637}," lost ≥10%, ",{"type":23,"tag":171,"props":2639,"children":2640},{},[2641],{"type":28,"value":2642},"47.8%",{"type":28,"value":2644}," lost ≥20%, and ",{"type":23,"tag":171,"props":2646,"children":2647},{},[2648],{"type":28,"value":2649},"26.1%",{"type":28,"value":2651}," lost ≥30%.",{"type":23,"tag":24,"props":2653,"children":2654},{},[2655,2657,2662],{"type":28,"value":2656},"It was not free of side effects. As with every drug in this class, the trouble is mostly gastrointestinal — nausea, vomiting, diarrhoea — and ",{"type":23,"tag":171,"props":2658,"children":2659},{},[2660],{"type":28,"value":2661},"discontinuations due to adverse events were 5.9%",{"type":28,"value":2663},", versus 1.3% on placebo. That is a real number, but it sits in a normal range for potent incretin drugs.",{"type":23,"tag":24,"props":2665,"children":2666},{},[2667,2669,2674,2676,2681],{"type":28,"value":2668},"On the strength of that, Roche launched its Phase 3 programme, ",{"type":23,"tag":171,"props":2670,"children":2671},{},[2672],{"type":28,"value":2673},"ENITH",{"type":28,"value":2675},", in early 2026, with a realistic launch somewhere around ",{"type":23,"tag":171,"props":2677,"children":2678},{},[2679],{"type":28,"value":2680},"2030",{"type":28,"value":2682},". In other words: the efficacy signal is strong, and the timeline is long.",{"type":23,"tag":43,"props":2684,"children":2686},{"id":2685},"how-it-differs-from-the-drugs-you-already-know",[2687],{"type":28,"value":2688},"How it differs from the drugs you already know",{"type":23,"tag":24,"props":2690,"children":2691},{},[2692,2694,2698],{"type":28,"value":2693},"Here is the landscape, and the single most useful thing to understand is that these molecules are not all doing the same job. Some hit incretin receptors (GLP-1, GIP, glucagon); others mimic ",{"type":23,"tag":171,"props":2695,"children":2696},{},[2697],{"type":28,"value":1194},{"type":28,"value":2699},", a different satiety hormone entirely.",{"type":23,"tag":55,"props":2701,"children":2702},{},[2703,2726],{"type":23,"tag":59,"props":2704,"children":2705},{},[2706],{"type":23,"tag":63,"props":2707,"children":2708},{},[2709,2713,2717,2722],{"type":23,"tag":67,"props":2710,"children":2711},{},[2712],{"type":28,"value":1372},{"type":23,"tag":67,"props":2714,"children":2715},{},[2716],{"type":28,"value":1377},{"type":23,"tag":67,"props":2718,"children":2719},{},[2720],{"type":28,"value":2721},"Peak weight loss in its own trial",{"type":23,"tag":67,"props":2723,"children":2724},{},[2725],{"type":28,"value":772},{"type":23,"tag":78,"props":2727,"children":2728},{},[2729,2762,2795,2825,2854,2886],{"type":23,"tag":63,"props":2730,"children":2731},{},[2732,2740,2752,2757],{"type":23,"tag":85,"props":2733,"children":2734},{},[2735],{"type":23,"tag":171,"props":2736,"children":2737},{},[2738],{"type":28,"value":2739},"Enicepatide (CT-388)",{"type":23,"tag":85,"props":2741,"children":2742},{},[2743,2745,2750],{"type":28,"value":2744},"Balanced, signalling-biased ",{"type":23,"tag":171,"props":2746,"children":2747},{},[2748],{"type":28,"value":2749},"GLP-1\u002FGIP",{"type":28,"value":2751}," dual agonist (Roche)",{"type":23,"tag":85,"props":2753,"children":2754},{},[2755],{"type":28,"value":2756},"~22.5% at 48 wks",{"type":23,"tag":85,"props":2758,"children":2759},{},[2760],{"type":28,"value":2761},"Phase 3 (ENITH)",{"type":23,"tag":63,"props":2763,"children":2764},{},[2765,2773,2785,2790],{"type":23,"tag":85,"props":2766,"children":2767},{},[2768],{"type":23,"tag":171,"props":2769,"children":2770},{},[2771],{"type":28,"value":2772},"Semaglutide",{"type":23,"tag":85,"props":2774,"children":2775},{},[2776,2778,2783],{"type":28,"value":2777},"Pure ",{"type":23,"tag":171,"props":2779,"children":2780},{},[2781],{"type":28,"value":2782},"GLP-1",{"type":28,"value":2784}," agonist (Novo — Wegovy\u002FOzempic)",{"type":23,"tag":85,"props":2786,"children":2787},{},[2788],{"type":28,"value":2789},"~15% at 68 wks",{"type":23,"tag":85,"props":2791,"children":2792},{},[2793],{"type":28,"value":2794},"Approved",{"type":23,"tag":63,"props":2796,"children":2797},{},[2798,2806,2816,2821],{"type":23,"tag":85,"props":2799,"children":2800},{},[2801],{"type":23,"tag":171,"props":2802,"children":2803},{},[2804],{"type":28,"value":2805},"Tirzepatide",{"type":23,"tag":85,"props":2807,"children":2808},{},[2809,2814],{"type":23,"tag":171,"props":2810,"children":2811},{},[2812],{"type":28,"value":2813},"GIP\u002FGLP-1",{"type":28,"value":2815}," dual agonist, GIP-leaning (Lilly — Zepbound\u002FMounjaro)",{"type":23,"tag":85,"props":2817,"children":2818},{},[2819],{"type":28,"value":2820},"~20–25%",{"type":23,"tag":85,"props":2822,"children":2823},{},[2824],{"type":28,"value":2794},{"type":23,"tag":63,"props":2826,"children":2827},{},[2828,2835,2845,2850],{"type":23,"tag":85,"props":2829,"children":2830},{},[2831],{"type":23,"tag":171,"props":2832,"children":2833},{},[2834],{"type":28,"value":1532},{"type":23,"tag":85,"props":2836,"children":2837},{},[2838,2843],{"type":23,"tag":171,"props":2839,"children":2840},{},[2841],{"type":28,"value":2842},"GLP-1\u002FGIP\u002Fglucagon",{"type":28,"value":2844}," triple agonist (Lilly)",{"type":23,"tag":85,"props":2846,"children":2847},{},[2848],{"type":28,"value":2849},"up to ~24%+",{"type":23,"tag":85,"props":2851,"children":2852},{},[2853],{"type":28,"value":1547},{"type":23,"tag":63,"props":2855,"children":2856},{},[2857,2865,2876,2881],{"type":23,"tag":85,"props":2858,"children":2859},{},[2860],{"type":23,"tag":171,"props":2861,"children":2862},{},[2863],{"type":28,"value":2864},"Cagrilintide",{"type":23,"tag":85,"props":2866,"children":2867},{},[2868,2870,2874],{"type":28,"value":2869},"Long-acting ",{"type":23,"tag":171,"props":2871,"children":2872},{},[2873],{"type":28,"value":1194},{"type":28,"value":2875}," analog (Novo)",{"type":23,"tag":85,"props":2877,"children":2878},{},[2879],{"type":28,"value":2880},"modest alone; paired with semaglutide as CagriSema",{"type":23,"tag":85,"props":2882,"children":2883},{},[2884],{"type":28,"value":2885},"Phase 3 (as CagriSema)",{"type":23,"tag":63,"props":2887,"children":2888},{},[2889,2896,2907,2912],{"type":23,"tag":85,"props":2890,"children":2891},{},[2892],{"type":23,"tag":171,"props":2893,"children":2894},{},[2895],{"type":28,"value":1234},{"type":23,"tag":85,"props":2897,"children":2898},{},[2899,2901,2905],{"type":28,"value":2900},"Selective ",{"type":23,"tag":171,"props":2902,"children":2903},{},[2904],{"type":28,"value":1194},{"type":28,"value":2906}," agonist (Lilly)",{"type":23,"tag":85,"props":2908,"children":2909},{},[2910],{"type":28,"value":2911},"~9.5–20.1% at 48 wks",{"type":23,"tag":85,"props":2913,"children":2914},{},[2915],{"type":28,"value":1547},{"type":23,"tag":24,"props":2917,"children":2918},{},[2919],{"type":28,"value":2920},"A few honest words on each, because the table flattens real differences:",{"type":23,"tag":184,"props":2922,"children":2923},{},[2924,2940,2963,2987],{"type":23,"tag":188,"props":2925,"children":2926},{},[2927,2931,2933,2938],{"type":23,"tag":171,"props":2928,"children":2929},{},[2930],{"type":28,"value":2772},{"type":28,"value":2932}," is the one-receptor original. Everything newer is, in some sense, an answer to \"can we beat pure GLP-1?\" Our ",{"type":23,"tag":292,"props":2934,"children":2935},{"href":478},[2936],{"type":28,"value":2937},"semaglutide reference",{"type":28,"value":2939}," has the background.",{"type":23,"tag":188,"props":2941,"children":2942},{},[2943,2947,2949,2954,2956,2961],{"type":23,"tag":171,"props":2944,"children":2945},{},[2946],{"type":28,"value":2805},{"type":28,"value":2948}," was the first to prove two receptors beat one. Enicepatide's pitch is that it engages those same two receptors ",{"type":23,"tag":35,"props":2950,"children":2951},{},[2952],{"type":28,"value":2953},"more evenly and more durably",{"type":28,"value":2955}," — see the ",{"type":23,"tag":292,"props":2957,"children":2958},{"href":909},[2959],{"type":28,"value":2960},"tirzepatide reference",{"type":28,"value":2962}," for the incumbent it is measured against.",{"type":23,"tag":188,"props":2964,"children":2965},{},[2966,2970,2972,2978,2980,2985],{"type":23,"tag":171,"props":2967,"children":2968},{},[2969],{"type":28,"value":1532},{"type":28,"value":2971}," adds a third receptor, glucagon, and currently posts the highest incretin weight-loss numbers of all — we covered its latest Phase 3 read-outs in ",{"type":23,"tag":292,"props":2973,"children":2975},{"href":2974},"\u002Fblog\u002Fretatrutide-triumph-2-3-results",[2976],{"type":28,"value":2977},"Retatrutide TRIUMPH-2 and TRIUMPH-3",{"type":28,"value":2979}," and the full picture lives on our ",{"type":23,"tag":292,"props":2981,"children":2982},{"href":1529},[2983],{"type":28,"value":2984},"retatrutide reference",{"type":28,"value":2986},". Enicepatide is not trying to out-muscle it; it is trying to get similar results from a cleaner two-receptor design.",{"type":23,"tag":188,"props":2988,"children":2989},{},[2990,2995,2997,3001],{"type":23,"tag":171,"props":2991,"children":2992},{},[2993],{"type":28,"value":2994},"Cagrilintide and eloralintide",{"type":28,"value":2996}," are not incretins at all — they are ",{"type":23,"tag":171,"props":2998,"children":2999},{},[3000],{"type":28,"value":1194},{"type":28,"value":3002}," drugs, working through a separate satiety pathway. That distinction is the whole reason the next section exists.",{"type":23,"tag":24,"props":3004,"children":3005},{},[3006,3008,3013],{"type":28,"value":3007},"One caution you should carry through all of this: ",{"type":23,"tag":171,"props":3009,"children":3010},{},[3011],{"type":28,"value":3012},"none of these numbers are head-to-head.",{"type":28,"value":3014}," Different trials, different lengths, different populations. A 22.5% in one study and a 24% in another do not settle which drug is \"stronger\" — only a direct trial can do that, and most of those have not been run.",{"type":23,"tag":43,"props":3016,"children":3018},{"id":3017},"can-you-combine-it-cagrisema-reta-cagri-and-roches-own-answer",[3019],{"type":28,"value":3020},"Can you combine it? CagriSema, \"reta + cagri\", and Roche's own answer",{"type":23,"tag":24,"props":3022,"children":3023},{},[3024],{"type":28,"value":3025},"This is the question that fills forums, and it is worth answering carefully, because the popular framing is a little confused.",{"type":23,"tag":24,"props":3027,"children":3028},{},[3029],{"type":23,"tag":3030,"props":3031,"children":3034},"img",{"alt":3032,"src":3033},"An incretin-style ribbon and a small amylin loop feeding one injection pen — the incretin-plus-amylin combination idea","\u002Fassets\u002Fenicepatide_combo.png",[],{"type":23,"tag":24,"props":3036,"children":3037},{},[3038,3040,3045,3047,3051,3053,3058,3060,3065],{"type":28,"value":3039},"First, the taxonomy. ",{"type":23,"tag":171,"props":3041,"children":3042},{},[3043],{"type":28,"value":3044},"CagriSema is not two GLP-1 drugs",{"type":28,"value":3046}," — it is one GLP-1 drug (semaglutide) plus one ",{"type":23,"tag":171,"props":3048,"children":3049},{},[3050],{"type":28,"value":1194},{"type":28,"value":3052}," drug (cagrilintide) in a single pen, hitting two ",{"type":23,"tag":35,"props":3054,"children":3055},{},[3056],{"type":28,"value":3057},"different",{"type":28,"value":3059}," hormone systems. That is the important pattern: the entire industry is converging on ",{"type":23,"tag":171,"props":3061,"children":3062},{},[3063],{"type":28,"value":3064},"\"incretin + amylin\"",{"type":28,"value":3066}," as the next step, because the two pathways suppress appetite in complementary ways rather than piling onto the same receptor.",{"type":23,"tag":24,"props":3068,"children":3069},{},[3070],{"type":28,"value":3071},"Once you see that, the combination question answers itself:",{"type":23,"tag":184,"props":3073,"children":3074},{},[3075,3097,3134],{"type":23,"tag":188,"props":3076,"children":3077},{},[3078,3083,3085,3089,3091,3095],{"type":23,"tag":171,"props":3079,"children":3080},{},[3081],{"type":28,"value":3082},"Stacking two incretin drugs is mostly pointless.",{"type":28,"value":3084}," Enicepatide already covers GLP-1 and GIP. Adding ",{"type":23,"tag":292,"props":3086,"children":3087},{"href":478},[3088],{"type":28,"value":481},{"type":28,"value":3090}," (more GLP-1) or ",{"type":23,"tag":292,"props":3092,"children":3093},{"href":909},[3094],{"type":28,"value":912},{"type":28,"value":3096}," (more of the same two) does not open a new mechanism — it just doubles the receptor you are already hitting, which tends to add side effects without adding much benefit. That is why no serious programme develops \"GLP-1 plus another GLP-1.\"",{"type":23,"tag":188,"props":3098,"children":3099},{},[3100,3105,3107,3112,3114,3119,3121,3125,3127,3132],{"type":23,"tag":171,"props":3101,"children":3102},{},[3103],{"type":28,"value":3104},"The rational partner is an amylin.",{"type":28,"value":3106}," And here is the tell: Roche is doing exactly this. Alongside enicepatide it is developing ",{"type":23,"tag":171,"props":3108,"children":3109},{},[3110],{"type":28,"value":3111},"petrelintide",{"type":28,"value":3113},", an amylin analog (~9% weight loss on its own at 42 weeks), and in ",{"type":23,"tag":171,"props":3115,"children":3116},{},[3117],{"type":28,"value":3118},"mid-2026 it started a Phase 2 trial of the two combined",{"type":28,"value":3120}," — a fixed-dose enicepatide + petrelintide, explicitly to chase more weight loss with better tolerability. Novo's version of that idea is ",{"type":23,"tag":171,"props":3122,"children":3123},{},[3124],{"type":28,"value":1203},{"type":28,"value":3126},"; Lilly's is ",{"type":23,"tag":171,"props":3128,"children":3129},{},[3130],{"type":28,"value":3131},"tirzepatide + eloralintide",{"type":28,"value":3133},". Roche's is enicepatide + petrelintide. Same recipe, three kitchens.",{"type":23,"tag":188,"props":3135,"children":3136},{},[3137,3142,3144,3149,3151,3156],{"type":23,"tag":171,"props":3138,"children":3139},{},[3140],{"type":28,"value":3141},"The biohacking \"reta + cagri\" stack",{"type":28,"value":3143}," — ",{"type":23,"tag":292,"props":3145,"children":3146},{"href":1529},[3147],{"type":28,"value":3148},"retatrutide",{"type":28,"value":3150}," plus cagrilintide — is the grey-market echo of the same logic: a triple incretin plus an amylin. Mechanistically it rhymes with what the companies are testing. Practically, it is a different animal: there is ",{"type":23,"tag":171,"props":3152,"children":3153},{},[3154],{"type":28,"value":3155},"no controlled human safety data for the do-it-yourself version",{"type":28,"value":3157},", the side effects (nausea, vomiting, dehydration, and the discontinuations that go with them) stack too, and every vial in that scenario is unregulated material of unverified identity and purity. The fact that a combination makes pharmacological sense in a sponsored trial does not make a self-mixed version safe, dosed correctly, or legal.",{"type":23,"tag":24,"props":3159,"children":3160},{},[3161,3163,3168],{"type":28,"value":3162},"So: can you combine enicepatide? On paper, the sensible combination is enicepatide ",{"type":23,"tag":171,"props":3164,"children":3165},{},[3166],{"type":28,"value":3167},"with an amylin",{"type":28,"value":3169},", not with another GLP-1 — and that combination is being built by Roche itself, under clinical supervision, years before anyone can buy either piece.",{"type":23,"tag":43,"props":3171,"children":3172},{"id":1662},[3173],{"type":28,"value":1665},{"type":23,"tag":24,"props":3175,"children":3176},{},[3177,3179,3184,3186,3190,3192,3196],{"type":28,"value":3178},"Be clear-eyed about the timeline. Enicepatide is ",{"type":23,"tag":171,"props":3180,"children":3181},{},[3182],{"type":28,"value":3183},"investigational",{"type":28,"value":3185},". It is not approved anywhere, you cannot get a prescription for it, and the Phase 3 programme points to a possible launch around 2030. Anything sold online right now as \"enicepatide\" or \"CT-388\" is, by definition, unapproved grey-market material of unknown identity and purity — a committee slide deck and a clinical trial do not vouch for a vial a stranger mailed you. If you want the wider legal picture, our pillar on ",{"type":23,"tag":292,"props":3187,"children":3188},{"href":1626},[3189],{"type":28,"value":2317},{"type":28,"value":3191}," walks through the categories, and ",{"type":23,"tag":292,"props":3193,"children":3194},{"href":470},[3195],{"type":28,"value":473},{"type":28,"value":3197}," is the ground-up primer.",{"type":23,"tag":24,"props":3199,"children":3200},{},[3201,3203,3207,3209,3213,3215,3219],{"type":28,"value":3202},"For the drugs people actually do track today, the neutral part is the arithmetic. If you keep a record of what you have, at what concentration, and when, ",{"type":23,"tag":292,"props":3204,"children":3205},{"href":1673},[3206],{"type":28,"value":1676},{"type":28,"value":3208}," is built for exactly that; if reconstitution is the shaky step, ",{"type":23,"tag":292,"props":3210,"children":3211},{"href":1681},[3212],{"type":28,"value":1684},{"type":28,"value":3214}," turns a target dose into the units on the syringe once you know the vial strength and the bacteriostatic water you added; and because these are weekly injections whose levels rise and fall between shots, ",{"type":23,"tag":292,"props":3216,"children":3217},{"href":1689},[3218],{"type":28,"value":1692},{"type":28,"value":3220}," draws that curve. None of that is a recommendation to use anything — it is the maths, kept honest.",{"type":23,"tag":43,"props":3222,"children":3223},{"id":441},[3224],{"type":28,"value":444},{"type":23,"tag":24,"props":3226,"children":3227},{},[3228,3230,3235,3237,3242],{"type":28,"value":3229},"Enicepatide (CT-388) is Roche's balanced, signalling-biased GLP-1\u002FGIP agonist, and its ~22.5% Phase 2 weight loss earns it a real seat at the table next to tirzepatide and retatrutide — with a cleaner two-receptor design and a longer runway to market. The combination story is the more interesting one: the field has moved on to ",{"type":23,"tag":171,"props":3231,"children":3232},{},[3233],{"type":28,"value":3234},"incretin + amylin",{"type":28,"value":3236},", and Roche's own answer is enicepatide ",{"type":23,"tag":171,"props":3238,"children":3239},{},[3240],{"type":28,"value":3241},"plus petrelintide",{"type":28,"value":3243},", not enicepatide plus another GLP-1. Stacking two incretins is redundant; the DIY \"reta + cagri\" version borrows the right idea and none of the safety data. For now, enicepatide is a drug to watch, not a drug to get — because you can't, and the version a forum sells you is not the version that produced these numbers.",{"type":23,"tag":43,"props":3245,"children":3246},{"id":485},[3247],{"type":28,"value":488},{"type":23,"tag":184,"props":3249,"children":3250},{},[3251,3262,3273,3283,3295,3307,3319],{"type":23,"tag":188,"props":3252,"children":3253},{},[3254,3255],{"type":28,"value":1820},{"type":23,"tag":292,"props":3256,"children":3259},{"href":3257,"rel":3258},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-01-27",[501],[3260],{"type":28,"value":3261},"Positive Phase II results for its dual GLP-1\u002FGIP receptor agonist CT-388 (enicepatide)",{"type":23,"tag":188,"props":3263,"children":3264},{},[3265,3266],{"type":28,"value":1820},{"type":23,"tag":292,"props":3267,"children":3270},{"href":3268,"rel":3269},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-06-01",[501],[3271],{"type":28,"value":3272},"New data advancing its obesity portfolio at the ADA 2026 Scientific Sessions",{"type":23,"tag":188,"props":3274,"children":3275},{},[3276,3277],{"type":28,"value":1820},{"type":23,"tag":292,"props":3278,"children":3280},{"href":1823,"rel":3279},[501],[3281],{"type":28,"value":3282},"Positive Phase II results for petrelintide, an amylin analog",{"type":23,"tag":188,"props":3284,"children":3285},{},[3286,3288],{"type":28,"value":3287},"Medical Dialogues, ",{"type":23,"tag":292,"props":3289,"children":3292},{"href":3290,"rel":3291},"https:\u002F\u002Fmedicaldialogues.in\u002Fnews\u002Findustry\u002Fpharma\u002Froche-obesity-drug-enicepatide-delivers-227-weight-loss-in-mid-stage-trial-challenges-wegovy-zepbound-172251",[501],[3293],{"type":28,"value":3294},"Roche obesity drug enicepatide delivers 22.7% weight loss in mid-stage trial",{"type":23,"tag":188,"props":3296,"children":3297},{},[3298,3300],{"type":28,"value":3299},"PMC \u002F peer-reviewed, ",{"type":23,"tag":292,"props":3301,"children":3304},{"href":3302,"rel":3303},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12771327\u002F",[501],[3305],{"type":28,"value":3306},"Effects of CT-388, a once-weekly signaling-biased dual GLP-1\u002FGIP receptor agonist",{"type":23,"tag":188,"props":3308,"children":3309},{},[3310,3312],{"type":28,"value":3311},"Lilly, ",{"type":23,"tag":292,"props":3313,"children":3316},{"href":3314,"rel":3315},"https:\u002F\u002Flilly.gcs-web.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated",[501],[3317],{"type":28,"value":3318},"Selective amylin agonist eloralintide — Phase 2 results",{"type":23,"tag":188,"props":3320,"children":3321},{},[3322,3324],{"type":28,"value":3323},"HCPLive, ",{"type":23,"tag":292,"props":3325,"children":3328},{"href":3326,"rel":3327},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fcagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial",[501],[3329],{"type":28,"value":3330},"CagriSema achieves 22.7% weight loss in Phase 3 REDEFINE 1",{"title":8,"searchDepth":578,"depth":578,"links":3332},[3333,3334,3335,3336,3337,3338,3339],{"id":2478,"depth":578,"text":2481},{"id":2576,"depth":578,"text":2579},{"id":2685,"depth":578,"text":2688},{"id":3017,"depth":578,"text":3020},{"id":1662,"depth":578,"text":1665},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"content:blog:en:enicepatide-ct-388-roche.md","blog\u002Fen\u002Fenicepatide-ct-388-roche.md","blog\u002Fen\u002Fenicepatide-ct-388-roche",{"_path":3344,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":3345,"description":3346,"cat":3347,"icon":3348,"accent":3349,"date":2447,"dateLabel":2448,"read":3350,"author":17,"image":3351,"body":3352,"_type":590,"_id":3831,"_source":592,"_file":3832,"_stem":3833,"_extension":595},"\u002Fblog\u002Fen\u002Ffda-peptides-503a-vote","The FDA panel voted yes on BPC-157 and TB-500 — here is what that does and does not change","This is general educational information, not medical advice and not a suggestion to obtain or use any substance. It explains a regulatory process. None of the peptides below is an FDA-approved drug, an advisory-committee vote does not make one legal to buy, and nothing here is dosing or purchasing guidance.","Regulation","tabler:building-bank","#3E7BB6","9 min","\u002Fassets\u002Ffda_peptides_hero.png",{"type":20,"children":3353,"toc":3821},[3354,3358,3377,3383,3388,3571,3576,3584,3590,3602,3607,3612,3618,3623,3628,3634,3639,3645,3650,3673,3685,3691,3696,3701,3733,3737,3742,3746],{"type":23,"tag":24,"props":3355,"children":3356},{},[3357],{"type":28,"value":3346},{"type":23,"tag":24,"props":3359,"children":3360},{},[3361,3363,3368,3370,3376],{"type":28,"value":3362},"The short version: on 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend four peptides — BPC-157, KPV, TB-500 and MOTS-c — for the list that would let compounding pharmacies legally prepare them. The votes were narrow, and they went ",{"type":23,"tag":171,"props":3364,"children":3365},{},[3366],{"type":28,"value":3367},"against the FDA's own staff scientists",{"type":28,"value":3369},", who had recommended saying no to all seven under review. That is the headline, and it is genuinely notable. Here is the part the excitement skips: a committee vote is a recommendation, not a decision. It does not approve these peptides, it does not put them on a pharmacy shelf, and it did not change a single line of the law on the day it happened. The FDA still has to decide, and that comes later. If you want the background on why this meeting existed at all, we wrote it up before the vote in ",{"type":23,"tag":292,"props":3371,"children":3373},{"href":3372},"\u002Fblog\u002Ffda-peptide-review-2026",[3374],{"type":28,"value":3375},"the July 2026 FDA hearing explainer",{"type":28,"value":299},{"type":23,"tag":43,"props":3378,"children":3380},{"id":3379},"what-actually-got-decided",[3381],{"type":28,"value":3382},"What actually got decided",{"type":23,"tag":24,"props":3384,"children":3385},{},[3386],{"type":28,"value":3387},"PCAC met over two days at the FDA's Silver Spring headquarters. Day one (23 July) covered BPC-157, KPV, TB-500 and MOTS-c. Day two (24 July) covered Emideltide (DSIP), Semax and Epitalon. Each peptide got its own vote on a single question: is there enough of a case to add it to the Section 503A \"bulk drug substances\" list, the list a pharmacist needs a substance to be on before they can legally compound with it.",{"type":23,"tag":55,"props":3389,"children":3390},{},[3391,3417],{"type":23,"tag":59,"props":3392,"children":3393},{},[3394],{"type":23,"tag":63,"props":3395,"children":3396},{},[3397,3402,3407,3412],{"type":23,"tag":67,"props":3398,"children":3399},{},[3400],{"type":28,"value":3401},"Peptide",{"type":23,"tag":67,"props":3403,"children":3404},{},[3405],{"type":28,"value":3406},"Context the panel weighed",{"type":23,"tag":67,"props":3408,"children":3409},{},[3410],{"type":28,"value":3411},"Committee vote (yes–no–abstain)",{"type":23,"tag":67,"props":3413,"children":3414},{},[3415],{"type":28,"value":3416},"Recommendation",{"type":23,"tag":78,"props":3418,"children":3419},{},[3420,3442,3463,3484,3506,3529,3550],{"type":23,"tag":63,"props":3421,"children":3422},{},[3423,3427,3432,3437],{"type":23,"tag":85,"props":3424,"children":3425},{},[3426],{"type":28,"value":2334},{"type":23,"tag":85,"props":3428,"children":3429},{},[3430],{"type":28,"value":3431},"gut and tissue repair (ulcerative colitis)",{"type":23,"tag":85,"props":3433,"children":3434},{},[3435],{"type":28,"value":3436},"8–6–1",{"type":23,"tag":85,"props":3438,"children":3439},{},[3440],{"type":28,"value":3441},"Add to the list",{"type":23,"tag":63,"props":3443,"children":3444},{},[3445,3450,3455,3459],{"type":23,"tag":85,"props":3446,"children":3447},{},[3448],{"type":28,"value":3449},"KPV",{"type":23,"tag":85,"props":3451,"children":3452},{},[3453],{"type":28,"value":3454},"wound healing, inflammation",{"type":23,"tag":85,"props":3456,"children":3457},{},[3458],{"type":28,"value":3436},{"type":23,"tag":85,"props":3460,"children":3461},{},[3462],{"type":28,"value":3441},{"type":23,"tag":63,"props":3464,"children":3465},{},[3466,3471,3476,3480],{"type":23,"tag":85,"props":3467,"children":3468},{},[3469],{"type":28,"value":3470},"TB-500",{"type":23,"tag":85,"props":3472,"children":3473},{},[3474],{"type":28,"value":3475},"wound and tissue repair",{"type":23,"tag":85,"props":3477,"children":3478},{},[3479],{"type":28,"value":3436},{"type":23,"tag":85,"props":3481,"children":3482},{},[3483],{"type":28,"value":3441},{"type":23,"tag":63,"props":3485,"children":3486},{},[3487,3492,3497,3502],{"type":23,"tag":85,"props":3488,"children":3489},{},[3490],{"type":28,"value":3491},"MOTS-c",{"type":23,"tag":85,"props":3493,"children":3494},{},[3495],{"type":28,"value":3496},"metabolic, weight",{"type":23,"tag":85,"props":3498,"children":3499},{},[3500],{"type":28,"value":3501},"7–5–2",{"type":23,"tag":85,"props":3503,"children":3504},{},[3505],{"type":28,"value":3441},{"type":23,"tag":63,"props":3507,"children":3508},{},[3509,3514,3519,3524],{"type":23,"tag":85,"props":3510,"children":3511},{},[3512],{"type":28,"value":3513},"Emideltide (DSIP)",{"type":23,"tag":85,"props":3515,"children":3516},{},[3517],{"type":28,"value":3518},"sleep",{"type":23,"tag":85,"props":3520,"children":3521},{},[3522],{"type":28,"value":3523},"day two — no final result at press time",{"type":23,"tag":85,"props":3525,"children":3526},{},[3527],{"type":28,"value":3528},"Pending",{"type":23,"tag":63,"props":3530,"children":3531},{},[3532,3537,3542,3546],{"type":23,"tag":85,"props":3533,"children":3534},{},[3535],{"type":28,"value":3536},"Semax",{"type":23,"tag":85,"props":3538,"children":3539},{},[3540],{"type":28,"value":3541},"cognition",{"type":23,"tag":85,"props":3543,"children":3544},{},[3545],{"type":28,"value":3523},{"type":23,"tag":85,"props":3547,"children":3548},{},[3549],{"type":28,"value":3528},{"type":23,"tag":63,"props":3551,"children":3552},{},[3553,3558,3563,3567],{"type":23,"tag":85,"props":3554,"children":3555},{},[3556],{"type":28,"value":3557},"Epitalon",{"type":23,"tag":85,"props":3559,"children":3560},{},[3561],{"type":28,"value":3562},"longevity",{"type":23,"tag":85,"props":3564,"children":3565},{},[3566],{"type":28,"value":3523},{"type":23,"tag":85,"props":3568,"children":3569},{},[3570],{"type":28,"value":3528},{"type":23,"tag":24,"props":3572,"children":3573},{},[3574],{"type":28,"value":3575},"All four day-one peptides cleared, but read the margins: 8 to 6 with an abstention is one vote from a tie. This was not a landslide of confidence — it was a divided room narrowly siding with access. The three day-two peptides were still being heard as this went to press; we will update the table once those results are public rather than guess at them.",{"type":23,"tag":24,"props":3577,"children":3578},{},[3579],{"type":23,"tag":3030,"props":3580,"children":3583},{"alt":3581,"src":3582},"Seven peptide vials beside a review checklist, four of them ticked","\u002Fassets\u002Ffda_peptides_seven.png",[],{"type":23,"tag":43,"props":3585,"children":3587},{"id":3586},"why-the-fdas-own-scientists-said-no",[3588],{"type":28,"value":3589},"Why the FDA's own scientists said no",{"type":23,"tag":24,"props":3591,"children":3592},{},[3593,3595,3600],{"type":28,"value":3594},"This is the detail that makes the story more interesting than \"panel approves peptides.\" The FDA's staff reviewers recommended against ",{"type":23,"tag":171,"props":3596,"children":3597},{},[3598],{"type":28,"value":3599},"all seven",{"type":28,"value":3601},", and their reasoning was not squeamishness. It was evidence.",{"type":23,"tag":24,"props":3603,"children":3604},{},[3605],{"type":28,"value":3606},"Their case, in plain terms: these substances are poorly characterised, and the human data on whether they actually work is thin to non-existent. For BPC-157, reviewers said they could find essentially one small trial abstract — roughly 46 people, and delivered as an enema rather than the injection people actually use. For KPV, they found no human trials at all. The safety data is limited, the immunogenicity risk (the chance the body mounts an immune reaction to an injected peptide) is largely unassessed, and for conditions like ulcerative colitis there are already approved drugs that have cleared this bar. Layer on the compounding-specific worry: compounded products carry higher error rates than manufactured ones, and a 2025 analysis of compounded GLP-1 medicines found more adverse events than their approved counterparts. None of that is a claim the peptides are dangerous — it is a claim the evidence needed to wave them through simply is not there yet.",{"type":23,"tag":24,"props":3608,"children":3609},{},[3610],{"type":28,"value":3611},"One committee member, anaesthesiologist Dr. Elizabeth Rebello of UT MD Anderson, put the dissent bluntly: \"I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science.\" That is the crux of the no vote — not that these peptides are proven harmful, but that popularity is not evidence.",{"type":23,"tag":43,"props":3613,"children":3615},{"id":3614},"the-conflict-of-interest-problem",[3616],{"type":28,"value":3617},"The conflict-of-interest problem",{"type":23,"tag":24,"props":3619,"children":3620},{},[3621],{"type":28,"value":3622},"You cannot read this vote fairly without the part about who was in the room. The panel was overhauled shortly before the meeting: eight of its twelve members were appointed at the end of June 2026, and — according to reporting from STAT and other outlets — all but one of those new appointees have financial ties to businesses that sell or administer peptides. Reported examples include a physician who serves as a medical officer for a men's-health clinic chain that sells peptide injections, a doctor who charges for peptide consultations and promotes BPC-157, and a pharmacist who works at a family compounding pharmacy.",{"type":23,"tag":24,"props":3624,"children":3625},{},[3626],{"type":28,"value":3627},"That is not a minor footnote. When the people voting to widen access to a product are, in several cases, people who stand to profit from that access, the vote deserves the same skepticism you would give any lobbying — which is exactly why the dissent and the FDA staff position matter as counterweights. To its credit, the agency added temporary voting members with academic and clinical-research backgrounds to dilute the concern, but the criticism is real and worth carrying with you when you read the 8–6 margins above. Even members who voted yes framed it in patient-safety terms: Dr. Haleem Mohammed, one of the newer appointees, argued \"as a physician, I have to make sure that I'm keeping patients as safe as possible. That's my mandate, right? Do no harm.\" Reasonable people can hold both of those thoughts — the intent may be genuine and the conflict may still bias the outcome.",{"type":23,"tag":43,"props":3629,"children":3631},{"id":3630},"the-money-moved-before-anything-else-did",[3632],{"type":28,"value":3633},"The money moved before anything else did",{"type":23,"tag":24,"props":3635,"children":3636},{},[3637],{"type":28,"value":3638},"Here is a tell worth noticing. After the BPC-157 vote, shares in Hims & Hers — a telehealth company positioned to benefit from wider compounded-peptide access — rose more than 10%. Nothing about the law had changed. No peptide had been approved. No pharmacy had gained a new right. A committee had merely recommended something to the FDA, and the market repriced a stock by double digits within the day. That gap — between what actually happened (a non-binding recommendation) and how it was received (a green light) — is the whole reason we are writing this soberly. If the market can front-run the story, so can a marketing email aimed at you.",{"type":23,"tag":43,"props":3640,"children":3642},{"id":3641},"what-this-changes-for-patients-and-clinics-and-what-it-does-not",[3643],{"type":28,"value":3644},"What this changes for patients and clinics — and what it does not",{"type":23,"tag":24,"props":3646,"children":3647},{},[3648],{"type":28,"value":3649},"Let us be precise, because this is the part that gets distorted fastest.",{"type":23,"tag":24,"props":3651,"children":3652},{},[3653,3655,3659,3661,3665,3666,3671],{"type":28,"value":3654},"What did ",{"type":23,"tag":171,"props":3656,"children":3657},{},[3658],{"type":28,"value":270},{"type":28,"value":3660}," change on 23 July: the legal status of any of these peptides. BPC-157, TB-500, KPV and MOTS-c are exactly as legal — or not — today as they were the day before the vote. None became an approved drug. None became something a pharmacy may currently compound on the strength of this vote. Anything sold to you right now labelled \"BPC-157\" or \"TB-500,\" whether it is framed as a wellness product or \"for research use only,\" is still unapproved grey-market material of unverified identity and purity. A committee's opinion does not sterilise a vial or verify its contents. For the fuller legal picture, our pillar on ",{"type":23,"tag":292,"props":3662,"children":3663},{"href":1626},[3664],{"type":28,"value":2317},{"type":28,"value":3191},{"type":23,"tag":292,"props":3667,"children":3668},{"href":457},[3669],{"type":28,"value":3670},"FDA-approved peptides",{"type":28,"value":3672}," shows you which peptides genuinely have cleared approval — a very different, and much shorter, list.",{"type":23,"tag":24,"props":3674,"children":3675},{},[3676,3678,3683],{"type":28,"value":3677},"What ",{"type":23,"tag":35,"props":3679,"children":3680},{},[3681],{"type":28,"value":3682},"could",{"type":28,"value":3684}," change, later: if the FDA follows the recommendation, these peptides would get a lawful compounding route. Over time that tends to mean more consistent, pharmacy-grade product prepared under a prescription, and less reason for anyone to touch the grey market. That is the optimistic case, and it is a real one. But it is a future conditional, gated behind a decision the FDA has not made.",{"type":23,"tag":43,"props":3686,"children":3688},{"id":3687},"what-happens-next",[3689],{"type":28,"value":3690},"What happens next",{"type":23,"tag":24,"props":3692,"children":3693},{},[3694],{"type":28,"value":3695},"The committee advises; the FDA rules. The agency now weighs the recommendation and decides whether to open formal rulemaking to add any of these peptides to the 503A list — a process that realistically plays out over many months and can run into 2027. It can accept the recommendation, decline it, or land somewhere in between, peptide by peptide. Day two's votes on Emideltide, Semax and Epitalon will fill in the rest of the picture, and we will update this post with the confirmed tallies once they are public.",{"type":23,"tag":24,"props":3697,"children":3698},{},[3699],{"type":28,"value":3700},"The honest takeaway is not \"peptides are back\" and not \"peptides are banned.\" It is that the ground under a handful of specific peptides genuinely started moving on 23 July — in the direction of eventual legal compounding — while remaining, today, exactly where it was: unapproved, unregulated, and grey-market. Watching that shift is smart. Acting as though it has already finished is not.",{"type":23,"tag":24,"props":3702,"children":3703},{},[3704,3706,3710,3712,3716,3718,3723,3725,3731],{"type":28,"value":3705},"If you already track peptides, keeping a clear record of what you have, at what concentration, and when — something ",{"type":23,"tag":292,"props":3707,"children":3708},{"href":1673},[3709],{"type":28,"value":1676},{"type":28,"value":3711}," is built for — is worth far more than any forum's read on a committee vote. To understand this drug class from the ground up, start with ",{"type":23,"tag":292,"props":3713,"children":3714},{"href":470},[3715],{"type":28,"value":473},{"type":28,"value":3717},"; for the run-up to this meeting, see ",{"type":23,"tag":292,"props":3719,"children":3720},{"href":3372},[3721],{"type":28,"value":3722},"the FDA hearing explainer",{"type":28,"value":3724},"; and for a sister story on reading a big headline soberly, our ",{"type":23,"tag":292,"props":3726,"children":3728},{"href":3727},"\u002Fblog\u002Fretatrutide-triumph-1-results",[3729],{"type":28,"value":3730},"retatrutide TRIUMPH-1 write-up",{"type":28,"value":3732}," covers the same instinct on a different drug.",{"type":23,"tag":43,"props":3734,"children":3735},{"id":441},[3736],{"type":28,"value":444},{"type":23,"tag":24,"props":3738,"children":3739},{},[3740],{"type":28,"value":3741},"An FDA advisory committee narrowly recommended BPC-157, KPV, TB-500 and MOTS-c for compounding, overruling its own staff scientists, amid real questions about who was voting and thin human evidence that any of them work. A recommendation is not an approval, the FDA has not decided, and nothing about buying these peptides became safer or more legal on the day of the vote. Read the result as a signal that the rules may change — not as permission that they already have.",{"type":23,"tag":43,"props":3743,"children":3744},{"id":485},[3745],{"type":28,"value":488},{"type":23,"tag":184,"props":3747,"children":3748},{},[3749,3761,3773,3785,3797,3809],{"type":23,"tag":188,"props":3750,"children":3751},{},[3752,3754],{"type":28,"value":3753},"FDA, ",{"type":23,"tag":292,"props":3755,"children":3758},{"href":3756,"rel":3757},"https:\u002F\u002Fwww.fda.gov\u002Fadvisory-committees\u002Fadvisory-committee-calendar\u002Fjuly-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",[501],[3759],{"type":28,"value":3760},"Meeting of the Pharmacy Compounding Advisory Committee, 23–24 July 2026",{"type":23,"tag":188,"props":3762,"children":3763},{},[3764,3766],{"type":28,"value":3765},"TIME, ",{"type":23,"tag":292,"props":3767,"children":3770},{"href":3768,"rel":3769},"https:\u002F\u002Ftime.com\u002Farticle\u002F2026\u002F07\u002F23\u002Ffda-committee-peptides\u002F",[501],[3771],{"type":28,"value":3772},"An FDA committee just voted in favor of peptides — despite the agency's opposition",{"type":23,"tag":188,"props":3774,"children":3775},{},[3776,3778],{"type":28,"value":3777},"STAT, ",{"type":23,"tag":292,"props":3779,"children":3782},{"href":3780,"rel":3781},"https:\u002F\u002Fwww.statnews.com\u002F2026\u002F07\u002F23\u002Ffda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv\u002F",[501],[3783],{"type":28,"value":3784},"FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr.",{"type":23,"tag":188,"props":3786,"children":3787},{},[3788,3790],{"type":28,"value":3789},"RAPS, ",{"type":23,"tag":292,"props":3791,"children":3794},{"href":3792,"rel":3793},"https:\u002F\u002Fwww.raps.org\u002Fresource\u002Ffda-advisory-committee-backs-two-controversial-peptides.html",[501],[3795],{"type":28,"value":3796},"FDA advisory committee backs two controversial peptides",{"type":23,"tag":188,"props":3798,"children":3799},{},[3800,3802],{"type":28,"value":3801},"BioPharma Dive, ",{"type":23,"tag":292,"props":3803,"children":3806},{"href":3804,"rel":3805},"https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Ffda-peptides-advisory-committee-vote-bpc-kpv-tb-mots\u002F826062\u002F",[501],[3807],{"type":28,"value":3808},"FDA panel endorses broader use of certain peptides",{"type":23,"tag":188,"props":3810,"children":3811},{},[3812,3814],{"type":28,"value":3813},"The Hill, ",{"type":23,"tag":292,"props":3815,"children":3818},{"href":3816,"rel":3817},"https:\u002F\u002Fthehill.com\u002Fhomenews\u002F5987510-fda-committee-votes-peptides\u002F",[501],[3819],{"type":28,"value":3820},"FDA committee votes to add peptides to permitted compounding list despite opposition from agency scientists",{"title":8,"searchDepth":578,"depth":578,"links":3822},[3823,3824,3825,3826,3827,3828,3829,3830],{"id":3379,"depth":578,"text":3382},{"id":3586,"depth":578,"text":3589},{"id":3614,"depth":578,"text":3617},{"id":3630,"depth":578,"text":3633},{"id":3641,"depth":578,"text":3644},{"id":3687,"depth":578,"text":3690},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"content:blog:en:fda-peptides-503a-vote.md","blog\u002Fen\u002Ffda-peptides-503a-vote.md","blog\u002Fen\u002Ffda-peptides-503a-vote",{"_path":3835,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":3836,"description":3837,"cat":11,"icon":3838,"accent":3839,"date":3840,"dateLabel":2448,"read":3841,"author":17,"image":3842,"body":3843,"_type":590,"_id":4156,"_source":592,"_file":4157,"_stem":4158,"_extension":595},"\u002Fblog\u002Fen\u002Fretatrutide-triumph-2-3-results","Retatrutide TRIUMPH-2 and TRIUMPH-3: the phase-3 results in diabetes and heart disease","This is general educational information, not medical advice and not a recommendation to obtain or use anything. Retatrutide is investigational and not approved. The figures below are results a company reported from its own trials, not a promise of any outcome and not dosing guidance.","tabler:chart-line","#4C9F70","2026-07-23","6 min","\u002Fassets\u002Freta_triumph_hero.png",{"type":20,"children":3844,"toc":4147},[3845,3849,3854,3860,3865,3925,3930,3935,3943,3949,3954,3998,4003,4009,4014,4019,4024,4042,4048,4080,4086,4091,4095,4105,4109],{"type":23,"tag":24,"props":3846,"children":3847},{},[3848],{"type":28,"value":3837},{"type":23,"tag":24,"props":3850,"children":3851},{},[3852],{"type":28,"value":3853},"The short version: on 23 July 2026, Eli Lilly announced topline results from two more phase-3 trials of retatrutide, its triple agonist. TRIUMPH-2 was in adults with type 2 diabetes; TRIUMPH-3 was in adults with severe obesity and established cardiovascular disease. Both hit their weight-loss endpoints, and the diabetes trial also improved blood-sugar control. The numbers are strong. The asterisk is the same one we flagged for TRIUMPH-1: this is a company press release, not the full peer-reviewed dataset, retatrutide is still not approved, and anything sold under that name today is unapproved grey-market product.",{"type":23,"tag":43,"props":3855,"children":3857},{"id":3856},"triumph-2-the-type-2-diabetes-numbers",[3858],{"type":28,"value":3859},"TRIUMPH-2: the type-2-diabetes numbers",{"type":23,"tag":24,"props":3861,"children":3862},{},[3863],{"type":28,"value":3864},"TRIUMPH-2 enrolled 1,152 adults who had type 2 diabetes alongside obesity or overweight, and tested three doses of the once-weekly injection over 80 weeks.",{"type":23,"tag":55,"props":3866,"children":3867},{},[3868,3884],{"type":23,"tag":59,"props":3869,"children":3870},{},[3871],{"type":23,"tag":63,"props":3872,"children":3873},{},[3874,3879],{"type":23,"tag":67,"props":3875,"children":3876},{},[3877],{"type":28,"value":3878},"Weekly dose",{"type":23,"tag":67,"props":3880,"children":3881},{},[3882],{"type":28,"value":3883},"Average weight loss, 80 weeks",{"type":23,"tag":78,"props":3885,"children":3886},{},[3887,3900,3912],{"type":23,"tag":63,"props":3888,"children":3889},{},[3890,3895],{"type":23,"tag":85,"props":3891,"children":3892},{},[3893],{"type":28,"value":3894},"4 mg",{"type":23,"tag":85,"props":3896,"children":3897},{},[3898],{"type":28,"value":3899},"~12.7% (about 13.5 kg \u002F 29.8 lb)",{"type":23,"tag":63,"props":3901,"children":3902},{},[3903,3907],{"type":23,"tag":85,"props":3904,"children":3905},{},[3906],{"type":28,"value":1305},{"type":23,"tag":85,"props":3908,"children":3909},{},[3910],{"type":28,"value":3911},"~19.1% (about 20.6 kg \u002F 45.4 lb)",{"type":23,"tag":63,"props":3913,"children":3914},{},[3915,3920],{"type":23,"tag":85,"props":3916,"children":3917},{},[3918],{"type":28,"value":3919},"12 mg",{"type":23,"tag":85,"props":3921,"children":3922},{},[3923],{"type":28,"value":3924},"~20.8% (about 22.5 kg \u002F 49.6 lb)",{"type":23,"tag":24,"props":3926,"children":3927},{},[3928],{"type":28,"value":3929},"On top of the weight loss, A1C, the standard three-month marker of blood-sugar control, fell by up to an average of 1.6 percentage points, against 0.2 for placebo. For a drug being developed in diabetes, that combined effect on weight and glucose is the entire point.",{"type":23,"tag":24,"props":3931,"children":3932},{},[3933],{"type":28,"value":3934},"Retatrutide is a triple agonist: one molecule that acts on the GIP, GLP-1 and glucagon receptors at once. That third target, glucagon, is the reason it is argued to hit harder than the GLP-1 and GLP-1\u002FGIP drugs before it.",{"type":23,"tag":24,"props":3936,"children":3937},{},[3938],{"type":23,"tag":3030,"props":3939,"children":3942},{"alt":3940,"src":3941},"A downward weight-loss chart beside a slimming silhouette","\u002Fassets\u002Freta_triumph_chart.png",[],{"type":23,"tag":43,"props":3944,"children":3946},{"id":3945},"triumph-3-the-harder-population",[3947],{"type":28,"value":3948},"TRIUMPH-3: the harder population",{"type":23,"tag":24,"props":3950,"children":3951},{},[3952],{"type":28,"value":3953},"TRIUMPH-3 tested a tougher group: 1,949 adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, on the two higher doses over 80 weeks.",{"type":23,"tag":55,"props":3955,"children":3956},{},[3957,3971],{"type":23,"tag":59,"props":3958,"children":3959},{},[3960],{"type":23,"tag":63,"props":3961,"children":3962},{},[3963,3967],{"type":23,"tag":67,"props":3964,"children":3965},{},[3966],{"type":28,"value":3878},{"type":23,"tag":67,"props":3968,"children":3969},{},[3970],{"type":28,"value":3883},{"type":23,"tag":78,"props":3972,"children":3973},{},[3974,3986],{"type":23,"tag":63,"props":3975,"children":3976},{},[3977,3981],{"type":23,"tag":85,"props":3978,"children":3979},{},[3980],{"type":28,"value":1305},{"type":23,"tag":85,"props":3982,"children":3983},{},[3984],{"type":28,"value":3985},"~21.6%",{"type":23,"tag":63,"props":3987,"children":3988},{},[3989,3993],{"type":23,"tag":85,"props":3990,"children":3991},{},[3992],{"type":28,"value":3919},{"type":23,"tag":85,"props":3994,"children":3995},{},[3996],{"type":28,"value":3997},"~22.6% (about 25.3 kg \u002F 55.8 lb)",{"type":23,"tag":24,"props":3999,"children":4000},{},[4001],{"type":28,"value":4002},"Lilly also reported improvements in cardiometabolic markers in this group, blood pressure and triglycerides among them, which is exactly the kind of data that carries weight in people who already have heart disease. As with everything here, treat those as topline figures until the full dataset is out.",{"type":23,"tag":43,"props":4004,"children":4006},{"id":4005},"the-asterisk-is-still-there",[4007],{"type":28,"value":4008},"The asterisk is still there",{"type":23,"tag":24,"props":4010,"children":4011},{},[4012],{"type":28,"value":4013},"Three things temper the excitement, and they are the same three we raised for the first trial.",{"type":23,"tag":24,"props":4015,"children":4016},{},[4017],{"type":28,"value":4018},"It is not approved. Topline phase-3 data is a milestone toward a filing, not a finish line. Until a regulator has reviewed the full package, there is no legal, prescribed retatrutide, for diabetes or for weight.",{"type":23,"tag":24,"props":4020,"children":4021},{},[4022],{"type":28,"value":4023},"\"Topline\" is not the full dataset. A press release gives you the best-framed headline numbers. The complete results, the safety detail, and the always-important dropout and adverse-event breakdown come later, at a medical congress and in a journal.",{"type":23,"tag":24,"props":4025,"children":4026},{},[4027,4029,4034,4036,4041],{"type":28,"value":4028},"And most practically: everything circulating right now is grey market. Because the real drug is not approved, what is sold online as \"retatrutide\" is unregulated research-grade material of unknown identity and purity. The trial figures were produced with a known compound, dosed and monitored in a clinical setting. They tell you nothing about the vial someone is selling on a forum. We went through this in detail in our ",{"type":23,"tag":292,"props":4030,"children":4031},{"href":3727},[4032],{"type":28,"value":4033},"TRIUMPH-1 breakdown",{"type":28,"value":4035}," and our ",{"type":23,"tag":292,"props":4037,"children":4038},{"href":294},[4039],{"type":28,"value":4040},"retatrutide liver-damage fact-check",{"type":28,"value":299},{"type":23,"tag":43,"props":4043,"children":4045},{"id":4044},"the-doses-you-will-see-quoted-and-what-they-are-not",[4046],{"type":28,"value":4047},"The doses you will see quoted, and what they are not",{"type":23,"tag":24,"props":4049,"children":4050},{},[4051,4053,4058,4060,4066,4068,4073,4075,4079],{"type":28,"value":4052},"The trial doses, 4 mg, 9 mg and 12 mg once a week, are now all over the coverage, and that is exactly where people start reverse-engineering a \"retatrutide dosage chart\" for grey-market vials. We are not going to hand you one: the doses above are what Lilly gave under clinical supervision, not a protocol for you to copy. What a tool can do is the neutral arithmetic. If you already know a vial's strength and how much bacteriostatic water went in, our ",{"type":23,"tag":292,"props":4054,"children":4055},{"href":1681},[4056],{"type":28,"value":4057},"retatrutide reconstitution calculator",{"type":28,"value":4059}," converts a target dose into the exact units on the syringe; if the mixing step is the fuzzy part, ",{"type":23,"tag":292,"props":4061,"children":4063},{"href":4062},"\u002Fcalculator\u002Fbac-water",[4064],{"type":28,"value":4065},"how much bacteriostatic water to add",{"type":28,"value":4067}," does just that one calculation. Because it is a once-weekly shot, the level in your body rises and falls between injections, and you can see that curve for retatrutide's half-life in the ",{"type":23,"tag":292,"props":4069,"children":4070},{"href":1689},[4071],{"type":28,"value":4072},"half-life plotter",{"type":28,"value":4074},". For the doses as they appear in the published literature, plus the basics of the molecule, see our ",{"type":23,"tag":292,"props":4076,"children":4077},{"href":1529},[4078],{"type":28,"value":2984},{"type":28,"value":299},{"type":23,"tag":43,"props":4081,"children":4083},{"id":4082},"what-comes-next",[4084],{"type":28,"value":4085},"What comes next",{"type":23,"tag":24,"props":4087,"children":4088},{},[4089],{"type":28,"value":4090},"Lilly has said it plans to file retatrutide with the FDA by the first quarter of 2027. That is the step that turns a topline press release into a reviewable application, and until a regulator has actually looked at the full safety and efficacy package, there is no approved, prescribed retatrutide. The complete TRIUMPH-2 and TRIUMPH-3 data will also surface at a medical congress and in a journal, where independent researchers can check the detail a press release leaves out.",{"type":23,"tag":43,"props":4092,"children":4093},{"id":441},[4094],{"type":28,"value":444},{"type":23,"tag":24,"props":4096,"children":4097},{},[4098,4100,4104],{"type":28,"value":4099},"Two more phase-3 wins: up to 20.8% weight loss and a 1.6-point A1C drop in type 2 diabetes, up to 22.6% in people with established heart disease. Retatrutide keeps looking like the strongest incretin drug in development. It is also still unapproved, reported so far only as topline, and impossible to obtain in a regulated form today. Reading the result and reading a purchase page are two very different activities. To understand the drug class from scratch, start with ",{"type":23,"tag":292,"props":4101,"children":4102},{"href":470},[4103],{"type":28,"value":473},{"type":28,"value":299},{"type":23,"tag":43,"props":4106,"children":4107},{"id":485},[4108],{"type":28,"value":488},{"type":23,"tag":184,"props":4110,"children":4111},{},[4112,4124,4136],{"type":23,"tag":188,"props":4113,"children":4114},{},[4115,4117],{"type":28,"value":4116},"Eli Lilly (investor release), 23 July 2026, ",{"type":23,"tag":292,"props":4118,"children":4121},{"href":4119,"rel":4120},"https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-triple-agonist-retatrutide-successful-two-additional",[501],[4122],{"type":28,"value":4123},"Lilly's triple agonist retatrutide successful in two additional phase-3 obesity trials",{"type":23,"tag":188,"props":4125,"children":4126},{},[4127,4129],{"type":28,"value":4128},"PharmExec, ",{"type":23,"tag":292,"props":4130,"children":4133},{"href":4131,"rel":4132},"https:\u002F\u002Fwww.pharmexec.com\u002Fview\u002Fretatrutide-delivers-22-weight-loss-two-phase-iii-trials",[501],[4134],{"type":28,"value":4135},"Retatrutide delivers up to 22.6% weight loss in two new phase-III trials",{"type":23,"tag":188,"props":4137,"children":4138},{},[4139,4140],{"type":28,"value":3323},{"type":23,"tag":292,"props":4141,"children":4144},{"href":4142,"rel":4143},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fretatrutide-meets-phase-3-weight-loss-endpoints-in-2-obesity-trials",[501],[4145],{"type":28,"value":4146},"Retatrutide meets phase-3 weight-loss endpoints in two obesity trials",{"title":8,"searchDepth":578,"depth":578,"links":4148},[4149,4150,4151,4152,4153,4154,4155],{"id":3856,"depth":578,"text":3859},{"id":3945,"depth":578,"text":3948},{"id":4005,"depth":578,"text":4008},{"id":4044,"depth":578,"text":4047},{"id":4082,"depth":578,"text":4085},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"content:blog:en:retatrutide-triumph-2-3-results.md","blog\u002Fen\u002Fretatrutide-triumph-2-3-results.md","blog\u002Fen\u002Fretatrutide-triumph-2-3-results",{"_path":4160,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4161,"description":4162,"cat":3347,"icon":3348,"accent":3349,"date":4163,"dateLabel":2448,"read":3841,"author":17,"image":3351,"body":4164,"_type":590,"_id":4390,"_source":592,"_file":4391,"_stem":4392,"_extension":595},"\u002Fblog\u002Fen\u002Ffda-peptide-review-2026","The July 2026 FDA hearing on BPC-157, TB-500 and five more peptides","This is general educational information, not medical advice and not a suggestion to obtain or use any substance. It explains a regulatory process, nothing more. Several of the substances below are not approved for human use.","2026-07-01",{"type":20,"children":4165,"toc":4382},[4166,4170,4182,4188,4193,4241,4246,4253,4259,4264,4269,4275,4280,4286,4291,4309,4314,4320,4337,4342,4346],{"type":23,"tag":24,"props":4167,"children":4168},{},[4169],{"type":28,"value":4162},{"type":23,"tag":24,"props":4171,"children":4172},{},[4173,4175,4181],{"type":28,"value":4174},"The short version: on 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets to decide what to recommend on seven peptides that a lot of people already talk about, including BPC-157 and TB-500. The question is narrow but consequential: should these go on the Section 503A \"bulk drug substances\" list, which is what lets a compounding pharmacy legally make them for a patient. The committee only advises; the FDA makes the final call. Details are on the ",{"type":23,"tag":292,"props":4176,"children":4178},{"href":3756,"rel":4177},[501],[4179],{"type":28,"value":4180},"FDA's own meeting page",{"type":28,"value":299},{"type":23,"tag":43,"props":4183,"children":4185},{"id":4184},"which-peptides-and-when",[4186],{"type":28,"value":4187},"Which peptides, and when",{"type":23,"tag":24,"props":4189,"children":4190},{},[4191],{"type":28,"value":4192},"The agenda splits over two days.",{"type":23,"tag":55,"props":4194,"children":4195},{},[4196,4212],{"type":23,"tag":59,"props":4197,"children":4198},{},[4199],{"type":23,"tag":63,"props":4200,"children":4201},{},[4202,4207],{"type":23,"tag":67,"props":4203,"children":4204},{},[4205],{"type":28,"value":4206},"Day",{"type":23,"tag":67,"props":4208,"children":4209},{},[4210],{"type":28,"value":4211},"Peptides under review",{"type":23,"tag":78,"props":4213,"children":4214},{},[4215,4228],{"type":23,"tag":63,"props":4216,"children":4217},{},[4218,4223],{"type":23,"tag":85,"props":4219,"children":4220},{},[4221],{"type":28,"value":4222},"23 July 2026",{"type":23,"tag":85,"props":4224,"children":4225},{},[4226],{"type":28,"value":4227},"BPC-157, KPV, TB-500, MOTS-c",{"type":23,"tag":63,"props":4229,"children":4230},{},[4231,4236],{"type":23,"tag":85,"props":4232,"children":4233},{},[4234],{"type":28,"value":4235},"24 July 2026",{"type":23,"tag":85,"props":4237,"children":4238},{},[4239],{"type":28,"value":4240},"Emideltide (DSIP), Semax, Epitalon",{"type":23,"tag":24,"props":4242,"children":4243},{},[4244],{"type":28,"value":4245},"If those names look familiar, it is because they are the backbone of the \"research peptide\" and recovery\u002Flongevity scene. Until now most of them have sat in an awkward legal spot, which is exactly what this meeting is about.",{"type":23,"tag":24,"props":4247,"children":4248},{},[4249],{"type":23,"tag":3030,"props":4250,"children":4252},{"alt":4251,"src":3582},"Seven vials under a magnifier beside a review clipboard",[],{"type":23,"tag":43,"props":4254,"children":4256},{"id":4255},"what-the-503a-list-actually-is",[4257],{"type":28,"value":4258},"What the 503A list actually is",{"type":23,"tag":24,"props":4260,"children":4261},{},[4262],{"type":28,"value":4263},"Compounding pharmacies make customised medicines for individual patients. They cannot compound from just any raw ingredient. For a bulk substance that is not already an approved drug ingredient, it generally has to be on the FDA's 503A bulk list before a pharmacist can legally compound with it. On the list means there is a lawful route to have it made by a licensed pharmacy. Off the list means there is not, and what circulates instead is the grey market, labelled \"for research use only,\" with no such route and no quality guarantee.",{"type":23,"tag":24,"props":4265,"children":4266},{},[4267],{"type":28,"value":4268},"So this is not a debate about whether the peptides work. It is a narrower administrative question: is there enough of a case, on safety and standards, to let regulated pharmacies compound them at all.",{"type":23,"tag":43,"props":4270,"children":4272},{"id":4271},"why-they-were-flagged-in-the-first-place",[4273],{"type":28,"value":4274},"Why they were flagged in the first place",{"type":23,"tag":24,"props":4276,"children":4277},{},[4278],{"type":28,"value":4279},"These seven did not arrive here by accident. They had previously been placed in the FDA's \"Category 2\" bucket, meaning the agency had flagged significant safety questions or insufficient information. Being sent to PCAC is the formal step where that gets aired in public, with data presented and experts voting on a recommendation. It can go either way, and the committee's vote is advice, not the final rule.",{"type":23,"tag":43,"props":4281,"children":4283},{"id":4282},"what-the-outcome-would-change",[4284],{"type":28,"value":4285},"What the outcome would change",{"type":23,"tag":24,"props":4287,"children":4288},{},[4289],{"type":28,"value":4290},"Broadly, three things can happen for any given peptide:",{"type":23,"tag":184,"props":4292,"children":4293},{},[4294,4299,4304],{"type":23,"tag":188,"props":4295,"children":4296},{},[4297],{"type":28,"value":4298},"Recommended onto the list. A legal compounding path opens, which over time tends to mean more consistent, pharmacy-grade product and less reason to touch the grey market.",{"type":23,"tag":188,"props":4300,"children":4301},{},[4302],{"type":28,"value":4303},"Kept off. The status quo holds: no lawful compounding route, and what is sold online stays unapproved and unregulated.",{"type":23,"tag":188,"props":4305,"children":4306},{},[4307],{"type":28,"value":4308},"Deferred for more data. Common when the evidence is thin either way.",{"type":23,"tag":24,"props":4310,"children":4311},{},[4312],{"type":28,"value":4313},"For readers, the practical takeaway is not \"buy now\" or \"avoid\", it is that the legal ground under these specific peptides may shift within weeks, and it is worth watching rather than assuming today's situation is permanent. There is also a political layer this cycle: the committee's makeup and a broader push to loosen access have drawn public debate, which is worth reading with the same skepticism you would give any lobbying.",{"type":23,"tag":43,"props":4315,"children":4317},{"id":4316},"what-to-watch",[4318],{"type":28,"value":4319},"What to watch",{"type":23,"tag":24,"props":4321,"children":4322},{},[4323,4325,4330,4332,4336],{"type":28,"value":4324},"The meeting is 23 to 24 July. Recommendations usually follow quickly; the FDA's actual decision can take longer. We will update this once the votes and any decision are public. If you want the legal backdrop first, see ",{"type":23,"tag":292,"props":4326,"children":4327},{"href":1626},[4328],{"type":28,"value":4329},"are peptides legal",{"type":28,"value":4331},"; for what these compounds are at all, start with ",{"type":23,"tag":292,"props":4333,"children":4334},{"href":470},[4335],{"type":28,"value":473},{"type":28,"value":299},{"type":23,"tag":24,"props":4338,"children":4339},{},[4340],{"type":28,"value":4341},"Whatever the committee decides, nothing about a \"research use only\" label changes what a substance is, and nothing here is a recommendation to use one. This is about the rules, not a green light.",{"type":23,"tag":43,"props":4343,"children":4344},{"id":485},[4345],{"type":28,"value":488},{"type":23,"tag":184,"props":4347,"children":4348},{},[4349,4358,4370],{"type":23,"tag":188,"props":4350,"children":4351},{},[4352,4353],{"type":28,"value":3753},{"type":23,"tag":292,"props":4354,"children":4356},{"href":3756,"rel":4355},[501],[4357],{"type":28,"value":3760},{"type":23,"tag":188,"props":4359,"children":4360},{},[4361,4363],{"type":28,"value":4362},"Drug Topics, ",{"type":23,"tag":292,"props":4364,"children":4367},{"href":4365,"rel":4366},"https:\u002F\u002Fwww.drugtopics.com\u002Fview\u002Ffda-set-to-review-peptide-access-for-compounding-pharmacies",[501],[4368],{"type":28,"value":4369},"FDA set to review peptide access for compounding pharmacies",{"type":23,"tag":188,"props":4371,"children":4372},{},[4373,4375],{"type":28,"value":4374},"Lengea Law, ",{"type":23,"tag":292,"props":4376,"children":4379},{"href":4377,"rel":4378},"https:\u002F\u002Flengealaw.com\u002Ffda-puts-bpc-157-tb-500-and-5-other-peptides-under-the-microscope-what-prescribers-need-to-know-about-the-503a-review\u002F",[501],[4380],{"type":28,"value":4381},"FDA puts BPC-157, TB-500 and five other peptides under the 503A microscope",{"title":8,"searchDepth":578,"depth":578,"links":4383},[4384,4385,4386,4387,4388,4389],{"id":4184,"depth":578,"text":4187},{"id":4255,"depth":578,"text":4258},{"id":4271,"depth":578,"text":4274},{"id":4282,"depth":578,"text":4285},{"id":4316,"depth":578,"text":4319},{"id":485,"depth":578,"text":488},"content:blog:en:fda-peptide-review-2026.md","blog\u002Fen\u002Ffda-peptide-review-2026.md","blog\u002Fen\u002Ffda-peptide-review-2026",{"_path":4394,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4395,"description":4396,"cat":1859,"icon":4397,"accent":1861,"date":4163,"dateLabel":2448,"read":4398,"author":17,"image":4399,"body":4400,"_type":590,"_id":4689,"_source":592,"_file":4690,"_stem":4691,"_extension":595},"\u002Fblog\u002Fen\u002Fglp1-dosing-errors","GLP-1 dosing errors: why poison-control calls are surging","This is general educational information, not medical advice and not dosing guidance. It reports what a study found and where the mistakes cluster, so you can spot the traps. For anything about your own treatment, ask the prescriber and pharmacist who know your case.","tabler:alert-triangle","7 min","\u002Fassets\u002Fglp1_errors_hero.png",{"type":20,"children":4401,"toc":4680},[4402,4406,4420,4426,4431,4436,4444,4450,4549,4554,4560,4565,4570,4576,4603,4608,4614,4619,4623,4638,4642],{"type":23,"tag":24,"props":4403,"children":4404},{},[4405],{"type":28,"value":4396},{"type":23,"tag":24,"props":4407,"children":4408},{},[4409,4411,4418],{"type":28,"value":4410},"The short version: US poison-control centers have seen GLP-1 calls climb about 1,500% since 2019, and a new analysis out of UT San Antonio (covered by ",{"type":23,"tag":292,"props":4412,"children":4415},{"href":4413,"rel":4414},"https:\u002F\u002Fwww.usnews.com\u002Fnews\u002Fhealth-news\u002Farticles\u002F2026-06-25\u002Fglp-1-weight-loss-boom-linked-to-surge-in-poison-control-calls",[501],[4416],{"type":28,"value":4417},"U.S. News\u002FHealthDay, 25 June 2026",{"type":28,"value":4419},") found that roughly 91% of the cases were therapeutic errors, not overdoses in the dramatic sense, just people getting the dose or the timing wrong. Most were mild. But the share serious enough to send someone to a clinic crept up from 23% to about 33% over the study window. Almost all of it was avoidable.",{"type":23,"tag":43,"props":4421,"children":4423},{"id":4422},"what-the-numbers-actually-say",[4424],{"type":28,"value":4425},"What the numbers actually say",{"type":23,"tag":24,"props":4427,"children":4428},{},[4429],{"type":28,"value":4430},"Before semaglutide got its 2021 obesity approval, poison centers logged somewhere around 1,000 to 1,500 GLP-1 cases a year. By 2023 that was north of 8,000. Semaglutide alone accounts for about 64% of the calls, which makes sense: it is the one most people are on.",{"type":23,"tag":24,"props":4432,"children":4433},{},[4434],{"type":28,"value":4435},"The pattern matters more than the raw count. These are not, for the most part, people trying to take too much. They are people who lost track of a schedule or a number. That is a fixable problem, and it is worth understanding exactly where the confusion happens.",{"type":23,"tag":24,"props":4437,"children":4438},{},[4439],{"type":23,"tag":3030,"props":4440,"children":4443},{"alt":4441,"src":4442},"An insulin syringe with unit markings beside a magnifier and a weekly calendar","\u002Fassets\u002Fglp1_errors_units.png",[],{"type":23,"tag":43,"props":4445,"children":4447},{"id":4446},"the-four-mistakes-that-show-up-again-and-again",[4448],{"type":28,"value":4449},"The four mistakes that show up again and again",{"type":23,"tag":55,"props":4451,"children":4452},{},[4453,4474],{"type":23,"tag":59,"props":4454,"children":4455},{},[4456],{"type":23,"tag":63,"props":4457,"children":4458},{},[4459,4464,4469],{"type":23,"tag":67,"props":4460,"children":4461},{},[4462],{"type":28,"value":4463},"Slip-up",{"type":23,"tag":67,"props":4465,"children":4466},{},[4467],{"type":28,"value":4468},"What happened",{"type":23,"tag":67,"props":4470,"children":4471},{},[4472],{"type":28,"value":4473},"Why it happens",{"type":23,"tag":78,"props":4475,"children":4476},{},[4477,4495,4513,4531],{"type":23,"tag":63,"props":4478,"children":4479},{},[4480,4485,4490],{"type":23,"tag":85,"props":4481,"children":4482},{},[4483],{"type":28,"value":4484},"Weekly taken as daily",{"type":23,"tag":85,"props":4486,"children":4487},{},[4488],{"type":28,"value":4489},"A once-weekly dose injected every day",{"type":23,"tag":85,"props":4491,"children":4492},{},[4493],{"type":28,"value":4494},"The habit of \"take your meds daily\" is strong; weekly dosing is unusual",{"type":23,"tag":63,"props":4496,"children":4497},{},[4498,4503,4508],{"type":23,"tag":85,"props":4499,"children":4500},{},[4501],{"type":28,"value":4502},"Straight to the full dose",{"type":23,"tag":85,"props":4504,"children":4505},{},[4506],{"type":28,"value":4507},"Starting high instead of titrating up",{"type":23,"tag":85,"props":4509,"children":4510},{},[4511],{"type":28,"value":4512},"Missing or ignoring the step-up schedule the drug is designed around",{"type":23,"tag":63,"props":4514,"children":4515},{},[4516,4521,4526],{"type":23,"tag":85,"props":4517,"children":4518},{},[4519],{"type":28,"value":4520},"Double dose",{"type":23,"tag":85,"props":4522,"children":4523},{},[4524],{"type":28,"value":4525},"Two doses close together",{"type":23,"tag":85,"props":4527,"children":4528},{},[4529],{"type":28,"value":4530},"Losing track of whether the last one was actually done",{"type":23,"tag":63,"props":4532,"children":4533},{},[4534,4539,4544],{"type":23,"tag":85,"props":4535,"children":4536},{},[4537],{"type":28,"value":4538},"Vial-and-syringe math",{"type":23,"tag":85,"props":4540,"children":4541},{},[4542],{"type":28,"value":4543},"Drawing the wrong number of units from a multi-dose vial",{"type":23,"tag":85,"props":4545,"children":4546},{},[4547],{"type":28,"value":4548},"Converting a milligram dose into syringe units, by hand, under-caffeinated",{"type":23,"tag":24,"props":4550,"children":4551},{},[4552],{"type":28,"value":4553},"The last one is the one this site cares about most, because it is pure arithmetic and pure arithmetic is where a tired person at the kitchen table goes wrong. A pen meters the dose for you. A vial does not: you have to turn \"this many milligrams\" into \"this many units on the barrel,\" and if the concentration in your vial is not what you assumed, the number you draw is off.",{"type":23,"tag":43,"props":4555,"children":4557},{"id":4556},"why-the-vial-crowd-is-exposed",[4558],{"type":28,"value":4559},"Why the vial crowd is exposed",{"type":23,"tag":24,"props":4561,"children":4562},{},[4563],{"type":28,"value":4564},"The surge tracks the rise of telehealth and compounded GLP-1s supplied in multi-dose vials rather than pre-filled pens. A pen is a closed system with a dial; a vial hands you the whole calculation. That is more flexible and often cheaper, and it also removes the guardrail. When the reports talk about \"double doses\" and \"doses taken too close together,\" a lot of that is someone unsure whether last week's draw actually went in, or misreading the barrel.",{"type":23,"tag":24,"props":4566,"children":4567},{},[4568],{"type":28,"value":4569},"None of this means vials are bad. It means the measuring step deserves respect. Two habits do most of the work: keep one clear record of when you last dosed, and check the units-from-milligrams math with something other than your own tired head.",{"type":23,"tag":43,"props":4571,"children":4573},{"id":4572},"keeping-the-math-honest-without-it-being-advice",[4574],{"type":28,"value":4575},"Keeping the math honest (without it being \"advice\")",{"type":23,"tag":24,"props":4577,"children":4578},{},[4579,4581,4586,4588,4594,4596,4602],{"type":28,"value":4580},"We are not going to tell you a number to inject, that is between you and your clinician. What a tool can do is the neutral part: convert the values you already have. If you know the vial strength, the amount of bacteriostatic water you added, and the dose your prescriber set, the ",{"type":23,"tag":292,"props":4582,"children":4583},{"href":1681},[4584],{"type":28,"value":4585},"reconstitution calculator",{"type":28,"value":4587}," turns that into the exact units on the syringe, so the conversion is not happening in your head at 6am. It recommends nothing; it just does the arithmetic you would otherwise do by hand. If the mixing step itself is fuzzy, start with ",{"type":23,"tag":292,"props":4589,"children":4591},{"href":4590},"\u002Freconstitute-peptides",[4592],{"type":28,"value":4593},"how reconstitution works",{"type":28,"value":4595}," and ",{"type":23,"tag":292,"props":4597,"children":4599},{"href":4598},"\u002Fbacteriostatic-vs-sterile-water",[4600],{"type":28,"value":4601},"bacteriostatic vs sterile water",{"type":28,"value":299},{"type":23,"tag":24,"props":4604,"children":4605},{},[4606],{"type":28,"value":4607},"The other half is boring and works: write down the date of each dose. Most double-dose calls trace back to \"I could not remember if I had done it.\" A dated log removes the guess.",{"type":23,"tag":43,"props":4609,"children":4611},{"id":4610},"the-bigger-backdrop",[4612],{"type":28,"value":4613},"The bigger backdrop",{"type":23,"tag":24,"props":4615,"children":4616},{},[4617],{"type":28,"value":4618},"The poison-control jump is not happening in isolation. Medication-error reports to the FDA involving these drugs have risen sharply over the same period, and the common thread is the shift from a clinic-administered injection to self-dosing at home, often from a vial. More people, more self-administration, same human tendency to misread a number. The study authors are blunt that most of these events were preventable with better patient education. That is the whole point of covering it here.",{"type":23,"tag":43,"props":4620,"children":4621},{"id":441},[4622],{"type":28,"value":444},{"type":23,"tag":24,"props":4624,"children":4625},{},[4626,4628,4632,4633,4637],{"type":28,"value":4627},"The scary headline (\"poison-control calls up 1,500%\") describes something fairly undramatic underneath: mostly mild, mostly avoidable, mostly a schedule or a unit-conversion gone sideways. If you are dosing from a vial, the two things that keep you out of that statistic are a dated record of every dose and a reliable way to convert milligrams into units. Neither is medical advice. Both are just refusing to do important arithmetic from memory. For the drug-specific background, see ",{"type":23,"tag":292,"props":4629,"children":4630},{"href":478},[4631],{"type":28,"value":481},{"type":28,"value":4595},{"type":23,"tag":292,"props":4634,"children":4635},{"href":909},[4636],{"type":28,"value":912},{"type":28,"value":299},{"type":23,"tag":43,"props":4639,"children":4640},{"id":485},[4641],{"type":28,"value":488},{"type":23,"tag":184,"props":4643,"children":4644},{},[4645,4656,4668],{"type":23,"tag":188,"props":4646,"children":4647},{},[4648,4650],{"type":28,"value":4649},"U.S. News \u002F HealthDay, 25 Jun 2026, ",{"type":23,"tag":292,"props":4651,"children":4653},{"href":4413,"rel":4652},[501],[4654],{"type":28,"value":4655},"GLP-1 weight-loss boom linked to surge in poison-control calls",{"type":23,"tag":188,"props":4657,"children":4658},{},[4659,4661],{"type":28,"value":4660},"News-Medical, 26 Jun 2026, ",{"type":23,"tag":292,"props":4662,"children":4665},{"href":4663,"rel":4664},"https:\u002F\u002Fwww.news-medical.net\u002Fnews\u002F20260626\u002FSemaglutide-approval-drove-a-surge-in-GLP-1-poison-center-exposures.aspx",[501],[4666],{"type":28,"value":4667},"Semaglutide approval drove a surge in GLP-1 poison-center exposures",{"type":23,"tag":188,"props":4669,"children":4670},{},[4671,4673],{"type":28,"value":4672},"Bioengineer, Jun 2026, ",{"type":23,"tag":292,"props":4674,"children":4677},{"href":4675,"rel":4676},"https:\u002F\u002Fbioengineer.org\u002Ffda-approval-of-semaglutide-for-weight-loss-spurs-surge-in-u-s-poison-control-calls-ut-san-antonio-study-finds\u002F",[501],[4678],{"type":28,"value":4679},"UT San Antonio study on the semaglutide-era poison-control surge",{"title":8,"searchDepth":578,"depth":578,"links":4681},[4682,4683,4684,4685,4686,4687,4688],{"id":4422,"depth":578,"text":4425},{"id":4446,"depth":578,"text":4449},{"id":4556,"depth":578,"text":4559},{"id":4572,"depth":578,"text":4575},{"id":4610,"depth":578,"text":4613},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"content:blog:en:glp1-dosing-errors.md","blog\u002Fen\u002Fglp1-dosing-errors.md","blog\u002Fen\u002Fglp1-dosing-errors",{"_path":4693,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4694,"description":4695,"cat":11,"icon":3838,"accent":3839,"date":4163,"dateLabel":2448,"read":4398,"author":17,"image":3842,"body":4696,"_type":590,"_id":4923,"_source":592,"_file":4924,"_stem":4925,"_extension":595},"\u002Fblog\u002Fen\u002Fretatrutide-triumph-1-results","Retatrutide TRIUMPH-1: the phase-3 numbers, and the asterisk","This is general educational information, not medical advice and not a recommendation to obtain or use anything. Retatrutide is investigational and not approved. The figures below are results a company reported from its own trial, not a promise of any outcome and not dosing guidance.",{"type":20,"children":4697,"toc":4915},[4698,4702,4707,4713,4718,4791,4796,4802,4808,4813,4818,4823,4828,4834,4844,4848,4853,4857,4873,4877],{"type":23,"tag":24,"props":4699,"children":4700},{},[4701],{"type":28,"value":4695},{"type":23,"tag":24,"props":4703,"children":4704},{},[4705],{"type":28,"value":4706},"The short version: on 21 May 2026 Eli Lilly announced topline results from TRIUMPH-1, its first phase-3 obesity trial of retatrutide. The headline was an average 28.3% body-weight reduction on the top 12 mg dose over 80 weeks, and 45.3% of participants lost at least 30% of their weight, a range that used to belong to bariatric surgery. The numbers are real and large. The asterisk: retatrutide is still not approved, this is a company press release rather than the full peer-reviewed dataset, and anything sold under that name today is unapproved grey-market product.",{"type":23,"tag":43,"props":4708,"children":4710},{"id":4709},"the-numbers-lilly-reported",[4711],{"type":28,"value":4712},"The numbers Lilly reported",{"type":23,"tag":24,"props":4714,"children":4715},{},[4716],{"type":28,"value":4717},"TRIUMPH-1 enrolled 2,339 adults with obesity, or overweight with a weight-related condition, and tested three doses of the once-weekly injection over 80 weeks.",{"type":23,"tag":55,"props":4719,"children":4720},{},[4721,4736],{"type":23,"tag":59,"props":4722,"children":4723},{},[4724],{"type":23,"tag":63,"props":4725,"children":4726},{},[4727,4732],{"type":23,"tag":67,"props":4728,"children":4729},{},[4730],{"type":28,"value":4731},"Metric (topline)",{"type":23,"tag":67,"props":4733,"children":4734},{},[4735],{"type":28,"value":76},{"type":23,"tag":78,"props":4737,"children":4738},{},[4739,4752,4765,4778],{"type":23,"tag":63,"props":4740,"children":4741},{},[4742,4747],{"type":23,"tag":85,"props":4743,"children":4744},{},[4745],{"type":28,"value":4746},"Average weight loss, 12 mg, 80 weeks",{"type":23,"tag":85,"props":4748,"children":4749},{},[4750],{"type":28,"value":4751},"~28.3% (about 70 lb)",{"type":23,"tag":63,"props":4753,"children":4754},{},[4755,4760],{"type":23,"tag":85,"props":4756,"children":4757},{},[4758],{"type":28,"value":4759},"Participants losing ≥30% of body weight",{"type":23,"tag":85,"props":4761,"children":4762},{},[4763],{"type":28,"value":4764},"45.3%",{"type":23,"tag":63,"props":4766,"children":4767},{},[4768,4773],{"type":23,"tag":85,"props":4769,"children":4770},{},[4771],{"type":28,"value":4772},"Extension in higher-BMI group, 104 weeks",{"type":23,"tag":85,"props":4774,"children":4775},{},[4776],{"type":28,"value":4777},"up to ~30.3% (about 85 lb)",{"type":23,"tag":63,"props":4779,"children":4780},{},[4781,4786],{"type":23,"tag":85,"props":4782,"children":4783},{},[4784],{"type":28,"value":4785},"Trial size",{"type":23,"tag":85,"props":4787,"children":4788},{},[4789],{"type":28,"value":4790},"2,339 adults",{"type":23,"tag":24,"props":4792,"children":4793},{},[4794],{"type":28,"value":4795},"Retatrutide is a triple agonist: one molecule that acts on the GIP, GLP-1 and glucagon receptors at once. That third target, glucagon, is what people argue makes it hit harder than the GLP-1 and GLP-1\u002FGIP drugs that came before. On these topline figures, it is the most effective obesity drug to report phase-3 data so far.",{"type":23,"tag":24,"props":4797,"children":4798},{},[4799],{"type":23,"tag":3030,"props":4800,"children":4801},{"alt":3940,"src":3941},[],{"type":23,"tag":43,"props":4803,"children":4805},{"id":4804},"the-asterisk-nobody-puts-in-the-headline",[4806],{"type":28,"value":4807},"The asterisk nobody puts in the headline",{"type":23,"tag":24,"props":4809,"children":4810},{},[4811],{"type":28,"value":4812},"Three things temper the excitement, and they are the reason we are covering it soberly.",{"type":23,"tag":24,"props":4814,"children":4815},{},[4816],{"type":28,"value":4817},"First, it is not approved. Topline phase-3 data is a milestone on the way to a filing, not a finish line. Lilly still has to submit its application and the FDA still has to review it, which realistically lands later. Until then there is no legal, prescribed retatrutide for weight loss.",{"type":23,"tag":24,"props":4819,"children":4820},{},[4821],{"type":28,"value":4822},"Second, \"topline\" is not the full dataset. A press release gives you the best-framed headline numbers. The complete results, safety detail, and the always-important dropout and adverse-event breakdown come later, at a medical congress and in a journal. Treat the 28.3% as promising and provisional, not settled.",{"type":23,"tag":24,"props":4824,"children":4825},{},[4826],{"type":28,"value":4827},"Third, and most practically: everything circulating right now is grey market. Because the real drug is not approved, what is sold online as \"retatrutide\" is unregulated research-grade material of unknown identity and purity. The trial figures were produced with a known compound, dosed and monitored in a clinical setting. They tell you nothing about the vial someone is selling on a forum.",{"type":23,"tag":43,"props":4829,"children":4831},{"id":4830},"the-parts-the-numbers-do-not-cover",[4832],{"type":28,"value":4833},"The parts the numbers do not cover",{"type":23,"tag":24,"props":4835,"children":4836},{},[4837,4839,4843],{"type":28,"value":4838},"Efficacy is only half a drug. The known trade-offs from this class apply here too. The side effects are mostly gastrointestinal, nausea, vomiting, diarrhoea, constipation, dose-dependent and worst while the dose is being escalated. And rapid weight loss on any of these drugs costs lean mass, not just fat; a meaningful share of the weight lost can be muscle, which is why protein and resistance training keep coming up. We went deep on that muscle-loss point, and on the difference between phase-2 and phase-3 data, in our ",{"type":23,"tag":292,"props":4840,"children":4841},{"href":294},[4842],{"type":28,"value":4040},{"type":28,"value":299},{"type":23,"tag":43,"props":4845,"children":4846},{"id":4082},[4847],{"type":28,"value":4085},{"type":23,"tag":24,"props":4849,"children":4850},{},[4851],{"type":28,"value":4852},"TRIUMPH-1 is the first readout of a larger program. Lilly has said more will follow later in 2026: TRIUMPH-2 in people with type 2 diabetes, and TRIUMPH-3 in people with established cardiovascular disease. Those matter, because diabetes and heart-outcome data are what turn a weight-loss number into a broader case. Full TRIUMPH-1 data at a congress will also let independent researchers pick over the safety and durability rather than take a press release at face value.",{"type":23,"tag":43,"props":4854,"children":4855},{"id":441},[4856],{"type":28,"value":444},{"type":23,"tag":24,"props":4858,"children":4859},{},[4860,4862,4866,4868,4872],{"type":28,"value":4861},"28.3% is a genuinely big number and retatrutide looks like the strongest incretin drug yet on the data available. It is also unapproved, reported so far only as topline, and impossible to obtain in a regulated form today. Reading the result and reading a purchase page are two very different activities. For the doses as reported in the published literature, see our ",{"type":23,"tag":292,"props":4863,"children":4864},{"href":1529},[4865],{"type":28,"value":2984},{"type":28,"value":4867},"; to understand the drug class from scratch, start with ",{"type":23,"tag":292,"props":4869,"children":4870},{"href":470},[4871],{"type":28,"value":473},{"type":28,"value":299},{"type":23,"tag":43,"props":4874,"children":4875},{"id":485},[4876],{"type":28,"value":488},{"type":23,"tag":184,"props":4878,"children":4879},{},[4880,4892,4904],{"type":23,"tag":188,"props":4881,"children":4882},{},[4883,4885],{"type":28,"value":4884},"Eli Lilly (investor release), 21 May 2026, ",{"type":23,"tag":292,"props":4886,"children":4889},{"href":4887,"rel":4888},"https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",[501],[4890],{"type":28,"value":4891},"Retatrutide delivered powerful weight loss in pivotal phase-3 obesity trial",{"type":23,"tag":188,"props":4893,"children":4894},{},[4895,4897],{"type":28,"value":4896},"AJMC, ",{"type":23,"tag":292,"props":4898,"children":4901},{"href":4899,"rel":4900},"https:\u002F\u002Fwww.ajmc.com\u002Fview\u002Fretatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial",[501],[4902],{"type":28,"value":4903},"Retatrutide achieves up to 30.3% average weight loss in phase-3 TRIUMPH-1",{"type":23,"tag":188,"props":4905,"children":4906},{},[4907,4908],{"type":28,"value":3801},{"type":23,"tag":292,"props":4909,"children":4912},{"href":4910,"rel":4911},"https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Flillys-retatrutide-tripleG-phase3-obesity-data\u002F820851\u002F",[501],[4913],{"type":28,"value":4914},"Lilly's triple-acting obesity drug hits goal in phase-3 trial",{"title":8,"searchDepth":578,"depth":578,"links":4916},[4917,4918,4919,4920,4921,4922],{"id":4709,"depth":578,"text":4712},{"id":4804,"depth":578,"text":4807},{"id":4830,"depth":578,"text":4833},{"id":4082,"depth":578,"text":4085},{"id":441,"depth":578,"text":444},{"id":485,"depth":578,"text":488},"content:blog:en:retatrutide-triumph-1-results.md","blog\u002Fen\u002Fretatrutide-triumph-1-results.md","blog\u002Fen\u002Fretatrutide-triumph-1-results",{"_path":4927,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":4928,"description":8,"cat":4929,"icon":4930,"accent":4931,"date":4932,"dateLabel":4933,"read":4934,"author":17,"image":4935,"body":4936,"_type":590,"_id":7307,"_source":592,"_file":7308,"_stem":7309,"_extension":595},"\u002Fblog\u002Fen\u002Fretatrutide-liver-damage-myths","Retatrutide liver damage: a fact-check","Fact-check","tabler:microscope","#F2A93B","2026-06-27","June 2026","20 min","\u002Fassets\u002Freta_hero.png",{"type":20,"children":4937,"toc":7286},[4938,5036,5042,5054,5223,5228,5234,5240,5245,5253,5303,5322,5328,5364,5382,5388,5393,5401,5437,5463,5469,5474,5482,5502,5567,5573,5578,5586,5633,5639,5644,5687,5693,5698,5703,5707,5713,5718,5724,5744,5772,5778,5799,5834,5840,5874,5914,5920,5972,5993,6029,6047,6132,6149,6241,6246,6252,6271,6317,6323,6335,6362,6368,6400,6406,6420,6426,6451,6473,6479],{"type":23,"tag":4939,"props":4940,"children":4941},"disclaimer",{},[4942,4952,4983,4993,5011,5028],{"type":23,"tag":24,"props":4943,"children":4944},{},[4945,4950],{"type":23,"tag":35,"props":4946,"children":4947},{},[4948],{"type":28,"value":4949},"This is opinion and scientific commentary — not medical advice, and not a statement of fact about any person beyond what is sourced.",{"type":28,"value":4951}," This article engages, as a matter of public interest and fair comment, with medical claims that a public figure chose to publish to a large audience.",{"type":23,"tag":24,"props":4953,"children":4954},{},[4955,4960,4962,4967,4969,4974,4976,4981],{"type":23,"tag":171,"props":4956,"children":4957},{},[4958],{"type":28,"value":4959},"Facts vs. opinion.",{"type":28,"value":4961}," Where we state verifiable facts — professional-licensing status, business ownership, the wording of publicly available records and videos — we link the primary sources so you can check them yourself. Everything we describe as an ",{"type":23,"tag":35,"props":4963,"children":4964},{},[4965],{"type":28,"value":4966},"assessment",{"type":28,"value":4968},", a ",{"type":23,"tag":35,"props":4970,"children":4971},{},[4972],{"type":28,"value":4973},"reading of the data",{"type":28,"value":4975},", or our ",{"type":23,"tag":35,"props":4977,"children":4978},{},[4979],{"type":28,"value":4980},"view",{"type":28,"value":4982}," is opinion and fair comment on statements made publicly. We do not claim to know anyone's private intent; where we describe motive or effect, we describe it as we see it, not as established fact.",{"type":23,"tag":24,"props":4984,"children":4985},{},[4986,4991],{"type":23,"tag":171,"props":4987,"children":4988},{},[4989],{"type":28,"value":4990},"Sources may be incomplete.",{"type":28,"value":4992}," All information here is drawn from publicly available sources and is presented in good faith and to the best of our knowledge at the time of writing. Public records and third-party reports can be incomplete, can change, or can be superseded; we may have missed context, and we may be wrong on points of detail.",{"type":23,"tag":24,"props":4994,"children":4995},{},[4996,5001,5003,5009],{"type":23,"tag":171,"props":4997,"children":4998},{},[4999],{"type":28,"value":5000},"Right of reply and correction.",{"type":28,"value":5002}," If you are mentioned here and believe any factual statement is inaccurate or out of date — or you wish to add your perspective — contact us via our ",{"type":23,"tag":292,"props":5004,"children":5006},{"href":5005},"\u002Flegal-notice",[5007],{"type":28,"value":5008},"legal notice",{"type":28,"value":5010}," and we will review and correct or update the article where warranted. We welcome documented corrections.",{"type":23,"tag":24,"props":5012,"children":5013},{},[5014,5019,5021,5026],{"type":23,"tag":171,"props":5015,"children":5016},{},[5017],{"type":28,"value":5018},"Not medical advice — and not a recommendation to use anything.",{"type":28,"value":5020}," Nothing here tells you what to do with your own body, and nothing here endorses or instructs you to obtain, dose, or use retatrutide or any other substance — several of which are investigational and not approved for human use in many places. The trial figures we cite describe results reported in published studies; they are not promises of any outcome and not dosing guidance. If you are considering or using any of these substances, ",{"type":23,"tag":171,"props":5022,"children":5023},{},[5024],{"type":28,"value":5025},"see the doctor you distrust the least — in person —",{"type":28,"value":5027}," before acting on anything you read online, here or elsewhere.",{"type":23,"tag":24,"props":5029,"children":5030},{},[5031],{"type":23,"tag":35,"props":5032,"children":5033},{},[5034],{"type":28,"value":5035},"Last updated: 27 June 2026. This article is opinion and commentary and may be revised as new information becomes available.",{"type":23,"tag":43,"props":5037,"children":5039},{"id":5038},"tldr",[5040],{"type":28,"value":5041},"TL;DR",{"type":23,"tag":24,"props":5043,"children":5044},{},[5045,5047,5052],{"type":28,"value":5046},"A 45-minute video titled ",{"type":23,"tag":35,"props":5048,"children":5049},{},[5050],{"type":28,"value":5051},"\"Mega Dosing vs Micro Dosing Retatrutide: Which Damages Your Liver More?\"",{"type":28,"value":5053}," argues that retatrutide quietly injures your liver and pancreas unless you follow a specific dosing protocol — which the presenter then sells, alongside the peptides themselves. We checked it. The short version:",{"type":23,"tag":184,"props":5055,"children":5056},{},[5057,5091,5140,5164,5204],{"type":23,"tag":188,"props":5058,"children":5059},{},[5060,5065,5067,5072,5074,5081,5083,5090],{"type":23,"tag":171,"props":5061,"children":5062},{},[5063],{"type":28,"value":5064},"The messenger.",{"type":28,"value":5066}," \"Dr\" Trevor Bachmeyer is not a physician. He is a former chiropractor whose California licence (DC 29377) was ",{"type":23,"tag":171,"props":5068,"children":5069},{},[5070],{"type":28,"value":5071},"revoked effective 8 July 2020",{"type":28,"value":5073},", as recorded by the ",{"type":23,"tag":292,"props":5075,"children":5078},{"href":5076,"rel":5077},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fabout_us\u002Fmeetings\u002F20201029_materials.pdf",[501],[5079],{"type":28,"value":5080},"California Board of Chiropractic Examiners",{"type":28,"value":5082},". The same video funnels viewers to his paid coaching and to his own research-peptide shop, ",{"type":23,"tag":292,"props":5084,"children":5087},{"href":5085,"rel":5086},"https:\u002F\u002Felitebiogenix.com\u002F",[501],[5088],{"type":28,"value":5089},"EliteBiogenix",{"type":28,"value":299},{"type":23,"tag":188,"props":5092,"children":5093},{},[5094,5099,5101,5105,5107,5112,5114,5121,5123,5130,5131,5138],{"type":23,"tag":171,"props":5095,"children":5096},{},[5097],{"type":28,"value":5098},"\"Glucagon floods your body with fat.\"",{"type":28,"value":5100}," Misleading. In humans, physiological glucagon does ",{"type":23,"tag":171,"props":5102,"children":5103},{},[5104],{"type":28,"value":270},{"type":28,"value":5106}," directly break down body (white adipose) fat — it drives fat oxidation ",{"type":23,"tag":35,"props":5108,"children":5109},{},[5110],{"type":28,"value":5111},"inside the liver",{"type":28,"value":5113}," (",{"type":23,"tag":292,"props":5115,"children":5118},{"href":5116,"rel":5117},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32132708\u002F",[501],[5119],{"type":28,"value":5120},"Perry et al., Nature 2020",{"type":28,"value":5122},"; ",{"type":23,"tag":292,"props":5124,"children":5127},{"href":5125,"rel":5126},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9576180\u002F",[501],[5128],{"type":28,"value":5129},"Vasileva et al., 2022",{"type":28,"value":5122},{"type":23,"tag":292,"props":5132,"children":5135},{"href":5133,"rel":5134},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F11344211\u002F",[501],[5136],{"type":28,"value":5137},"Gravholt et al., 2001",{"type":28,"value":5139},").",{"type":23,"tag":188,"props":5141,"children":5142},{},[5143,5148,5150,5155,5156,5163],{"type":23,"tag":171,"props":5144,"children":5145},{},[5146],{"type":28,"value":5147},"\"Lipase rises mean your pancreas is failing.\"",{"type":28,"value":5149}," Mostly false. Mild, symptom-free enzyme rises are common and benign; large trial datasets show ",{"type":23,"tag":171,"props":5151,"children":5152},{},[5153],{"type":28,"value":5154},"no increase in acute pancreatitis",{"type":28,"value":5113},{"type":23,"tag":292,"props":5157,"children":5160},{"href":5158,"rel":5159},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28476871\u002F",[501],[5161],{"type":28,"value":5162},"Steinberg et al., Diabetes Care 2017",{"type":28,"value":5139},{"type":23,"tag":188,"props":5165,"children":5166},{},[5167,5172,5174,5179,5181,5186,5188,5195,5197,5202],{"type":23,"tag":171,"props":5168,"children":5169},{},[5170],{"type":28,"value":5171},"\"Retatrutide overloads and damages the liver.\"",{"type":28,"value":5173}," The opposite of the data. In the phase-2 liver-fat trial it ",{"type":23,"tag":171,"props":5175,"children":5176},{},[5177],{"type":28,"value":5178},"cut liver fat by up to 86%",{"type":28,"value":5180},", and ",{"type":23,"tag":171,"props":5182,"children":5183},{},[5184],{"type":28,"value":5185},"~93% of patients on the top dose normalised",{"type":28,"value":5187}," their liver fat (",{"type":23,"tag":292,"props":5189,"children":5192},{"href":5190,"rel":5191},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11271400\u002F",[501],[5193],{"type":28,"value":5194},"Sanyal et al., Nature Medicine 2024",{"type":28,"value":5196},"). Retatrutide is being developed ",{"type":23,"tag":35,"props":5198,"children":5199},{},[5200],{"type":28,"value":5201},"as a treatment",{"type":28,"value":5203}," for fatty liver disease.",{"type":23,"tag":188,"props":5205,"children":5206},{},[5207,5212,5214,5221],{"type":23,"tag":171,"props":5208,"children":5209},{},[5210],{"type":28,"value":5211},"What he gets right.",{"type":28,"value":5213}," Two things: don't panic-stop over an isolated lipase number, and rapid weight loss really does cost muscle (",{"type":23,"tag":292,"props":5215,"children":5218},{"href":5216,"rel":5217},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12471476\u002F",[501],[5219],{"type":28,"value":5220},"Koceva et al., 2025",{"type":28,"value":5222},"). Valid points wrapped in an invalid scare.",{"type":23,"tag":24,"props":5224,"children":5225},{},[5226],{"type":28,"value":5227},"The fuller picture, and the science behind every line above, follows. The deep-dive at the end is a referenced primer on the whole drug class — written so you can check us, not just trust us.",{"type":23,"tag":5229,"props":5230,"children":5233},"youtube",{"id":5231,"title":5232},"gb-XEtsMr-w","The video this article examines — Bachmeyer on retatrutide dosing",[],{"type":23,"tag":43,"props":5235,"children":5237},{"id":5236},"who-is-making-the-claim",[5238],{"type":28,"value":5239},"Who is making the claim",{"type":23,"tag":24,"props":5241,"children":5242},{},[5243],{"type":28,"value":5244},"Before the science, the source. He brands himself \"Dr Trevor Bachmeyer, The Spartan\" and \"World's #1 Health Authority\" to an audience of hundreds of thousands. Two verifiable facts matter.",{"type":23,"tag":24,"props":5246,"children":5247},{},[5248],{"type":23,"tag":3030,"props":5249,"children":5252},{"alt":5250,"src":5251},"How a health scare can be funnelled toward a product sale","\u002Fassets\u002Freta_funnel.png",[],{"type":23,"tag":24,"props":5254,"children":5255},{},[5256,5258,5263,5265,5270,5272,5276,5278,5284,5285,5292,5294,5301],{"type":28,"value":5257},"First, ",{"type":23,"tag":171,"props":5259,"children":5260},{},[5261],{"type":28,"value":5262},"he is not a medical doctor.",{"type":28,"value":5264}," He is a former ",{"type":23,"tag":171,"props":5266,"children":5267},{},[5268],{"type":28,"value":5269},"chiropractor",{"type":28,"value":5271},", and even that licence is gone: California licence DC 29377 was ",{"type":23,"tag":171,"props":5273,"children":5274},{},[5275],{"type":28,"value":5071},{"type":28,"value":5277}," by the California Board of Chiropractic Examiners. The action is recorded in the Board's own documents (",{"type":23,"tag":292,"props":5279,"children":5281},{"href":5076,"rel":5280},[501],[5282],{"type":28,"value":5283},"meeting materials, 29 Oct 2020",{"type":28,"value":5122},{"type":23,"tag":292,"props":5286,"children":5289},{"href":5287,"rel":5288},"https:\u002F\u002Fwww.chiro.ca.gov\u002Fenforcement\u002Factions.shtml",[501],[5290],{"type":28,"value":5291},"Final Disciplinary Actions",{"type":28,"value":5293},") and is verifiable through the state ",{"type":23,"tag":292,"props":5295,"children":5298},{"href":5296,"rel":5297},"https:\u002F\u002Fsearch.dca.ca.gov\u002F",[501],[5299],{"type":28,"value":5300},"licence lookup",{"type":28,"value":5302}," — readers can consult the linked records for the precise findings. He continues to present himself as \"Dr\", a usage that, in our view, invites readers to assume a current medical qualification he does not hold.",{"type":23,"tag":24,"props":5304,"children":5305},{},[5306,5308,5313,5315,5320],{"type":28,"value":5307},"Second, ",{"type":23,"tag":171,"props":5309,"children":5310},{},[5311],{"type":28,"value":5312},"he sells the subject of his own advice.",{"type":28,"value":5314}," The video routes viewers to a paid \"Black Card\" coaching membership and to ",{"type":23,"tag":292,"props":5316,"children":5318},{"href":5085,"rel":5317},[501],[5319],{"type":28,"value":5089},{"type":28,"value":5321},", his shop selling research peptides and SARMs \"for in-vitro research only.\" So the person warning you that retatrutide will injure you unless you dose it correctly is also selling the dosing guidance and the peptides. That isn't disqualifying on its own — but it is exactly the conflict a careful viewer should keep in mind, and it is why this article exists.",{"type":23,"tag":43,"props":5323,"children":5325},{"id":5324},"what-he-actually-argues-in-fairness",[5326],{"type":28,"value":5327},"What he actually argues — in fairness",{"type":23,"tag":24,"props":5329,"children":5330},{},[5331,5333,5338,5340,5345,5347,5352,5353,5358,5359],{"type":28,"value":5332},"It would be easy to strawman him, so let's be exact. His own video description states that ",{"type":23,"tag":35,"props":5334,"children":5335},{},[5336],{"type":28,"value":5337},"\"retatrutide itself doesn't directly cause liver or pancreatic damage; irresponsible dosing and poor monitoring causes biological damage.\"",{"type":28,"value":5339}," His chapter list runs ",{"type":23,"tag":35,"props":5341,"children":5342},{},[5343],{"type":28,"value":5344},"\"Glucagon Fat Flood → Pancreas Overload → Fatty Liver Cascade → Insulin Resistance Spiral,\"",{"type":28,"value":5346}," then pivots to a ",{"type":23,"tag":35,"props":5348,"children":5349},{},[5350],{"type":28,"value":5351},"\"Damage Control Protocol,\"",{"type":28,"value":2157},{"type":23,"tag":35,"props":5354,"children":5355},{},[5356],{"type":28,"value":5357},"\"Safe Dosing Rules,\"",{"type":28,"value":4595},{"type":23,"tag":35,"props":5360,"children":5361},{},[5362],{"type":28,"value":5363},"\"Use It Responsibly.\"",{"type":23,"tag":24,"props":5365,"children":5366},{},[5367,5369,5373,5375,5380],{"type":28,"value":5368},"So his thesis is ",{"type":23,"tag":171,"props":5370,"children":5371},{},[5372],{"type":28,"value":270},{"type":28,"value":5374}," \"this drug is poison, avoid it.\" It is \"this drug will damage you ",{"type":23,"tag":35,"props":5376,"children":5377},{},[5378],{"type":28,"value":5379},"unless you dose it my way",{"type":28,"value":5381},".\" That is subtler, more credible-sounding, and far more marketable — and it is what we are checking. The problem isn't that he invents fake studies. It's that he builds a frightening mechanism out of real terminology, and the trial data don't support the scary part.",{"type":23,"tag":43,"props":5383,"children":5385},{"id":5384},"claim-1-the-glucagon-fat-flood",[5386],{"type":28,"value":5387},"Claim 1: the \"glucagon fat flood\"",{"type":23,"tag":24,"props":5389,"children":5390},{},[5391],{"type":28,"value":5392},"His engine is retatrutide's glucagon component: it supposedly unleashes a flood of fat — free fatty acids pouring out of your body fat and overwhelming the liver and pancreas.",{"type":23,"tag":24,"props":5394,"children":5395},{},[5396],{"type":23,"tag":3030,"props":5397,"children":5400},{"alt":5398,"src":5399},"Glucagon drives fat oxidation in the liver, not in body fat","\u002Fassets\u002Freta_glucagon.png",[],{"type":23,"tag":24,"props":5402,"children":5403},{},[5404,5406,5411,5413,5419,5421,5427,5428,5435],{"type":28,"value":5405},"This is the oldest myth in glucagon physiology. Yes, glucagon is a powerful fat-burning signal — ",{"type":23,"tag":171,"props":5407,"children":5408},{},[5409],{"type":28,"value":5410},"but in the liver, not in your body fat.",{"type":28,"value":5412}," The glucagon receptor is densely expressed on liver cells and barely present on human fat cells. When researchers deleted the glucagon receptor specifically from fat tissue in mice, nothing about their fat metabolism, body weight, or circulating free fatty acids changed (",{"type":23,"tag":292,"props":5414,"children":5416},{"href":5125,"rel":5415},[501],[5417],{"type":28,"value":5418},"Vasileva et al., AJP-Endocrinology 2022",{"type":28,"value":5420},"). In humans, raising glucagon to physiological levels does not increase lipolysis in abdominal fat at all (",{"type":23,"tag":292,"props":5422,"children":5424},{"href":5133,"rel":5423},[501],[5425],{"type":28,"value":5426},"Gravholt et al., JCEM 2001",{"type":28,"value":5122},{"type":23,"tag":292,"props":5429,"children":5432},{"href":5430,"rel":5431},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F1991802\u002F",[501],[5433],{"type":28,"value":5434},"Jensen et al., JCEM 1991",{"type":28,"value":5436},"). The lipolytic effect only appears in a test tube at supraphysiological concentrations the bloodstream never reaches.",{"type":23,"tag":24,"props":5438,"children":5439},{},[5440,5442,5446,5448,5453,5454,5461],{"type":28,"value":5441},"What glucagon actually does is drive fat oxidation ",{"type":23,"tag":171,"props":5443,"children":5444},{},[5445],{"type":28,"value":5111},{"type":28,"value":5447}," — through a cAMP\u002FPKA and calcium pathway that activates hepatic fat breakdown (",{"type":23,"tag":292,"props":5449,"children":5451},{"href":5116,"rel":5450},[501],[5452],{"type":28,"value":5120},{"type":28,"value":5122},{"type":23,"tag":292,"props":5455,"children":5458},{"href":5456,"rel":5457},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F38300523\u002F",[501],[5459],{"type":28,"value":5460},"Kajani et al., Physiological Reviews 2024",{"type":28,"value":5462},") — and raises whole-body energy expenditure. The image of glucagon \"melting\" your belly fat and flooding your organs with it is an in-vitro artefact, not human physiology. The foundation of his \"flood\" is cracked from the first chapter.",{"type":23,"tag":43,"props":5464,"children":5466},{"id":5465},"claim-2-the-pancreas-overload",[5467],{"type":28,"value":5468},"Claim 2: the pancreas \"overload\"",{"type":23,"tag":24,"props":5470,"children":5471},{},[5472],{"type":28,"value":5473},"Next, elevated lipase as proof your pancreas is being driven toward failure.",{"type":23,"tag":24,"props":5475,"children":5476},{},[5477],{"type":23,"tag":3030,"props":5478,"children":5481},{"alt":5479,"src":5480},"A mild lipase rise reflects a harmless enzyme leak, not pancreatic destruction","\u002Fassets\u002Freta_pancreas.png",[],{"type":23,"tag":24,"props":5483,"children":5484},{},[5485,5487,5492,5494,5501],{"type":28,"value":5486},"The boring reality: mild, symptom-free rises in lipase and amylase are ",{"type":23,"tag":171,"props":5488,"children":5489},{},[5490],{"type":28,"value":5491},"common and usually harmless",{"type":28,"value":5493}," on this drug class. They reflect stimulated but intact acinar cells leaking a little enzyme into the blood — a physiological \"leak,\" not the organ digesting itself. We even know the receptor mechanism: GLP-1 receptors sit on pancreatic acinar cells and nudge them to release enzyme, in healthy tissue, with no damage (",{"type":23,"tag":292,"props":5495,"children":5498},{"href":5496,"rel":5497},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4698438\u002F",[501],[5499],{"type":28,"value":5500},"Hou… Williams et al., AJP-GI 2016",{"type":28,"value":5139},{"type":23,"tag":24,"props":5503,"children":5504},{},[5505,5507,5512,5513,5518,5520,5527,5529,5534,5536,5543,5545,5550,5552,5556,5558,5565],{"type":28,"value":5506},"And the hard endpoints are reassuring. In the large liraglutide trial programmes, amylase and lipase rose modestly ",{"type":23,"tag":171,"props":5508,"children":5509},{},[5510],{"type":28,"value":5511},"without predicting acute pancreatitis",{"type":28,"value":5113},{"type":23,"tag":292,"props":5514,"children":5516},{"href":5158,"rel":5515},[501],[5517],{"type":28,"value":5162},{"type":28,"value":5519},"). A 2026 living systematic review pooling 31 placebo-controlled trials and over 40,000 patients found essentially identical pancreatitis rates on drug versus placebo (odds ratio ≈ 0.99) — though, in fairness, that one is still a ",{"type":23,"tag":292,"props":5521,"children":5524},{"href":5522,"rel":5523},"https:\u002F\u002Fwww.medrxiv.org\u002Fcontent\u002F10.64898\u002F2026.03.19.26348844v1",[501],[5525],{"type":28,"value":5526},"preprint",{"type":28,"value":5528}," and not yet peer-reviewed. A 2024 analysis even reported ",{"type":23,"tag":171,"props":5530,"children":5531},{},[5532],{"type":28,"value":5533},"fewer",{"type":28,"value":5535}," recurrent pancreatitis episodes in high-risk patients on GLP-1 drugs (",{"type":23,"tag":292,"props":5537,"children":5540},{"href":5538,"rel":5539},"https:\u002F\u002Fwww.endocrine.org\u002Fnews-and-advocacy\u002Fnews-room\u002F2024\u002Fendo-2024-press-nassar",[501],[5541],{"type":28,"value":5542},"Nassar et al., ENDO 2024 — conference abstract",{"type":28,"value":5544},"), plausibly because the drugs fix the underlying triggers. Crucially, acute pancreatitis is a clinical diagnosis — the revised Atlanta criteria require real pain ",{"type":23,"tag":35,"props":5546,"children":5547},{},[5548],{"type":28,"value":5549},"plus",{"type":28,"value":5551}," lipase over three times the upper limit ",{"type":23,"tag":35,"props":5553,"children":5554},{},[5555],{"type":28,"value":5549},{"type":28,"value":5557}," imaging (",{"type":23,"tag":292,"props":5559,"children":5562},{"href":5560,"rel":5561},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F23100216\u002F",[501],[5563],{"type":28,"value":5564},"Banks et al., Gut 2013",{"type":28,"value":5566},"). A lone lab number doesn't qualify, and the jump from \"your lipase is up\" to \"your pancreas is overloading toward failure\" isn't supported.",{"type":23,"tag":43,"props":5568,"children":5570},{"id":5569},"claim-3-the-fatty-liver-cascade",[5571],{"type":28,"value":5572},"Claim 3: the \"fatty liver cascade\"",{"type":23,"tag":24,"props":5574,"children":5575},{},[5576],{"type":28,"value":5577},"This is the central inversion, and the one most worth getting right.",{"type":23,"tag":24,"props":5579,"children":5580},{},[5581],{"type":23,"tag":3030,"props":5582,"children":5585},{"alt":5583,"src":5584},"Retatrutide sharply reduces liver fat in clinical trials","\u002Fassets\u002Freta_liverfat.png",[],{"type":23,"tag":24,"props":5587,"children":5588},{},[5589,5591,5596,5598,5603,5605,5610,5612,5617,5619,5624,5626,5631],{"type":28,"value":5590},"He frames retatrutide as overloading and damaging the liver — a \"fatty liver cascade,\" a \"liver overload.\" The trial data show ",{"type":23,"tag":171,"props":5592,"children":5593},{},[5594],{"type":28,"value":5595},"the exact opposite.",{"type":28,"value":5597}," In the phase-2 liver-fat study, retatrutide reduced liver fat dose-dependently: at 48 weeks, ",{"type":23,"tag":171,"props":5599,"children":5600},{},[5601],{"type":28,"value":5602},"−81.7%",{"type":28,"value":5604}," at 8 mg and ",{"type":23,"tag":171,"props":5606,"children":5607},{},[5608],{"type":28,"value":5609},"−86.0%",{"type":28,"value":5611}," at 12 mg, versus −4.6% on placebo. In the top-dose group, ",{"type":23,"tag":171,"props":5613,"children":5614},{},[5615],{"type":28,"value":5616},"about 93% of patients saw their liver fat fall below the 5% threshold",{"type":28,"value":5618}," — effectively a medical normalisation of their fatty liver (",{"type":23,"tag":292,"props":5620,"children":5622},{"href":5190,"rel":5621},[501],[5623],{"type":28,"value":5194},{"type":28,"value":5625},"). This is among the largest liver-fat reductions reported in the drug's clinical development so far. Retatrutide isn't a hidden liver hazard; it is being developed ",{"type":23,"tag":171,"props":5627,"children":5628},{},[5629],{"type":28,"value":5630},"as a treatment for fatty liver disease (MASLD)",{"type":28,"value":5632},". Its net effect on the liver, in controlled trials, is profoundly protective — the reverse of the cascade he describes.",{"type":23,"tag":43,"props":5634,"children":5636},{"id":5635},"what-he-gets-right",[5637],{"type":28,"value":5638},"What he gets right",{"type":23,"tag":24,"props":5640,"children":5641},{},[5642],{"type":28,"value":5643},"A fair fact-check names the hits, not just the misses — and two of his underlying points are legitimate.",{"type":23,"tag":24,"props":5645,"children":5646},{},[5647,5649,5654,5656,5661,5663,5668,5669,5676,5678,5685],{"type":28,"value":5648},"He is right that you should ",{"type":23,"tag":171,"props":5650,"children":5651},{},[5652],{"type":28,"value":5653},"not panic and stop the drug over an isolated, symptom-free lipase rise",{"type":28,"value":5655},"; that genuinely matches what gastroenterology guidance implies. And he is right that rapid weight loss on these drugs costs ",{"type":23,"tag":171,"props":5657,"children":5658},{},[5659],{"type":28,"value":5660},"lean mass",{"type":28,"value":5662}," — roughly a quarter to nearly half of the weight lost can be fat-free mass, much of it muscle (",{"type":23,"tag":292,"props":5664,"children":5666},{"href":5216,"rel":5665},[501],[5667],{"type":28,"value":5220},{"type":28,"value":5122},{"type":23,"tag":292,"props":5670,"children":5673},{"href":5671,"rel":5672},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11450469\u002F",[501],[5674],{"type":28,"value":5675},"Tinsley et al., 2024",{"type":28,"value":5677},"), which is why protein intake and resistance training belong in any serious plan (",{"type":23,"tag":292,"props":5679,"children":5682},{"href":5680,"rel":5681},"https:\u002F\u002Fdiabetesjournals.org\u002Fcare\u002Farticle\u002F47\u002F10\u002F1718\u002F154535\u002F",[501],[5683],{"type":28,"value":5684},"Locatelli et al., Diabetes Care 2024",{"type":28,"value":5686},"). Those points are real. The problem is the packaging around them.",{"type":23,"tag":43,"props":5688,"children":5690},{"id":5689},"the-pattern",[5691],{"type":28,"value":5692},"The pattern",{"type":23,"tag":24,"props":5694,"children":5695},{},[5696],{"type":28,"value":5697},"In our assessment, the structure here is a familiar one: real terminology is used to project authority; a frightening \"damage cascade\" is assembled that, on our reading of the trial data, the evidence does not support; other voices are labelled \"misinformation\"; and the proposed remedy is a paid protocol and peptides from the author's own shop. We do not claim to know his intent — we describe the effect as we see it, and readers can weigh the commercial context for themselves.",{"type":23,"tag":24,"props":5699,"children":5700},{},[5701],{"type":28,"value":5702},"Retatrutide is a serious investigational drug with a real side-effect profile (mostly gastrointestinal, dose-dependent, worst during dose escalation) and genuine open questions about long-term use and muscle loss. It deserves caution and a prescribing clinician. It does not deserve a manufactured organ-failure narrative from someone selling the antidote.",{"type":23,"tag":5704,"props":5705,"children":5706},"hr",{},[],{"type":23,"tag":43,"props":5708,"children":5710},{"id":5709},"the-full-scientific-picture",[5711],{"type":28,"value":5712},"The full scientific picture",{"type":23,"tag":24,"props":5714,"children":5715},{},[5716],{"type":28,"value":5717},"The section above is the verdict. This part is the homework: a referenced primer on what these drugs actually do, so you can judge the claims yourself rather than take anyone's word — ours or his. It is dense on purpose.",{"type":23,"tag":43,"props":5719,"children":5721},{"id":5720},"from-nafld-to-masld",[5722],{"type":28,"value":5723},"From NAFLD to MASLD",{"type":23,"tag":24,"props":5725,"children":5726},{},[5727,5729,5734,5736,5743],{"type":28,"value":5728},"For decades, fat building up in the liver without heavy drinking was called non-alcoholic fatty liver disease (NAFLD) — now the most common chronic liver condition on earth, affecting roughly 30–38% of adults. In 2023 an international consensus renamed it ",{"type":23,"tag":171,"props":5730,"children":5731},{},[5732],{"type":28,"value":5733},"MASLD — metabolic dysfunction-associated steatotic liver disease",{"type":28,"value":5735}," — to put the metabolic root cause front and centre rather than defining the disease by what it isn't (",{"type":23,"tag":292,"props":5737,"children":5740},{"href":5738,"rel":5739},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10653297\u002F",[501],[5741],{"type":28,"value":5742},"Rinella et al., 2023",{"type":28,"value":5139},{"type":23,"tag":24,"props":5745,"children":5746},{},[5747,5749,5754,5756,5763,5765,5770],{"type":28,"value":5748},"The progression is described by a ",{"type":23,"tag":171,"props":5750,"children":5751},{},[5752],{"type":28,"value":5753},"\"multiple-hit\" model",{"type":28,"value":5755},": the first hit is fat accumulating in liver cells, which then makes the liver vulnerable to further insults — oxidative stress, mitochondrial dysfunction, gut-liver dysbiosis, inflammation (",{"type":23,"tag":292,"props":5757,"children":5760},{"href":5758,"rel":5759},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26823198\u002F",[501],[5761],{"type":28,"value":5762},"Buzzetti et al., 2016",{"type":28,"value":5764},"). The spectrum runs from simple steatosis, through steatohepatitis (MASH) with inflammation and cell injury, to fibrosis, cirrhosis and liver cancer. The driver of that progression is ",{"type":23,"tag":171,"props":5766,"children":5767},{},[5768],{"type":28,"value":5769},"lipotoxicity",{"type":28,"value":5771}," — not inert triglyceride itself, but toxic lipid intermediates like ceramides and diacylglycerols that damage cell machinery and switch on inflammatory pathways.",{"type":23,"tag":43,"props":5773,"children":5775},{"id":5774},"selective-hepatic-insulin-resistance",[5776],{"type":28,"value":5777},"Selective hepatic insulin resistance",{"type":23,"tag":24,"props":5779,"children":5780},{},[5781,5783,5790,5791,5798],{"type":28,"value":5782},"One of the most important ideas here, developed largely by Samuel and Shulman, resolves a paradox: why a diabetic liver ignores insulin's signal to stop making glucose, yet still obeys insulin's signal to make fat (",{"type":23,"tag":292,"props":5784,"children":5787},{"href":5785,"rel":5786},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4701542\u002F",[501],[5788],{"type":28,"value":5789},"Samuel & Shulman, JCI 2016",{"type":28,"value":5122},{"type":23,"tag":292,"props":5792,"children":5795},{"href":5793,"rel":5794},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC5762395\u002F",[501],[5796],{"type":28,"value":5797},"Cell Metabolism 2018",{"type":28,"value":5139},{"type":23,"tag":24,"props":5800,"children":5801},{},[5802,5804,5809,5811,5816,5818,5825,5827,5832],{"type":28,"value":5803},"The mechanism: as fat accumulates in the liver, ",{"type":23,"tag":171,"props":5805,"children":5806},{},[5807],{"type":28,"value":5808},"diacylglycerol",{"type":28,"value":5810}," builds up and activates an enzyme (PKCε) that jams the proximal insulin signal. Insulin can no longer suppress glucose output — so blood sugar rises — but the fat-making machinery keeps running on raw substrate and high insulin levels. Add the fact that resistant fat tissue spills free fatty acids straight into the liver, and you get a self-reinforcing loop of fat accumulation. Isotope studies put numbers on the inflow: in fatty-liver patients, about ",{"type":23,"tag":171,"props":5812,"children":5813},{},[5814],{"type":28,"value":5815},"59% of stored liver triglyceride comes from circulating free fatty acids",{"type":28,"value":5817}," (peripheral lipolysis), ~26% from de-novo lipogenesis, and ~15% from diet (",{"type":23,"tag":292,"props":5819,"children":5822},{"href":5820,"rel":5821},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC1087172\u002F",[501],[5823],{"type":28,"value":5824},"Donnelly et al., JCI 2005",{"type":28,"value":5826},"). This is the genuine biology the video gestures at — and it is precisely why a drug that ",{"type":23,"tag":35,"props":5828,"children":5829},{},[5830],{"type":28,"value":5831},"reduces",{"type":28,"value":5833}," that fat inflow helps rather than harms.",{"type":23,"tag":43,"props":5835,"children":5837},{"id":5836},"what-glucagon-really-does-and-the-white-fat-myth",[5838],{"type":28,"value":5839},"What glucagon really does — and the white-fat myth",{"type":23,"tag":24,"props":5841,"children":5842},{},[5843,5845,5850,5852,5857,5858,5865,5866,5872],{"type":28,"value":5844},"Glucagon, long cast as just insulin's opposite, is now understood as a broad regulator of energy and lipid metabolism. Its main target is the liver, where it triggers glucose release and, importantly, ",{"type":23,"tag":171,"props":5846,"children":5847},{},[5848],{"type":28,"value":5849},"drives fat oxidation and suppresses new fat synthesis",{"type":28,"value":5851}," through a cAMP\u002FPKA pathway and a calcium-release mechanism that activates hepatic fat breakdown (",{"type":23,"tag":292,"props":5853,"children":5855},{"href":5116,"rel":5854},[501],[5856],{"type":28,"value":5120},{"type":28,"value":5122},{"type":23,"tag":292,"props":5859,"children":5862},{"href":5860,"rel":5861},"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Fphysiology\u002Farticles\u002F10.3389\u002Ffphys.2019.00413\u002Ffull",[501],[5863],{"type":28,"value":5864},"Galsgaard et al., 2019",{"type":28,"value":5122},{"type":23,"tag":292,"props":5867,"children":5869},{"href":5456,"rel":5868},[501],[5870],{"type":28,"value":5871},"Kajani et al., 2024",{"type":28,"value":5873},"). This hepatic \"fat-burning\" is exactly why drug developers bolted a glucagon signal onto retatrutide.",{"type":23,"tag":24,"props":5875,"children":5876},{},[5877,5879,5884,5886,5891,5893,5898,5899,5905,5907,5912],{"type":28,"value":5878},"But — and this is the myth correction — that action is ",{"type":23,"tag":171,"props":5880,"children":5881},{},[5882],{"type":28,"value":5883},"hepatic, not peripheral.",{"type":28,"value":5885}," Old in-vitro experiments showed isolated fat cells could break down fat when bathed in glucagon, but only at concentrations 10–100× higher than the body ever produces. Modern work settles it: knock the glucagon receptor out of fat tissue and lipid metabolism is unchanged (",{"type":23,"tag":292,"props":5887,"children":5889},{"href":5125,"rel":5888},[501],[5890],{"type":28,"value":5129},{"type":28,"value":5892},"); give humans physiological glucagon and abdominal-fat lipolysis doesn't budge (",{"type":23,"tag":292,"props":5894,"children":5896},{"href":5133,"rel":5895},[501],[5897],{"type":28,"value":5137},{"type":28,"value":5122},{"type":23,"tag":292,"props":5900,"children":5902},{"href":5430,"rel":5901},[501],[5903],{"type":28,"value":5904},"Jensen et al., 1991",{"type":28,"value":5906},"). Weight loss on glucagon-containing drugs comes from appetite suppression, raised energy expenditure, and ",{"type":23,"tag":171,"props":5908,"children":5909},{},[5910],{"type":28,"value":5911},"liver",{"type":28,"value":5913}," fat oxidation — not from glucagon dissolving your belly fat and flooding your organs.",{"type":23,"tag":43,"props":5915,"children":5917},{"id":5916},"the-poly-agonist-leap-from-semaglutide-to-retatrutide",[5918],{"type":28,"value":5919},"The poly-agonist leap: from semaglutide to retatrutide",{"type":23,"tag":24,"props":5921,"children":5922},{},[5923,5925,5930,5932,5939,5941,5946,5947,5954,5956,5963,5964,5971],{"type":28,"value":5924},"Incretin drugs are gut-hormone mimics, engineered to resist rapid breakdown so they last. The first wave were GLP-1 mono-agonists: semaglutide produced about ",{"type":23,"tag":171,"props":5926,"children":5927},{},[5928],{"type":28,"value":5929},"14.9%",{"type":28,"value":5931}," mean weight loss in its pivotal obesity trial (",{"type":23,"tag":292,"props":5933,"children":5936},{"href":5934,"rel":5935},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33567185\u002F",[501],[5937],{"type":28,"value":5938},"STEP 1, Wilding et al., NEJM 2021",{"type":28,"value":5940},"). Next came dual GLP-1\u002FGIP agonism: tirzepatide reached up to ",{"type":23,"tag":171,"props":5942,"children":5943},{},[5944],{"type":28,"value":5945},"20.9%",{"type":28,"value":5113},{"type":23,"tag":292,"props":5948,"children":5951},{"href":5949,"rel":5950},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F35658024\u002F",[501],[5952],{"type":28,"value":5953},"SURMOUNT-1, Jastreboff et al., NEJM 2022",{"type":28,"value":5955},"). For the physiology of how these hormones work together, see ",{"type":23,"tag":292,"props":5957,"children":5960},{"href":5958,"rel":5959},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39160334\u002F",[501],[5961],{"type":28,"value":5962},"Holst, Nature Metabolism 2024",{"type":28,"value":4595},{"type":23,"tag":292,"props":5965,"children":5968},{"href":5966,"rel":5967},"https:\u002F\u002Fdom-pubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fdom.14496",[501],[5969],{"type":28,"value":5970},"Nauck et al., 2021",{"type":28,"value":299},{"type":23,"tag":24,"props":5973,"children":5974},{},[5975,5977,5982,5984,5991],{"type":28,"value":5976},"Retatrutide (LY3437943) goes one further: a single molecule hitting ",{"type":23,"tag":171,"props":5978,"children":5979},{},[5980],{"type":28,"value":5981},"GLP-1, GIP and glucagon",{"type":28,"value":5983}," receptors (",{"type":23,"tag":292,"props":5985,"children":5988},{"href":5986,"rel":5987},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04881760",[501],[5989],{"type":28,"value":5990},"trial NCT04881760",{"type":28,"value":5992},"). The glucagon arm adds hepatic fat oxidation and energy expenditure; the GLP-1 and GIP arms supply appetite suppression, insulin support, and — crucially — cancel out glucagon's tendency to raise blood sugar.",{"type":23,"tag":24,"props":5994,"children":5995},{},[5996,5998,6003,6005,6012,6014,6020,6022,6027],{"type":28,"value":5997},"A note on naming: the ",{"type":23,"tag":171,"props":5999,"children":6000},{},[6001],{"type":28,"value":6002},"phase-2",{"type":28,"value":6004}," data below come from ",{"type":23,"tag":292,"props":6006,"children":6009},{"href":6007,"rel":6008},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37366315\u002F",[501],[6010],{"type":28,"value":6011},"Jastreboff et al., NEJM 2023",{"type":28,"value":6013}," and the ",{"type":23,"tag":292,"props":6015,"children":6017},{"href":5190,"rel":6016},[501],[6018],{"type":28,"value":6019},"MASLD substudy, Sanyal et al., Nature Medicine 2024",{"type":28,"value":6021},". \"TRIUMPH\" is the later ",{"type":23,"tag":35,"props":6023,"children":6024},{},[6025],{"type":28,"value":6026},"phase-3",{"type":28,"value":6028}," programme — so don't let anyone present phase-2 figures as TRIUMPH-1 results.",{"type":23,"tag":24,"props":6030,"children":6031},{},[6032,6037,6039,6045],{"type":23,"tag":171,"props":6033,"children":6034},{},[6035],{"type":28,"value":6036},"Weight change at 48 weeks",{"type":28,"value":6038}," (phase 2, n=338; ",{"type":23,"tag":292,"props":6040,"children":6042},{"href":6007,"rel":6041},[501],[6043],{"type":28,"value":6044},"Jastreboff et al., 2023",{"type":28,"value":6046},"):",{"type":23,"tag":55,"props":6048,"children":6049},{},[6050,6065],{"type":23,"tag":59,"props":6051,"children":6052},{},[6053],{"type":23,"tag":63,"props":6054,"children":6055},{},[6056,6060],{"type":23,"tag":67,"props":6057,"children":6058},{},[6059],{"type":28,"value":3878},{"type":23,"tag":67,"props":6061,"children":6062},{},[6063],{"type":28,"value":6064},"Mean weight change",{"type":23,"tag":78,"props":6066,"children":6067},{},[6068,6080,6093,6106,6119],{"type":23,"tag":63,"props":6069,"children":6070},{},[6071,6075],{"type":23,"tag":85,"props":6072,"children":6073},{},[6074],{"type":28,"value":1331},{"type":23,"tag":85,"props":6076,"children":6077},{},[6078],{"type":28,"value":6079},"−2.1%",{"type":23,"tag":63,"props":6081,"children":6082},{},[6083,6088],{"type":23,"tag":85,"props":6084,"children":6085},{},[6086],{"type":28,"value":6087},"Retatrutide 1 mg",{"type":23,"tag":85,"props":6089,"children":6090},{},[6091],{"type":28,"value":6092},"−8.7%",{"type":23,"tag":63,"props":6094,"children":6095},{},[6096,6101],{"type":23,"tag":85,"props":6097,"children":6098},{},[6099],{"type":28,"value":6100},"Retatrutide 4 mg",{"type":23,"tag":85,"props":6102,"children":6103},{},[6104],{"type":28,"value":6105},"−17.1%",{"type":23,"tag":63,"props":6107,"children":6108},{},[6109,6114],{"type":23,"tag":85,"props":6110,"children":6111},{},[6112],{"type":28,"value":6113},"Retatrutide 8 mg",{"type":23,"tag":85,"props":6115,"children":6116},{},[6117],{"type":28,"value":6118},"−22.8%",{"type":23,"tag":63,"props":6120,"children":6121},{},[6122,6127],{"type":23,"tag":85,"props":6123,"children":6124},{},[6125],{"type":28,"value":6126},"Retatrutide 12 mg",{"type":23,"tag":85,"props":6128,"children":6129},{},[6130],{"type":28,"value":6131},"−24.2%",{"type":23,"tag":24,"props":6133,"children":6134},{},[6135,6140,6142,6148],{"type":23,"tag":171,"props":6136,"children":6137},{},[6138],{"type":28,"value":6139},"Liver-fat change at 48 weeks",{"type":28,"value":6141}," (MASLD substudy, n=98; ",{"type":23,"tag":292,"props":6143,"children":6145},{"href":5190,"rel":6144},[501],[6146],{"type":28,"value":6147},"Sanyal et al., 2024",{"type":28,"value":6046},{"type":23,"tag":55,"props":6150,"children":6151},{},[6152,6172],{"type":23,"tag":59,"props":6153,"children":6154},{},[6155],{"type":23,"tag":63,"props":6156,"children":6157},{},[6158,6162,6167],{"type":23,"tag":67,"props":6159,"children":6160},{},[6161],{"type":28,"value":3878},{"type":23,"tag":67,"props":6163,"children":6164},{},[6165],{"type":28,"value":6166},"Relative liver-fat change",{"type":23,"tag":67,"props":6168,"children":6169},{},[6170],{"type":28,"value":6171},"Liver fat normalised (\u003C5%)",{"type":23,"tag":78,"props":6173,"children":6174},{},[6175,6192,6209,6225],{"type":23,"tag":63,"props":6176,"children":6177},{},[6178,6182,6187],{"type":23,"tag":85,"props":6179,"children":6180},{},[6181],{"type":28,"value":1331},{"type":23,"tag":85,"props":6183,"children":6184},{},[6185],{"type":28,"value":6186},"−4.6%",{"type":23,"tag":85,"props":6188,"children":6189},{},[6190],{"type":28,"value":6191},"0%",{"type":23,"tag":63,"props":6193,"children":6194},{},[6195,6199,6204],{"type":23,"tag":85,"props":6196,"children":6197},{},[6198],{"type":28,"value":6087},{"type":23,"tag":85,"props":6200,"children":6201},{},[6202],{"type":28,"value":6203},"−51.3%",{"type":23,"tag":85,"props":6205,"children":6206},{},[6207],{"type":28,"value":6208},">50%",{"type":23,"tag":63,"props":6210,"children":6211},{},[6212,6216,6220],{"type":23,"tag":85,"props":6213,"children":6214},{},[6215],{"type":28,"value":6113},{"type":23,"tag":85,"props":6217,"children":6218},{},[6219],{"type":28,"value":5602},{"type":23,"tag":85,"props":6221,"children":6222},{},[6223],{"type":28,"value":6224},"—",{"type":23,"tag":63,"props":6226,"children":6227},{},[6228,6232,6236],{"type":23,"tag":85,"props":6229,"children":6230},{},[6231],{"type":28,"value":6126},{"type":23,"tag":85,"props":6233,"children":6234},{},[6235],{"type":28,"value":5609},{"type":23,"tag":85,"props":6237,"children":6238},{},[6239],{"type":28,"value":6240},"~93%",{"type":23,"tag":24,"props":6242,"children":6243},{},[6244],{"type":28,"value":6245},"A near-quarter of body weight gone in under a year, in dimensions previously reached only by bariatric surgery — and a fatty liver normalised in over nine of ten patients at the top dose. These are the data a \"liver overload\" narrative has to ignore.",{"type":23,"tag":43,"props":6247,"children":6249},{"id":6248},"gastrointestinal-effects-and-the-anesthesia-question",[6250],{"type":28,"value":6251},"Gastrointestinal effects and the anesthesia question",{"type":23,"tag":24,"props":6253,"children":6254},{},[6255,6257,6262,6264,6269],{"type":28,"value":6256},"The price of this efficacy is mostly gastrointestinal. Slowed stomach emptying and brainstem nausea signalling make ",{"type":23,"tag":171,"props":6258,"children":6259},{},[6260],{"type":28,"value":6261},"nausea, vomiting, diarrhoea and constipation",{"type":28,"value":6263}," the common side effects — dose-dependent, worst during dose escalation, and usually transient (",{"type":23,"tag":292,"props":6265,"children":6267},{"href":6007,"rel":6266},[501],[6268],{"type":28,"value":6044},{"type":28,"value":6270},"). Slow titration (starting low) is the standard mitigation.",{"type":23,"tag":24,"props":6272,"children":6273},{},[6274,6276,6283,6284,6291,6293,6300,6302,6309,6311,6315],{"type":28,"value":6275},"One real-world consequence has prompted genuine medical debate: because these drugs slow gastric emptying, food can linger in the stomach longer, raising the chance of retained stomach contents before anaesthesia and a theoretical aspiration risk. Meta-analyses do find significantly higher residual gastric content in users (",{"type":23,"tag":292,"props":6277,"children":6280},{"href":6278,"rel":6279},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11264430\u002F",[501],[6281],{"type":28,"value":6282},"do Nascimento et al., 2024",{"type":28,"value":5122},{"type":23,"tag":292,"props":6285,"children":6288},{"href":6286,"rel":6287},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40133086\u002F",[501],[6289],{"type":28,"value":6290},"Tan et al., 2025",{"type":28,"value":6292},"), even if actual aspiration events remain rare (",{"type":23,"tag":292,"props":6294,"children":6297},{"href":6295,"rel":6296},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11651700\u002F",[501],[6298],{"type":28,"value":6299},"Jalleh et al., JCEM 2024",{"type":28,"value":6301},"). Anaesthesia societies now advise pausing the drug before elective procedures (",{"type":23,"tag":292,"props":6303,"children":6306},{"href":6304,"rel":6305},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37982170\u002F",[501],[6307],{"type":28,"value":6308},"ASA guidance, 2024",{"type":28,"value":6310},"). This is a legitimate, well-characterised caution — and notably ",{"type":23,"tag":35,"props":6312,"children":6313},{},[6314],{"type":28,"value":270},{"type":28,"value":6316}," the one the video centres on.",{"type":23,"tag":43,"props":6318,"children":6320},{"id":6319},"the-pancreas-how-it-works-and-the-lipase-question",[6321],{"type":28,"value":6322},"The pancreas: how it works, and the lipase question",{"type":23,"tag":24,"props":6324,"children":6325},{},[6326,6328,6334],{"type":28,"value":6327},"Over 90% of the pancreas is exocrine tissue — acinar cells that make digestive enzymes. They store inactive enzyme precursors and release them on cue; premature activation inside the cell is what defines true pancreatitis. GLP-1 receptors are present on these acinar cells, so the drugs nudge enzyme release as a normal, receptor-mediated effect (",{"type":23,"tag":292,"props":6329,"children":6331},{"href":5496,"rel":6330},[501],[6332],{"type":28,"value":6333},"Hou… Williams et al., 2016",{"type":28,"value":5139},{"type":23,"tag":24,"props":6336,"children":6337},{},[6338,6340,6345,6347,6353,6355,6360],{"type":28,"value":6339},"That is why mild lipase and amylase elevations are so common on therapy — and why they are usually meaningless. They are stimulated enzyme ",{"type":23,"tag":35,"props":6341,"children":6342},{},[6343],{"type":28,"value":6344},"leak",{"type":28,"value":6346},", not tissue destruction. The trial evidence (above) shows these rises don't predict pancreatitis (",{"type":23,"tag":292,"props":6348,"children":6350},{"href":5158,"rel":6349},[501],[6351],{"type":28,"value":6352},"Steinberg et al., 2017",{"type":28,"value":6354},"), and pooled data show no excess pancreatitis risk versus placebo. The background risk that does exist tracks the population — people with obesity and type-2 diabetes carry a higher baseline pancreatitis risk from gallstones and high triglycerides, independent of any drug. Treating those drivers is plausibly why some data show ",{"type":23,"tag":171,"props":6356,"children":6357},{},[6358],{"type":28,"value":6359},"reduced",{"type":28,"value":6361}," recurrence on GLP-1 therapy.",{"type":23,"tag":43,"props":6363,"children":6365},{"id":6364},"the-real-caveat-losing-lean-mass",[6366],{"type":28,"value":6367},"The real caveat: losing lean mass",{"type":23,"tag":24,"props":6369,"children":6370},{},[6371,6373,6378,6380,6385,6386,6391,6393,6399],{"type":28,"value":6372},"If there is one warning that deserves the airtime the video spends on phantom organ damage, it's this. Across incretin trials, a substantial share of the weight lost is ",{"type":23,"tag":171,"props":6374,"children":6375},{},[6376],{"type":28,"value":6377},"fat-free mass",{"type":28,"value":6379}," — roughly 25–40%, much of it skeletal muscle (",{"type":23,"tag":292,"props":6381,"children":6383},{"href":5216,"rel":6382},[501],[6384],{"type":28,"value":5220},{"type":28,"value":5122},{"type":23,"tag":292,"props":6387,"children":6389},{"href":5671,"rel":6388},[501],[6390],{"type":28,"value":5675},{"type":28,"value":6392},"). This isn't unique to these drugs — any large, rapid weight loss does it — but losing muscle lowers metabolic rate (feeding the rebound after stopping), reduces insulin sensitivity, and raises frailty and fall risk in older people. The evidence-based fix is unglamorous: adequate protein and progressive resistance training alongside the medication (",{"type":23,"tag":292,"props":6394,"children":6396},{"href":5680,"rel":6395},[501],[6397],{"type":28,"value":6398},"Locatelli et al., 2024",{"type":28,"value":5139},{"type":23,"tag":43,"props":6401,"children":6403},{"id":6402},"new-frontiers-immunometabolism-and-cancer",[6404],{"type":28,"value":6405},"New frontiers: immunometabolism and cancer",{"type":23,"tag":24,"props":6407,"children":6408},{},[6409,6411,6418],{"type":28,"value":6410},"Finally, a glimpse of where the science is heading. Obesity drives chronic inflammation and metabolically \"exhausts\" the immune cells that fight tumours. Early work suggests GLP-1 drugs can partly reverse this: in obese mouse models of lung cancer, a GLP-1 agonist slowed tumour growth and improved the anti-tumour immune environment — an effect seen only in obese animals (",{"type":23,"tag":292,"props":6412,"children":6415},{"href":6413,"rel":6414},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F40857107\u002F",[501],[6416],{"type":28,"value":6417},"Pachimatla… Sanghvi et al., JCI Insight 2025",{"type":28,"value":6419},"). It is preclinical and early, but it hints that correcting metabolic dysfunction may have benefits well beyond the scale.",{"type":23,"tag":43,"props":6421,"children":6423},{"id":6422},"the-honest-verdict",[6424],{"type":28,"value":6425},"The honest verdict",{"type":23,"tag":24,"props":6427,"children":6428},{},[6429,6431,6436,6438,6443,6445,6449],{"type":28,"value":6430},"Put the evidence together and the picture is the reverse of the video's. In controlled trials retatrutide ",{"type":23,"tag":171,"props":6432,"children":6433},{},[6434],{"type":28,"value":6435},"lowers",{"type":28,"value":6437}," liver fat dramatically, ",{"type":23,"tag":171,"props":6439,"children":6440},{},[6441],{"type":28,"value":6442},"does not",{"type":28,"value":6444}," raise pancreatitis risk, and ",{"type":23,"tag":171,"props":6446,"children":6447},{},[6448],{"type":28,"value":6442},{"type":28,"value":6450}," dissolve your body fat through any glucagon flood. The real cautions — muscle loss, gastrointestinal effects, the anaesthesia interaction, and the blunt fact that gray-market product is unregulated and may not be what the label says — are precisely the ones a vendor selling you peptides has the least incentive to dwell on.",{"type":23,"tag":24,"props":6452,"children":6453},{},[6454,6456,6460,6462,6466,6468,6472],{"type":28,"value":6455},"If you are considering or already using any of this, the move is not a 45-minute video and a checkout button. It is bloodwork, a real prescriber, and honest expectations. If something feels wrong, ",{"type":23,"tag":171,"props":6457,"children":6458},{},[6459],{"type":28,"value":5025},{"type":28,"value":6461}," before you trust a protocol sold by the person who diagnosed you on YouTube. For the trial doses as reported in the published literature, see our ",{"type":23,"tag":292,"props":6463,"children":6464},{"href":1529},[6465],{"type":28,"value":2984},{"type":28,"value":6467},"; to understand the drug class first, start with ",{"type":23,"tag":292,"props":6469,"children":6470},{"href":470},[6471],{"type":28,"value":473},{"type":28,"value":299},{"type":23,"tag":43,"props":6474,"children":6476},{"id":6475},"references",[6477],{"type":28,"value":6478},"References",{"type":23,"tag":2238,"props":6480,"children":6481},{},[6482,6515,6546,6563,6585,6607,6631,6655,6678,6700,6723,6746,6771,6800,6823,6845,6867,6888,6910,6932,6954,6977,6999,7021,7043,7065,7086,7108,7130,7151,7173,7195,7213,7229,7246,7263],{"type":23,"tag":188,"props":6483,"children":6484},{},[6485,6487,6492,6493,6498,6500,6506,6508],{"type":28,"value":6486},"Jastreboff AM, Kaplan LM, Frías JP, et al. ",{"type":23,"tag":171,"props":6488,"children":6489},{},[6490],{"type":28,"value":6491},"Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6494,"children":6495},{},[6496],{"type":28,"value":6497},"N Engl J Med",{"type":28,"value":6499}," 2023. ",{"type":23,"tag":292,"props":6501,"children":6503},{"href":6007,"rel":6502},[501],[6504],{"type":28,"value":6505},"PubMed",{"type":28,"value":6507}," · ",{"type":23,"tag":292,"props":6509,"children":6512},{"href":6510,"rel":6511},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2301972",[501],[6513],{"type":28,"value":6514},"NEJM",{"type":23,"tag":188,"props":6516,"children":6517},{},[6518,6520,6525,6526,6531,6533,6539,6540],{"type":28,"value":6519},"Sanyal AJ, et al. ",{"type":23,"tag":171,"props":6521,"children":6522},{},[6523],{"type":28,"value":6524},"Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6527,"children":6528},{},[6529],{"type":28,"value":6530},"Nature Medicine",{"type":28,"value":6532}," 2024. ",{"type":23,"tag":292,"props":6534,"children":6536},{"href":5190,"rel":6535},[501],[6537],{"type":28,"value":6538},"PMC full text",{"type":28,"value":6507},{"type":23,"tag":292,"props":6541,"children":6544},{"href":6542,"rel":6543},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-024-03018-2",[501],[6545],{"type":28,"value":39},{"type":23,"tag":188,"props":6547,"children":6548},{},[6549,6551,6556,6557],{"type":28,"value":6550},"Phase-2 retatrutide obesity trial registration. ",{"type":23,"tag":35,"props":6552,"children":6553},{},[6554],{"type":28,"value":6555},"ClinicalTrials.gov",{"type":28,"value":2157},{"type":23,"tag":292,"props":6558,"children":6560},{"href":5986,"rel":6559},[501],[6561],{"type":28,"value":6562},"NCT04881760",{"type":23,"tag":188,"props":6564,"children":6565},{},[6566,6568,6573,6574,6578,6580],{"type":28,"value":6567},"Perry RJ, et al. ",{"type":23,"tag":171,"props":6569,"children":6570},{},[6571],{"type":28,"value":6572},"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6575,"children":6576},{},[6577],{"type":28,"value":39},{"type":28,"value":6579}," 2020. ",{"type":23,"tag":292,"props":6581,"children":6583},{"href":5116,"rel":6582},[501],[6584],{"type":28,"value":6505},{"type":23,"tag":188,"props":6586,"children":6587},{},[6588,6590,6595,6596,6601,6602],{"type":28,"value":6589},"Kajani S, et al. ",{"type":23,"tag":171,"props":6591,"children":6592},{},[6593],{"type":28,"value":6594},"Hepatic glucagon action: beyond glucose mobilization.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6597,"children":6598},{},[6599],{"type":28,"value":6600},"Physiological Reviews",{"type":28,"value":6532},{"type":23,"tag":292,"props":6603,"children":6605},{"href":5456,"rel":6604},[501],[6606],{"type":28,"value":6505},{"type":23,"tag":188,"props":6608,"children":6609},{},[6610,6612,6617,6618,6623,6625],{"type":28,"value":6611},"Galsgaard KD, et al. ",{"type":23,"tag":171,"props":6613,"children":6614},{},[6615],{"type":28,"value":6616},"Glucagon Receptor Signaling and Lipid Metabolism.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6619,"children":6620},{},[6621],{"type":28,"value":6622},"Front Physiol",{"type":28,"value":6624}," 2019. ",{"type":23,"tag":292,"props":6626,"children":6628},{"href":5860,"rel":6627},[501],[6629],{"type":28,"value":6630},"Full text",{"type":23,"tag":188,"props":6632,"children":6633},{},[6634,6636,6641,6642,6647,6649],{"type":28,"value":6635},"Vasileva A, et al. ",{"type":23,"tag":171,"props":6637,"children":6638},{},[6639],{"type":28,"value":6640},"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6643,"children":6644},{},[6645],{"type":28,"value":6646},"Am J Physiol Endocrinol Metab",{"type":28,"value":6648}," 2022. ",{"type":23,"tag":292,"props":6650,"children":6652},{"href":5125,"rel":6651},[501],[6653],{"type":28,"value":6654},"PMC",{"type":23,"tag":188,"props":6656,"children":6657},{},[6658,6660,6665,6666,6671,6673],{"type":28,"value":6659},"Gravholt CH, et al. ",{"type":23,"tag":171,"props":6661,"children":6662},{},[6663],{"type":28,"value":6664},"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6667,"children":6668},{},[6669],{"type":28,"value":6670},"JCEM",{"type":28,"value":6672}," 2001. ",{"type":23,"tag":292,"props":6674,"children":6676},{"href":5133,"rel":6675},[501],[6677],{"type":28,"value":6505},{"type":23,"tag":188,"props":6679,"children":6680},{},[6681,6683,6688,6689,6693,6695],{"type":28,"value":6682},"Jensen MD, et al. ",{"type":23,"tag":171,"props":6684,"children":6685},{},[6686],{"type":28,"value":6687},"Effects of glucagon on free fatty acid metabolism in humans.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6690,"children":6691},{},[6692],{"type":28,"value":6670},{"type":28,"value":6694}," 1991. ",{"type":23,"tag":292,"props":6696,"children":6698},{"href":5430,"rel":6697},[501],[6699],{"type":28,"value":6505},{"type":23,"tag":188,"props":6701,"children":6702},{},[6703,6705,6710,6711,6716,6718],{"type":28,"value":6704},"Hou Y, Ernst SA, Heidenreich K, Williams JA. ",{"type":23,"tag":171,"props":6706,"children":6707},{},[6708],{"type":28,"value":6709},"GLP-1 receptor is present in pancreatic acinar cells and regulates amylase secretion.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6712,"children":6713},{},[6714],{"type":28,"value":6715},"Am J Physiol Gastrointest Liver Physiol",{"type":28,"value":6717}," 2016. ",{"type":23,"tag":292,"props":6719,"children":6721},{"href":5496,"rel":6720},[501],[6722],{"type":28,"value":6654},{"type":23,"tag":188,"props":6724,"children":6725},{},[6726,6728,6733,6734,6739,6741],{"type":28,"value":6727},"Steinberg WM, et al. ",{"type":23,"tag":171,"props":6729,"children":6730},{},[6731],{"type":28,"value":6732},"Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide (LEADER).",{"type":28,"value":2157},{"type":23,"tag":35,"props":6735,"children":6736},{},[6737],{"type":28,"value":6738},"Diabetes Care",{"type":28,"value":6740}," 2017. ",{"type":23,"tag":292,"props":6742,"children":6744},{"href":5158,"rel":6743},[501],[6745],{"type":28,"value":6505},{"type":23,"tag":188,"props":6747,"children":6748},{},[6749,6751,6756,6758,6763,6765],{"type":28,"value":6750},"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review. ",{"type":23,"tag":35,"props":6752,"children":6753},{},[6754],{"type":28,"value":6755},"medRxiv",{"type":28,"value":6757}," 2026 (",{"type":23,"tag":171,"props":6759,"children":6760},{},[6761],{"type":28,"value":6762},"preprint, not yet peer-reviewed",{"type":28,"value":6764},"). ",{"type":23,"tag":292,"props":6766,"children":6768},{"href":5522,"rel":6767},[501],[6769],{"type":28,"value":6770},"Preprint",{"type":23,"tag":188,"props":6772,"children":6773},{},[6774,6776,6781,6782,6787,6788,6793,6794],{"type":28,"value":6775},"Nassar M, et al. ",{"type":23,"tag":171,"props":6777,"children":6778},{},[6779],{"type":28,"value":6780},"GLP-1 medications may lower risk of recurrent acute pancreatitis.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6783,"children":6784},{},[6785],{"type":28,"value":6786},"ENDO 2024",{"type":28,"value":5113},{"type":23,"tag":171,"props":6789,"children":6790},{},[6791],{"type":28,"value":6792},"conference abstract",{"type":28,"value":6764},{"type":23,"tag":292,"props":6795,"children":6797},{"href":5538,"rel":6796},[501],[6798],{"type":28,"value":6799},"Press release",{"type":23,"tag":188,"props":6801,"children":6802},{},[6803,6805,6810,6811,6816,6818],{"type":28,"value":6804},"Banks PA, et al. ",{"type":23,"tag":171,"props":6806,"children":6807},{},[6808],{"type":28,"value":6809},"Classification of acute pancreatitis — 2012: revision of the Atlanta classification.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6812,"children":6813},{},[6814],{"type":28,"value":6815},"Gut",{"type":28,"value":6817}," 2013. ",{"type":23,"tag":292,"props":6819,"children":6821},{"href":5560,"rel":6820},[501],[6822],{"type":28,"value":6505},{"type":23,"tag":188,"props":6824,"children":6825},{},[6826,6828,6833,6834,6839,6840],{"type":28,"value":6827},"Rinella ME, et al. ",{"type":23,"tag":171,"props":6829,"children":6830},{},[6831],{"type":28,"value":6832},"A multisociety Delphi consensus on new fatty liver disease nomenclature (MASLD).",{"type":28,"value":2157},{"type":23,"tag":35,"props":6835,"children":6836},{},[6837],{"type":28,"value":6838},"Hepatology \u002F J Hepatol",{"type":28,"value":6499},{"type":23,"tag":292,"props":6841,"children":6843},{"href":5738,"rel":6842},[501],[6844],{"type":28,"value":6654},{"type":23,"tag":188,"props":6846,"children":6847},{},[6848,6850,6855,6856,6861,6862],{"type":28,"value":6849},"Samuel VT, Shulman GI. ",{"type":23,"tag":171,"props":6851,"children":6852},{},[6853],{"type":28,"value":6854},"The pathogenesis of insulin resistance.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6857,"children":6858},{},[6859],{"type":28,"value":6860},"J Clin Invest",{"type":28,"value":6717},{"type":23,"tag":292,"props":6863,"children":6865},{"href":5785,"rel":6864},[501],[6866],{"type":28,"value":6654},{"type":23,"tag":188,"props":6868,"children":6869},{},[6870,6871,6876,6877,6881,6883],{"type":28,"value":6849},{"type":23,"tag":171,"props":6872,"children":6873},{},[6874],{"type":28,"value":6875},"NAFLD as a Nexus of Metabolic and Hepatic Diseases.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6878,"children":6879},{},[6880],{"type":28,"value":282},{"type":28,"value":6882}," 2018. ",{"type":23,"tag":292,"props":6884,"children":6886},{"href":5793,"rel":6885},[501],[6887],{"type":28,"value":6654},{"type":23,"tag":188,"props":6889,"children":6890},{},[6891,6893,6898,6899,6904,6905],{"type":28,"value":6892},"Buzzetti E, Pinzani M, Tsochatzis EA. ",{"type":23,"tag":171,"props":6894,"children":6895},{},[6896],{"type":28,"value":6897},"The multiple-hit pathogenesis of NAFLD.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6900,"children":6901},{},[6902],{"type":28,"value":6903},"Metabolism",{"type":28,"value":6717},{"type":23,"tag":292,"props":6906,"children":6908},{"href":5758,"rel":6907},[501],[6909],{"type":28,"value":6505},{"type":23,"tag":188,"props":6911,"children":6912},{},[6913,6915,6920,6921,6925,6927],{"type":28,"value":6914},"Donnelly KL, et al. ",{"type":23,"tag":171,"props":6916,"children":6917},{},[6918],{"type":28,"value":6919},"Sources of fatty acids stored in liver and secreted via lipoproteins in NAFLD.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6922,"children":6923},{},[6924],{"type":28,"value":6860},{"type":28,"value":6926}," 2005. ",{"type":23,"tag":292,"props":6928,"children":6930},{"href":5820,"rel":6929},[501],[6931],{"type":28,"value":6654},{"type":23,"tag":188,"props":6933,"children":6934},{},[6935,6937,6942,6943,6947,6948],{"type":28,"value":6936},"Locatelli JC, et al. ",{"type":23,"tag":171,"props":6938,"children":6939},{},[6940],{"type":28,"value":6941},"Incretin-Based Weight Loss and Resistance Exercise.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6944,"children":6945},{},[6946],{"type":28,"value":6738},{"type":28,"value":6532},{"type":23,"tag":292,"props":6949,"children":6951},{"href":5680,"rel":6950},[501],[6952],{"type":28,"value":6953},"Article",{"type":23,"tag":188,"props":6955,"children":6956},{},[6957,6959,6964,6965,6970,6972],{"type":28,"value":6958},"Koceva A, et al. ",{"type":23,"tag":171,"props":6960,"children":6961},{},[6962],{"type":28,"value":6963},"Impact of Incretin-Based Therapy on Skeletal Muscle Health.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6966,"children":6967},{},[6968],{"type":28,"value":6969},"Medicina",{"type":28,"value":6971}," 2025. ",{"type":23,"tag":292,"props":6973,"children":6975},{"href":5216,"rel":6974},[501],[6976],{"type":28,"value":6654},{"type":23,"tag":188,"props":6978,"children":6979},{},[6980,6982,6987,6988,6993,6994],{"type":28,"value":6981},"Tinsley GM, et al. ",{"type":23,"tag":171,"props":6983,"children":6984},{},[6985],{"type":28,"value":6986},"Body Composition Principles for Fat-Free and Skeletal Muscle Mass Changes.",{"type":28,"value":2157},{"type":23,"tag":35,"props":6989,"children":6990},{},[6991],{"type":28,"value":6992},"J Endocr Soc",{"type":28,"value":6532},{"type":23,"tag":292,"props":6995,"children":6997},{"href":5671,"rel":6996},[501],[6998],{"type":28,"value":6654},{"type":23,"tag":188,"props":7000,"children":7001},{},[7002,7004,7009,7010,7015,7016],{"type":28,"value":7003},"do Nascimento TS, et al. ",{"type":23,"tag":171,"props":7005,"children":7006},{},[7007],{"type":28,"value":7008},"GLP-1 receptor agonists and residual gastric content (perioperative).",{"type":28,"value":2157},{"type":23,"tag":35,"props":7011,"children":7012},{},[7013],{"type":28,"value":7014},"Perioper Med",{"type":28,"value":6532},{"type":23,"tag":292,"props":7017,"children":7019},{"href":6278,"rel":7018},[501],[7020],{"type":28,"value":6654},{"type":23,"tag":188,"props":7022,"children":7023},{},[7024,7026,7031,7032,7037,7038],{"type":28,"value":7025},"Tan Y, et al. ",{"type":23,"tag":171,"props":7027,"children":7028},{},[7029],{"type":28,"value":7030},"GLP-1 receptor agonists increase residual gastric content and aspiration risk.",{"type":28,"value":2157},{"type":23,"tag":35,"props":7033,"children":7034},{},[7035],{"type":28,"value":7036},"Dig Liver Dis",{"type":28,"value":6971},{"type":23,"tag":292,"props":7039,"children":7041},{"href":6286,"rel":7040},[501],[7042],{"type":28,"value":6505},{"type":23,"tag":188,"props":7044,"children":7045},{},[7046,7048,7053,7054,7059,7060],{"type":28,"value":7047},"Ushakumari DS, et al. ",{"type":23,"tag":171,"props":7049,"children":7050},{},[7051],{"type":28,"value":7052},"ASA Consensus-based Guidance on Preoperative Management of GLP-1 RAs.",{"type":28,"value":2157},{"type":23,"tag":35,"props":7055,"children":7056},{},[7057],{"type":28,"value":7058},"Anesthesiology",{"type":28,"value":6532},{"type":23,"tag":292,"props":7061,"children":7063},{"href":6304,"rel":7062},[501],[7064],{"type":28,"value":6505},{"type":23,"tag":188,"props":7066,"children":7067},{},[7068,7070,7075,7076,7080,7081],{"type":28,"value":7069},"Jalleh RJ, et al. ",{"type":23,"tag":171,"props":7071,"children":7072},{},[7073],{"type":28,"value":7074},"Clinical Consequences of Delayed Gastric Emptying With GLP-1 RAs.",{"type":28,"value":2157},{"type":23,"tag":35,"props":7077,"children":7078},{},[7079],{"type":28,"value":6670},{"type":28,"value":6532},{"type":23,"tag":292,"props":7082,"children":7084},{"href":6295,"rel":7083},[501],[7085],{"type":28,"value":6654},{"type":23,"tag":188,"props":7087,"children":7088},{},[7089,7091,7096,7097,7102,7103],{"type":28,"value":7090},"Pachimatla AG, … Sanghvi VR, et al. ",{"type":23,"tag":171,"props":7092,"children":7093},{},[7094],{"type":28,"value":7095},"GLP-1 receptor agonism improves lung cancer outcomes and tumor immunity (obese models).",{"type":28,"value":2157},{"type":23,"tag":35,"props":7098,"children":7099},{},[7100],{"type":28,"value":7101},"JCI Insight",{"type":28,"value":6971},{"type":23,"tag":292,"props":7104,"children":7106},{"href":6413,"rel":7105},[501],[7107],{"type":28,"value":6505},{"type":23,"tag":188,"props":7109,"children":7110},{},[7111,7113,7118,7119,7123,7125],{"type":28,"value":7112},"Wilding JPH, et al. ",{"type":23,"tag":171,"props":7114,"children":7115},{},[7116],{"type":28,"value":7117},"Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).",{"type":28,"value":2157},{"type":23,"tag":35,"props":7120,"children":7121},{},[7122],{"type":28,"value":6497},{"type":28,"value":7124}," 2021. ",{"type":23,"tag":292,"props":7126,"children":7128},{"href":5934,"rel":7127},[501],[7129],{"type":28,"value":6505},{"type":23,"tag":188,"props":7131,"children":7132},{},[7133,7135,7140,7141,7145,7146],{"type":28,"value":7134},"Jastreboff AM, et al. ",{"type":23,"tag":171,"props":7136,"children":7137},{},[7138],{"type":28,"value":7139},"Tirzepatide Once Weekly for Obesity (SURMOUNT-1).",{"type":28,"value":2157},{"type":23,"tag":35,"props":7142,"children":7143},{},[7144],{"type":28,"value":6497},{"type":28,"value":6648},{"type":23,"tag":292,"props":7147,"children":7149},{"href":5949,"rel":7148},[501],[7150],{"type":28,"value":6505},{"type":23,"tag":188,"props":7152,"children":7153},{},[7154,7156,7161,7162,7167,7168],{"type":28,"value":7155},"Holst JJ. ",{"type":23,"tag":171,"props":7157,"children":7158},{},[7159],{"type":28,"value":7160},"GLP-1 physiology in obesity and incretin-based drugs.",{"type":28,"value":2157},{"type":23,"tag":35,"props":7163,"children":7164},{},[7165],{"type":28,"value":7166},"Nature Metabolism",{"type":28,"value":6532},{"type":23,"tag":292,"props":7169,"children":7171},{"href":5958,"rel":7170},[501],[7172],{"type":28,"value":6505},{"type":23,"tag":188,"props":7174,"children":7175},{},[7176,7178,7183,7184,7189,7190],{"type":28,"value":7177},"Nauck MA, et al. ",{"type":23,"tag":171,"props":7179,"children":7180},{},[7181],{"type":28,"value":7182},"The evolving story of incretins (GIP and GLP-1).",{"type":28,"value":2157},{"type":23,"tag":35,"props":7185,"children":7186},{},[7187],{"type":28,"value":7188},"Diabetes Obes Metab",{"type":28,"value":7124},{"type":23,"tag":292,"props":7191,"children":7193},{"href":5966,"rel":7192},[501],[7194],{"type":28,"value":6953},{"type":23,"tag":188,"props":7196,"children":7197},{},[7198,7200,7205,7207],{"type":28,"value":7199},"California Board of Chiropractic Examiners. ",{"type":23,"tag":171,"props":7201,"children":7202},{},[7203],{"type":28,"value":7204},"Meeting materials, 29 Oct 2020",{"type":28,"value":7206}," (licence DC 29377, revoked 8 Jul 2020). ",{"type":23,"tag":292,"props":7208,"children":7210},{"href":5076,"rel":7209},[501],[7211],{"type":28,"value":7212},"PDF",{"type":23,"tag":188,"props":7214,"children":7215},{},[7216,7217,7222,7223],{"type":28,"value":7199},{"type":23,"tag":171,"props":7218,"children":7219},{},[7220],{"type":28,"value":7221},"Final Disciplinary Actions.",{"type":28,"value":2157},{"type":23,"tag":292,"props":7224,"children":7226},{"href":5287,"rel":7225},[501],[7227],{"type":28,"value":7228},"Page",{"type":23,"tag":188,"props":7230,"children":7231},{},[7232,7234,7239,7240],{"type":28,"value":7233},"California Department of Consumer Affairs. ",{"type":23,"tag":171,"props":7235,"children":7236},{},[7237],{"type":28,"value":7238},"License Search.",{"type":28,"value":2157},{"type":23,"tag":292,"props":7241,"children":7243},{"href":5296,"rel":7242},[501],[7244],{"type":28,"value":7245},"Lookup",{"type":23,"tag":188,"props":7247,"children":7248},{},[7249,7251,7256,7257],{"type":28,"value":7250},"EliteBiogenix. ",{"type":23,"tag":171,"props":7252,"children":7253},{},[7254],{"type":28,"value":7255},"Research peptides and SARMs vendor (in-vitro research only).",{"type":28,"value":2157},{"type":23,"tag":292,"props":7258,"children":7260},{"href":5085,"rel":7259},[501],[7261],{"type":28,"value":7262},"Site",{"type":23,"tag":188,"props":7264,"children":7265},{},[7266,7268,7272,7273,7278,7279],{"type":28,"value":7267},"Bachmeyer T. ",{"type":23,"tag":171,"props":7269,"children":7270},{},[7271],{"type":28,"value":5051},{"type":28,"value":2157},{"type":23,"tag":35,"props":7274,"children":7275},{},[7276],{"type":28,"value":7277},"YouTube.",{"type":28,"value":2157},{"type":23,"tag":292,"props":7280,"children":7283},{"href":7281,"rel":7282},"https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=gb-XEtsMr-w",[501],[7284],{"type":28,"value":7285},"Video",{"title":8,"searchDepth":578,"depth":578,"links":7287},[7288,7289,7290,7291,7292,7293,7294,7295,7296,7297,7298,7299,7300,7301,7302,7303,7304,7305,7306],{"id":5038,"depth":578,"text":5041},{"id":5236,"depth":578,"text":5239},{"id":5324,"depth":578,"text":5327},{"id":5384,"depth":578,"text":5387},{"id":5465,"depth":578,"text":5468},{"id":5569,"depth":578,"text":5572},{"id":5635,"depth":578,"text":5638},{"id":5689,"depth":578,"text":5692},{"id":5709,"depth":578,"text":5712},{"id":5720,"depth":578,"text":5723},{"id":5774,"depth":578,"text":5777},{"id":5836,"depth":578,"text":5839},{"id":5916,"depth":578,"text":5919},{"id":6248,"depth":578,"text":6251},{"id":6319,"depth":578,"text":6322},{"id":6364,"depth":578,"text":6367},{"id":6402,"depth":578,"text":6405},{"id":6422,"depth":578,"text":6425},{"id":6475,"depth":578,"text":6478},"content:blog:en:retatrutide-liver-damage-myths.md","blog\u002Fen\u002Fretatrutide-liver-damage-myths.md","blog\u002Fen\u002Fretatrutide-liver-damage-myths",{"_path":7311,"_dir":6,"_draft":7,"_partial":7,"_locale":8,"title":7312,"description":8,"cat":7313,"icon":7314,"accent":7315,"date":7316,"dateLabel":7317,"updated":7318,"read":7319,"author":17,"image":7320,"faq":7321,"body":7331,"_type":590,"_id":7525,"_source":592,"_file":7526,"_stem":7527,"_extension":595},"\u002Fblog\u002Fen\u002Frecovery-duo","BPC-157 and TB-500: what they are, and their status","Compounds","tabler:file-description","#4CAF50","2026-06-05","June 5, 2026","2026-09-04","3 min read","\u002Fassets\u002Fbpc157_tb500_status_hero.png",[7322,7325,7328],{"q":7323,"a":7324},"What are BPC-157 and TB-500?","BPC-157 is a synthetic peptide of 15 amino acids based on a sequence found in gastric juice; TB-500 is a synthetic fragment of thymosin beta-4. Neither is an approved medicine.",{"q":7326,"a":7327},"Are BPC-157 and TB-500 prohibited in sport?","Both are prohibited at all times, not only in competition. BPC-157 falls under S0, the section of the WADA Prohibited List for substances with no regulatory approval for human therapeutic use, where the 2026 edition names it among its examples; thymosin beta-4 and its derivatives, TB-500 among them, are named under S2.3 (growth factors).",{"q":7329,"a":7330},"What is the legal status of BPC-157?","It is not approved as a medicine in the United States, the European Union or Australia, and Australia lists it in Schedule 4 of the Poisons Standard, meaning prescription-only. Legality of possession and use depends on where you live.",{"type":20,"children":7332,"toc":7513},[7333,7341,7346,7352,7357,7363,7374,7380,7385,7401,7407,7413,7417,7422,7426,7431,7435,7439],{"type":23,"tag":4939,"props":7334,"children":7335},{},[7336],{"type":23,"tag":24,"props":7337,"children":7338},{},[7339],{"type":28,"value":7340},"This is general information only — not medical advice, not a dosing or usage recommendation, and not a suggestion to obtain or use any substance. Neither peptide is an approved medicine, and in Australia BPC-157 is prescription-only. Whether possession and use are legal depends on the law of your country of residence and is your own responsibility. For health questions, consult a licensed physician or pharmacist.",{"type":23,"tag":24,"props":7342,"children":7343},{},[7344],{"type":28,"value":7345},"These two names are rarely mentioned apart, which makes it easy to read them as one thing. What follows is a neutral overview: what each peptide is, what has been studied, and what their status is.",{"type":23,"tag":43,"props":7347,"children":7349},{"id":7348},"what-each-one-is",[7350],{"type":28,"value":7351},"What each one is",{"type":23,"tag":24,"props":7353,"children":7354},{},[7355],{"type":28,"value":7356},"BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids based on a sequence found in gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a protein described in connection with actin binding and cell migration. The pairing is a habit of online discussion, not a pharmacological category.",{"type":23,"tag":43,"props":7358,"children":7360},{"id":7359},"what-has-been-studied",[7361],{"type":28,"value":7362},"What has been studied",{"type":23,"tag":24,"props":7364,"children":7365},{},[7366,7368,7373],{"type":28,"value":7367},"Both have been examined almost entirely in preclinical settings: cell cultures and animal models. Public trial registries list no completed controlled efficacy trial in humans for BPC-157, and only limited registered human work on thymosin beta-4 derivatives. When FDA staff scientists reviewed the evidence in 2026, they reported finding essentially one small trial abstract for BPC-157, in roughly 46 people and not administered by injection; the same review noted that immunogenicity — the chance of an immune reaction to an injected peptide — is largely unassessed for this group of substances. Details of that review are in our write-up of ",{"type":23,"tag":292,"props":7369,"children":7370},{"href":2339},[7371],{"type":28,"value":7372},"the 503A vote",{"type":28,"value":299},{"type":23,"tag":43,"props":7375,"children":7377},{"id":7376},"regulatory-and-anti-doping-status",[7378],{"type":28,"value":7379},"Regulatory and anti-doping status",{"type":23,"tag":24,"props":7381,"children":7382},{},[7383],{"type":28,"value":7384},"Neither is approved as a medicine in the United States, the European Union or Australia, and Australia's Poisons Standard lists BPC-157 in Schedule 4, prescription-only. Both are prohibited in sport at all times: BPC-157 falls under S0, the WADA Prohibited List's section for substances with no regulatory approval for human therapeutic use, where the 2026 edition names it among its examples, while thymosin beta-4 and its derivatives — TB-500 among them — are named explicitly under S2.3 (growth factors).",{"type":23,"tag":24,"props":7386,"children":7387},{},[7388,7390,7395,7396,7400],{"type":28,"value":7389},"In the United States, FDA staff scientists recommended against all seven peptides under review; in separate votes on 23 July 2026 the Pharmacy Compounding Advisory Committee recommended BPC-157 and TB-500, each by 8–6–1, for the Section 503A list — the bulk-substances list a substance has to be on before a pharmacy may compound with it. A committee vote is a recommendation, not an approval. Wider context: the ",{"type":23,"tag":292,"props":7391,"children":7392},{"href":1673},[7393],{"type":28,"value":7394},"peptide list with approval status",{"type":28,"value":4595},{"type":23,"tag":292,"props":7397,"children":7398},{"href":1626},[7399],{"type":28,"value":2317},{"type":28,"value":299},{"type":23,"tag":43,"props":7402,"children":7404},{"id":7403},"common-questions",[7405],{"type":28,"value":7406},"Common questions",{"type":23,"tag":7408,"props":7409,"children":7411},"h3",{"id":7410},"what-are-bpc-157-and-tb-500",[7412],{"type":28,"value":7323},{"type":23,"tag":24,"props":7414,"children":7415},{},[7416],{"type":28,"value":7324},{"type":23,"tag":7408,"props":7418,"children":7420},{"id":7419},"are-bpc-157-and-tb-500-prohibited-in-sport",[7421],{"type":28,"value":7326},{"type":23,"tag":24,"props":7423,"children":7424},{},[7425],{"type":28,"value":7327},{"type":23,"tag":7408,"props":7427,"children":7429},{"id":7428},"what-is-the-legal-status-of-bpc-157",[7430],{"type":28,"value":7329},{"type":23,"tag":24,"props":7432,"children":7433},{},[7434],{"type":28,"value":7330},{"type":23,"tag":43,"props":7436,"children":7437},{"id":485},[7438],{"type":28,"value":488},{"type":23,"tag":184,"props":7440,"children":7441},{},[7442,7456,7470,7483,7494],{"type":23,"tag":188,"props":7443,"children":7444},{},[7445,7447,7454],{"type":28,"value":7446},"WADA, ",{"type":23,"tag":292,"props":7448,"children":7451},{"href":7449,"rel":7450},"https:\u002F\u002Fwww.wada-ama.org\u002Fen\u002Fprohibited-list",[501],[7452],{"type":28,"value":7453},"Prohibited List",{"type":28,"value":7455}," — S0 (non-approved substances) names BPC-157 among its examples; S2.3 (growth factors) names thymosin beta-4 and its derivatives, e.g. TB-500",{"type":23,"tag":188,"props":7457,"children":7458},{},[7459,7461,7468],{"type":28,"value":7460},"TGA, ",{"type":23,"tag":292,"props":7462,"children":7465},{"href":7463,"rel":7464},"https:\u002F\u002Fwww.tga.gov.au\u002Fproducts\u002Funapproved-therapeutic-goods\u002Fpoisons-standard-susmp",[501],[7466],{"type":28,"value":7467},"Poisons Standard (SUSMP)",{"type":28,"value":7469}," — BPC-157 in Schedule 4",{"type":23,"tag":188,"props":7471,"children":7472},{},[7473,7474,7481],{"type":28,"value":3753},{"type":23,"tag":292,"props":7475,"children":7478},{"href":7476,"rel":7477},"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fbulk-drug-substances-used-compounding-under-section-503a-fdc-act",[501],[7479],{"type":28,"value":7480},"Bulk drug substances used in compounding under section 503A",{"type":28,"value":7482}," — the interim policy on bulk drug substances nominated for compounding",{"type":23,"tag":188,"props":7484,"children":7485},{},[7486,7487,7492],{"type":28,"value":3753},{"type":23,"tag":292,"props":7488,"children":7490},{"href":3756,"rel":7489},[501],[7491],{"type":28,"value":3760},{"type":28,"value":7493}," — votes on BPC-157, KPV, TB-500 and MOTS-c",{"type":23,"tag":188,"props":7495,"children":7496},{},[7497,7499,7505,7506],{"type":28,"value":7498},"ClinicalTrials.gov, registry searches for ",{"type":23,"tag":292,"props":7500,"children":7503},{"href":7501,"rel":7502},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=BPC-157",[501],[7504],{"type":28,"value":2334},{"type":28,"value":4595},{"type":23,"tag":292,"props":7507,"children":7510},{"href":7508,"rel":7509},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=Thymosin+beta-4",[501],[7511],{"type":28,"value":7512},"thymosin beta-4",{"title":8,"searchDepth":578,"depth":578,"links":7514},[7515,7516,7517,7518,7524],{"id":7348,"depth":578,"text":7351},{"id":7359,"depth":578,"text":7362},{"id":7376,"depth":578,"text":7379},{"id":7403,"depth":578,"text":7406,"children":7519},[7520,7522,7523],{"id":7410,"depth":7521,"text":7323},3,{"id":7419,"depth":7521,"text":7326},{"id":7428,"depth":7521,"text":7329},{"id":485,"depth":578,"text":488},"content:blog:en:recovery-duo.md","blog\u002Fen\u002Frecovery-duo.md","blog\u002Fen\u002Frecovery-duo"]